---
document_datetime: 2025-09-10 12:18:23
document_pages: 89
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/imbruvica-h-c-003791-ii-0092-epar-assessment-report-variation_en.pdf
document_name: imbruvica-h-c-003791-ii-0092-epar-assessment-report-variation_en.pdf
version: success
processing_time: 213.0198797
conversion_datetime: 2025-12-21 16:29:41.546866
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

19 June 2025 EMA/CHMP/200822/2025 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

Imbruvica

International non-proprietary name: Ibrutinib

Procedure No. EMEA/H/C/003791/II/0092

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure ..............................................5                                                                                                                                                                                                             |                                                                                                         |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation                                                                                                                                                                                                                                                                                 | ..................................................................................................5     |
| 1.2. Steps taken for the assessment of the product.........................................................6                                                                                                                                                                                           |                                                                                                         |
| 2. Scientific discussion ................................................................................7                                                                                                                                                                                             |                                                                                                         |
| 2.1. Introduction.........................................................................................................7                                                                                                                                                                            |                                                                                                         |
| 2.1.1. Problem statement                                                                                                                                                                                                                                                                               | ............................................................................................7           |
| 2.1.2. About the product..............................................................................................9                                                                                                                                                                                |                                                                                                         |
| 2.1.3. The development programme/compliance with CHMP guidance/scientific advice                                                                                                                                                                                                                       | ......10                                                                                                |
| 2.1.4. General comments on compliance with GCP........................................................10                                                                                                                                                                                               |                                                                                                         |
| 2.2. Non-clinical aspects                                                                                                                                                                                                                                                                              | ............................................................................................10          |
| 2.2.1. Ecotoxicity/environmental risk assessment                                                                                                                                                                                                                                                       | .........................................................10                                             |
| 2.2.2. Discussion on non-clinical aspects......................................................................11                                                                                                                                                                                      |                                                                                                         |
| 2.2.3. Conclusion on the non-clinical aspects................................................................11                                                                                                                                                                                        |                                                                                                         |
| 2.3. Clinical aspects                                                                                                                                                                                                                                                                                  | ..................................................................................................11    |
| 2.3.1. Introduction....................................................................................................11                                                                                                                                                                              |                                                                                                         |
| 2.3.2. Pharmacokinetics.............................................................................................12                                                                                                                                                                                 |                                                                                                         |
| 2.3.3. Pharmacodynamics..........................................................................................12                                                                                                                                                                                    |                                                                                                         |
| 2.3.4. PK/PD modelling..............................................................................................12                                                                                                                                                                                 |                                                                                                         |
| 2.3.5. Discussion on clinical pharmacology...................................................................12                                                                                                                                                                                        |                                                                                                         |
| 2.3.6. Conclusions on clinical pharmacology.................................................................13                                                                                                                                                                                         |                                                                                                         |
| 2.4. There was no additional pharmacology information submitted with this application, however as discussed above, potential DDI concerns were alleviated as per the clinical observed.Clinical efficacy ...........................................................................................13 | effect                                                                                                  |
| 2.4.1. Dose response study(ies)                                                                                                                                                                                                                                                                        |                                                                                                         |
| .................................................................................13 2.4.2. Main study: Pivotal Study MCL3003 (Triangle)                                                                                                                                                                | ....................................................13                                                  |
| 2.4.3. Discussion on clinical efficacy............................................................................49                                                                                                                                                                                   |                                                                                                         |
| 2.4.4. Conclusions on the clinical efficacy.....................................................................56                                                                                                                                                                                     |                                                                                                         |
| ....................................................................................................57                                                                                                                                                                                                 |                                                                                                         |
| 2.5. Clinical safety 2.5.1. Discussion on clinical safety                                                                                                                                                                                                                                              | ..............................................................................80                        |
| 2.5.2. Conclusions on clinical safety                                                                                                                                                                                                                                                                  | ............................................................................82                          |
|                                                                                                                                                                                                                                                                                                        | .....................................................................................................82 |
| 2.5.3. PSUR cycle                                                                                                                                                                                                                                                                                      |                                                                                                         |
| 2.7. Update of the Product information                                                                                                                                                                                                                                                                 | ........................................................................84                              |
| 2.7.1. User consultation.............................................................................................84                                                                                                                                                                                |                                                                                                         |
| 3. Benefit-Risk Balance..............................................................................85                                                                                                                                                                                                |                                                                                                         |
| 3.1. Therapeutic Context                                                                                                                                                                                                                                                                               | ...........................................................................................85           |
| 3.1.1. Disease or condition.........................................................................................85                                                                                                                                                                                 |                                                                                                         |
| 3.1.2. Available therapies and unmet medical                                                                                                                                                                                                                                                           | need.......................................................85                                           |
| 3.1.3. Main clinical studies                                                                                                                                                                                                                                                                           | .........................................................................................85             |
| 3.2. Favourable effects                                                                                                                                                                                                                                                                                | ..............................................................................................85        |
| 3.3. Uncertainties and limitations about favourable effects.............................................86                                                                                                                                                                                             |                                                                                                         |
| 3.4. Unfavourable effects...........................................................................................86                                                                                                                                                                                 |                                                                                                         |
| 3.5. Uncertainties and limitations about unfavourable effects                                                                                                                                                                                                                                          | .........................................86                                                             |

<div style=\"page-break-after: always\"></div>

3.6. Effects Table  ......................................................................................................  86

3.7. Benefit-risk assessment and discussion  .................................................................  87

3.7.1. Importance of favourable and unfavourable effects  ..............................................  87

3.7.2. Balance of benefits and risks  .............................................................................  88

3.7.3. Additional considerations on the benefit-risk balance ...........................................  88

3.8. Conclusions .......................................................................................................  88

4. Recommendations .................................................................................  88

4.1. Conclusions .......................................................................................................  89

5. EPAR changes  ........................................................................................  89

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| AE       | adverse event                                                                                       |
|----------|-----------------------------------------------------------------------------------------------------|
| ASCT     | autologous stem cell transplant(ation)                                                              |
| BCNU     | bis-chloroethylnitrosourea (carmustine)                                                             |
| BEAM     | BCNU, etoposide, Ara-C, and melphalan                                                               |
| BTK      | Bruton's tyrosine kinase                                                                            |
| CCO      | clinical cutoff                                                                                     |
| CI       | confidence interval                                                                                 |
| COVID-19 | coronavirus disease 2019                                                                            |
| CR       | complete response                                                                                   |
| CrCL     | creatinine clearance                                                                                |
| CRR      | complete response rate                                                                              |
| CSR      | clinical study report                                                                               |
| CT       | computed tomography                                                                                 |
| DSMC     | Data Safety Monitoring Committee                                                                    |
| ECOG     | Eastern Cooperative Oncology Group                                                                  |
| EoI      | end of induction immunochemotherapy                                                                 |
| FAS      | full analysis set                                                                                   |
| FFS      | failure-free survival                                                                               |
| G-CSF    | granulocyte colony stimulating factor                                                               |
| GDPR     | General Data Protection Regulation                                                                  |
| HR       | hazard ratio                                                                                        |
| IA       | interim analysis                                                                                    |
| ICH      | International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use |
| ITT      | intent-to-treat                                                                                     |
| IV       | Intravenous                                                                                         |
| LDH      | lactate dehydrogenase                                                                               |
| LLC      | limited liability company                                                                           |

<div style=\"page-break-after: always\"></div>

| MCL    | mantle cell lymphoma                                                  |
|--------|-----------------------------------------------------------------------|
| MIPI   | Mantle Cell Lymphoma International Prognostic Index                   |
| MUE    | median unbiased estimate(or)                                          |
| NE     | non-evaluable                                                         |
| ORR    | overall response rate                                                 |
| OS     | overall survival                                                      |
| pASCT  | post autologous stem cell transplantation                             |
| PD     | progressive disease                                                   |
| PET    | positron emission tomography                                          |
| PFS    | progression-free survival                                             |
| PK     | Pharmacokinetic                                                       |
| PO     | per os (oral administration)                                          |
| PR     | partial response                                                      |
| Q1, Q3 | first quartile, third quartile                                        |
| R-CHOP | rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone |
| R-DHAP | rituximab, dexamethasone, cytarabine, and cisplatin                   |
| SAP    | statistical analysis plan                                             |
| SC     | Subcutaneous                                                          |
| SCE    | Summary of Clinical Efficacy                                          |
| SD     | stable disease                                                        |
| TBI    | total body irradiation                                                |
| tSPRT  | truncated sequential probability ratio test                           |
| THAM   | TBI, Ara-C, and melphalan                                             |

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Janssen-Cilag International N.V.

<div style=\"page-break-after: always\"></div>

submitted to the European Medicines Agency on 18 December 2024 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include IMBRUVICA in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are eligible for autologous stem cell transplantation (ASCT), based on results from study MCL3003. This is a randomized, 3-arm, parallel-group, openlabel, international, multicenter Phase 3 study. The purpose of Study MCL3003 is to compare 3 alternating courses of R CHOP/R-DHAP followed by ASCT (control Arm A), versus the combination with ibrutinib in induction and maintenance (experimental Arm A+I), or the experimental arm without ASCT (experimental Arm I) in participants with previously untreated MCL who are eligible for ASCT. Consequently, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet. Version 23.1 of the RMP was also submitted.

The variation requested amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included the EMA Decisions P/0149/2013 (Capsule, hard) and P/0298/2017 (Film-coated tablet) on the granting of a productspecific waiver.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the application included a critical report addressing the possible similarity with authorised orphan medicinal products.

## Scientific advice

The MAH did not seek scientific advice from the CHMP.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Filip Josephson

<div style=\"page-break-after: always\"></div>

| Timetable                                            | Actual dates     |
|------------------------------------------------------|------------------|
| Submission date                                      | 18 December 2024 |
| Start of procedure:                                  | 26 January 2025  |
| CHMP Rapporteur Assessment Report                    | 21 March 2025    |
| PRAC Rapporteur Assessment Report                    | 28 March 2025    |
| PRAC members comments                                | 2 April 2025     |
| CHMP Co-Rapporteur Assessment                        | 2 April 2025     |
| PRAC Outcome                                         | 10 April 2025    |
| CHMP members comments                                | 14 April 2025    |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report | 16 April 2025    |
| Request for supplementary information (RSI)          | 25 April 2025    |
| PRAC Rapporteur Assessment Report                    | 26 May 2025      |
| PRAC members comments                                | 28 May 2025      |
| Updated PRAC Rapporteur Assessment Report            | 2 June 2025      |
| CHMP Rapporteur Assessment Report                    | 4 June 2025      |
| PRAC Outcome                                         | 6 June 2025      |
| CHMP members comments                                | 10 June 2025     |
| Updated CHMP Rapporteur Assessment Report            | 12 June 2025     |
| Opinion                                              | 19 June 2025     |

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1. Problem statement

## Disease or condition

Mantle cell lymphoma (MCL) is a relatively rare subtype of lymphoid malignancy and has been recognized as a distinct entity in the Revised European-American Lymphoma (REAL) classification since 1994.

The initially sought indication was:

IMBRUVICA in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are eligible for autologous stem cell transplantation (ASCT).

The approved indication is:

IMBRUVICA in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (IMBRUVICA + R-CHOP) alternating with R-DHAP (or R-DHAOx) without IMBRUVICA, followed by IMBRUVICA monotherapy, is indicated for the treatment of adult patients with previously

<div style=\"page-break-after: always\"></div>

untreated mantle cell lymphoma (MCL) who would be eligible for autologous stem cell transplantation (ASCT)'

## Epidemiology

MCL is a mature B-cell Non-Hodgkin lymphoma (NHL) that accounts for about 6% of malignant lymphoma in Western Europe. The annual incidence of this disease has increased during recent decades to 1-2/100 000 recently. Median age of patients at diagnosis is about 70 years. Approximately three-quarters of patients with MCL are male.

## Biologic features

MCL is a subtype of B-cell non-Hodgkin lymphomas associated with increased cellular proliferation, a reduced response to DNA damage, and enhanced cell survival caused by impaired apoptosis. MCL is characterised by chromosomal translocation t(11;14)(q13:q32) that juxtaposes the cyclin D1 locus with the immunoglobulin heavy chain gene locus. This results in overexpression of the cyclin D1 (CCDN1) gene and increased proliferation.

MCL is also characterised by disturbances in pathways and factors that regulate apoptosis. MCL cells avoid apoptosis through expression of BCL2, upregulation of the PI3 kinase (PI3K)/AKT pro-survival signalling pathway, activation of nuclear factor-kB (NF-kB), and loss-of-function TP53 mutations.

## Clinical presentation, diagnosis and stage

MCL is a heterogenous subtype of B-cell NHL, which remains incurable and typically has a more aggressive disease course compared to indolent NHL. MCL is characterised by involvement of the lymph nodes, spleen, blood, and bone marrow.

The diagnosis is made on a biopsy of a lymph node, tissue, bone marrow, or blood phenotype. Most tumours have a classic morphology of small-medium sized cells with irregular nuclei.

Immunophenotyping is commonly used with the MCL cells being CD20+, CD5+, and positive for Cyclin D1. The hallmark chromosomal translocation t(11:14) (q13;32) that causes overexpression of cyclin D1 can be shown in most cases.

Although some patients obtain prolonged remission after first-line chemoimmunotherapy, many will need several treatment lines. Median OS for patients with MCL was recently presented to be about 5 years, in a non-selected nationwide cohort (n=1367, diagnosed 2006-2018 in Sweden) in which access to BTKi and CAR-T therapy was limited and a majority of patients did not receive rituximab maintenance (Jerkeman et al 2023).

Prognosis of MCL is affected by the clinical presentation, disease stage, and pathologic features. The Mantle Cell Lymphoma International Prognostic Index (MIPI) score prospectively divides patients into low-, intermediate-, and high-risk groups based on age, LDH, white blood cell count, and performance status.

Blastoid and pleomorphic subtypes, as well as high Ki-67 proliferation index ≥50%, are poor prognostic features. In addition, mutated p53 is associated with poor prognosis in MCL patients treated with conventional therapy including transplant.

## Management

<div style=\"page-break-after: always\"></div>

Newly diagnosed patients with MCL have so far typically been categorised into 2 subpopulations defined by their suitability and eligibility for intensive treatment including autologous stem cell transplant (ASCT).

- For most of the younger patients (&lt; 65 years) and transplant-eligible patients, an intensive treatment approach including induction therapy followed by ASCT with rituximab maintenance therapy has represented the present standard of care treatment (ESMO GL 2017). Combination regimens such as R-CHOP/R-DHAP are currently among the standards of care for induction therapy. The inclusion of rituximab maintenance after ASCT in guidelines is based on the LyMa trial (Le Gouill et al 2017) in which rituximab maintenance therapy, administered for 3 years after ASCT, improved OS in fit patients with previously untreated MCL.

In the current US-based National Comprehensive Cancer Network (NCCN) GL (version 1.2025 - Dec 20, 2024) it is stated that the results of the Triangle study (study MCL3003) suggest that alternating R-CHOP + ibrutinib/R-DHAP followed by maintenance ibrutinib + rituximab is an effective induction therapy for patients &lt;66 years of age and consolidation therapy with ASCT could be avoided in this group of patients. However, since first-line consolidation with ASCT has demonstrated promising outcomes in a number of studies and is considered as an appropriate option for consolidation therapy the NCCN GL also include ASCT followed by maintenance ibrutinib + rituximab as an option for patients with a CR following aggressive induction therapy.

- In transplant-ineligible patients, several chemoimmunotherapy combinations followed by rituximab maintenance are currently used. These include BR (rituximab-bendamustine), RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), and also VRCAP (bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone).

Despite intensive approach with ASCT, no curative treatment is available for MCL. Hence, there is an unmet medical need for more effective treatments with different mechanisms of action that provide alternative treatment options for patients with newly diagnosed MCL.

## 2.1.2. About the product

Ibrutinib is a small molecule inhibitor of Bruton's tyrosine kinase (BTK). Ibrutinib forms a covalent bond with a cysteine residue (Cys 481) in the BTK active site, leading to sustained inhibition of BTK enzymatic activity.

BTK, a member of the Tec kinase family, is an important signaling molecule of the B cell antigen receptor (BCR) and cytokine receptor pathways. The BCR pathway is implicated in the pathogenesis of several B cell malignancies, including MCL, diffuse large B cell lymphoma (DLBCL), follicular lymphoma, and CLL. BTK's pivotal role in signaling through the B cell surface receptors results in activation of pathways necessary for B cell trafficking, chemotaxis and adhesion. In preclinical studies, it has been observed that ibrutinib inhibits malignant B-cell proliferation and survival in vivo.

## Previously approved indications:

- -IMBRUVICA as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).
- -IMBRUVICA as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) (see section 5.1).

<div style=\"page-break-after: always\"></div>

- -IMBRUVICA as a single agent or in combination with bendamustine and rituximab (BR) is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.
- -IMBRUVICA as a single agent is indicated for the treatment of adult patients with Waldenström's macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. IMBRUVICA in combination with rituximab is indicated for the treatment of adult patients with WM.

## 2.1.3. The development programme/compliance with CHMP guidance/scientific advice

No scientific advice has been requested to the CHMP. The MAH discussed a potential regulatory submission to extend the indications of ibrutinib based on the results from the 8 th  interim analysis (CCO date of 22 May 2022) of Study MCL3003 with the FDA and the Swedish MPA in 2022.

## 2.1.4. General comments on compliance with GCP

According to the MAH, Study MCL3003 was conducted and reported in accordance with the ethical principles originating in the Declaration of Helsinki and in accordance with ICH GCP guidelines, applicable regulatory requirements, and in compliance with the protocol.

## 2.2. Non-clinical aspects

No new non-clinical data have been submitted in this application, which was considered acceptable by the CHMP.

## 2.2.1. Ecotoxicity/environmental risk assessment

The MAH has provided an updated ERA (according to the new guideline) in support of the extension of existing Mantle Cell Lymphoma (MCL) indication of Imbruvica to include the combination of ibrutinib with R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone) for the treatment of adult patients with previously untreated MCL who are eligible for ASCT (autologous stem cell transplantation). The ERA from the original MAA was updated with regard to predicted environmental concentration (PEC) using a new refined Fpen and resulting risk ratios.

## PBT assessment

The log DOW of ibrutinib was determined to be 3.8 (pH 5); 4.0 (pH 7) and 4.0 (pH 4.0). which is below the action limit of 4.5, and therefore, ibrutinib is not a potential PBT substance. However, since the log DOW is higher than 3,  a fish bioconcentration study was performed. This study demonstrated that bioconcentration factor (BCF) ranged from 13.5 to 68.0 L/kg which is below BCF values of &lt;2000 L/kg. therefore ibrutinib does not bioconcentrate in aquatic systems.

## Phase II Tier A: updated risk ratios (PEC/PNEC)

The previously submitted predicted environmental concentration in surface water PECSURFACEWATER of ibrutinib for MCL, CLL and WM was based on a default market penetration factor (FPEN). The predicted environmental concentration in PECSURFACEWATER of ibrutinib is based on the maximum proposed dose of 560 mg/day and a refined FPEN of 0.00026 (based on IARC data). The resulting PECSURFACEWATER is 0.72 µg

<div style=\"page-break-after: always\"></div>

Risk characterisation ratios (RCR) were calculated for each compartment as the ratio of the PEC/PNEC as follows:

| Parameter          | PEC         | PNEC         | RCR (action limit)              |
|--------------------|-------------|--------------|---------------------------------|
| Surface water      | 0.072 μ g/L | 1.55 μ g/L   | 0.047 (<1)                      |
| Groundwater        | 0.018 μ g/L | 0.155 μ g/L  | 0.117 (<1)                      |
| Microorganism      | 0.072 μ g/L | 100000 μ g/L | 0.00001 (<0.1)                  |
| Sediment           | 0.047 μ g/L | 2.37         | 0.020 (<1)                      |
| Collembola         | 0.001 μ g/L | 17 mg/kg     | 0.0001 (<1)                     |
| Earthworm          | 0.001 mg/kg | 5.20 mg/kg   | 0.0002 (<1)                     |
| Terrestrial plants | 0.001 μ g/L | 0.028        | 0.034 (<1)                      |
| N-transformation   |             |              | <25% effect compared to control |

## 2.2.2. Discussion on non-clinical aspects

No new non-clinical data have been submitted in this application, which is considered acceptable. An updated ERA was provided. The predicted environmental concentration in PECSURFACEWATER of ibrutinib is based on the maximum proposed dose of 560 mg/day and a refined FPEN of 0.00026 (based on IARC data). The resulting PECSURFACEWATER is 0.72 µg. The risk ratios (PEC/PNEC) were subsequently re-calculated which resulted in risk ratios remaining below the action limits. Hence, the clinical use of Imbruvica (in combination with R-CHOP) for the indication of MCL is not expected to pose a risk for the environment.

## 2.2.3. Conclusion on the non-clinical aspects

Based on the updated ERA submitted in this application, the extended indication does not lead to a significant increase in environmental exposure further to the use of ibrutinib.

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The clinical trial was performed in accordance with GCP as claimed by the MAH.

- Tabular overview of the clinical study

<div style=\"page-break-after: always\"></div>

| Study/Phase/Status                                        | Design/crossing                                                                                                                                                                                                                                            | Treatment                                                                                                                                                                                     | N                             | EfficacyEndpoints                                               | MedianTime onStudy        |
|-----------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------|-----------------------------------------------------------------|---------------------------|
| Study 54179060MCL3003 (TRIANGLE, MCL3003) Phase 3 Ongoing | Randomized (1:1:1), 3-arm, open-label,international multicenter trial comparing standard treatmentversus standard treatment (with or without ASCT) combined with ibrutinib in induction and maintenance (2 years) in patients with previously untreatedMCL | Arm A+I(experimental): Alternating3cycles R-CHOP+ibrutinibe(Cycles1,3,5)/3 cycles R-DHAPb (Cycles 2, 4, 6) induction, followed by THAM or BEAM and ASCT, and 2 years ibrutinib maintenance df | ITT: N=292/870 FAS: N=272/809 | Primary:FFS Secondary: OS, PFS,CRR,ORR,PR to CR conversion rate | 54.9 months (range: 0-91) |
| Study 54179060MCL3003 (TRIANGLE, MCL3003) Phase 3 Ongoing | Randomized (1:1:1), 3-arm, open-label,international multicenter trial comparing standard treatmentversus standard treatment (with or without ASCT) combined with ibrutinib in induction and maintenance (2 years) in patients with previously untreatedMCL | Arm I (experimental): Alternating 3 cycles R-CHOPa+ibrutinibe(Cycles 1,L5)/3 cycles R-DHAPb (Cycles 2,4,6) induction, followed by 2 years ibrutinib maintenancedf                             | ITT: N=290/870 FAS: N=268/809 | Primary:FFS Secondary: OS, PFS,CRR,ORR,PR to CR conversion rate | 54.9 months (range: 0-91) |
| Study 54179060MCL3003 (TRIANGLE, MCL3003) Phase 3 Ongoing | Randomized (1:1:1), 3-arm, open-label,international multicenter trial comparing standard treatmentversus standard treatment (with or without ASCT) combined with ibrutinib in induction and maintenance (2 years) in patients with previously untreatedMCL | Arm A (control): Alternating 3 cycles R-CHOPa(Cycles 1, 3, 5)/3 cycles R-DHAPb (Cycles 2, 4, 6) induction followed by THAM or BEAMandASCTd                                                    | ITT: N=288/870 FAS: N=269/809 | Primary:FFS Secondary: OS, PFS,CRR,ORR,PR to CR conversion rate | 54.9 months (range: 0-91) |

## 2.3.2. Pharmacokinetics

No new clinical pharmacological data are provided in the current submission.

## 2.3.3. Pharmacodynamics

No new clinical pharmacological data are provided in the current submission.

## 2.3.4. PK/PD modelling

No new clinical pharmacological data are provided in the current submission.

## 2.3.5. Discussion on clinical pharmacology

The mechanism of action of ibrutinib has been previously well characterised. However, the Phase 3 study TRIANGLE did not include PK sampling of ibrutinib which is considered a limitation in this submission. The potential concern from a PK-perspective is that the co-administered drugs during parts of the induction phase (R-CHOP) could cause drug-drug interactions (DDIs) with ibrutinib. The main risk for a DDI is from an object-perspective since ibrutinib is a CYP3A4 substrate.

The SmPC of Imbruvica states that co-administration with strong CYP3A4 inhibitors and moderate / strong CYP3A4 inducers should only be considered when the potential benefits clearly outweigh the potential risks. In this case, high doses of prednisolone induce CYP3A4 which may lead to lower ibrutinib exposure which could, in theory, lead to lack of efficacy. This concerns the induction phase where ibrutinib is to be co-administered with prednisolone, but not the monotherapy phase where ibrutinib is not co-administered with prednisolone. Despite the potential DDI resulting in lower ibrutinib exposure during the induction phase with coadministration of R-CHOP, the data from the TRIANGLE study suggest sufficient activity (see Discussion of Clinical Efficacy) for the dosing regimen proposed in the target population.

<div style=\"page-break-after: always\"></div>

## 2.3.6. Conclusions on clinical pharmacology

## 2.4. There was no additional pharmacology information submitted with this application, however as discussed above, potential DDI concerns were alleviated as per the clinical effect observed.Clinical efficacy

## 2.4.1. Dose response study(ies)

No dose response studies are provided in the current submission.

The rationale for the use of ibrutinib 560 mg once daily dose in combination with induction immunochemotherapy, followed by ibrutinib maintenance therapy at the same dose, in previously untreated MCL patients was based on the currently registered ibrutinib dose as a single agent for the treatment of adult patients with relapsed or refractory MCL.

- -The rationale for the dosing of ibrutinib in combination with R-CHOP was based on results from a Phase 1b study designed to determine the RP2D and preliminary efficacy data of ibrutinib in combination with R-CHOP in subjects with previously untreated B-cell lymphoma (including MCL; Younes 2014). Participants received the standard R-CHOP regimen every 21 days in combination with ibrutinib 280 mg, 420 mg, or 560 mg daily. While the maximum tolerated dose was not reached, the RP2D for ibrutinib was 560 mg daily. According to the MAH, the combination regimen was generally well tolerated with no new safety signals identified.
- -As data for the ibrutinib in combination with R-DHAP were not available at study start, ibrutinib was not to be administered during the R-DHAP cycles in Study MCL3003.

The rationale for 24 months of ibrutinib maintenance treatment in Study MCL3003 was based on preliminary results from the LyMa trial (Le Gouill 2014) in which rituximab maintenance therapy, administered after ASCT, substantially improved PFS and EFS in young and fit patients with previously untreated MCL. Based on these findings, it was hypothesized that a fixed duration of maintenance therapy with ibrutinib may result in even deeper and more durable remissions when administered after induction immunotherapy (with or without subsequent ASCT).

## 2.4.2. Main study: Pivotal Study MCL3003 (Triangle)

## Overview

MCL3003 is a randomized, 3-arm, parallel-group, open-label, international, multicenter Phase 3 study, conducted by the Klinikum der Universität München, Germany (hereafter referred to as study sponsor) on behalf of the European MCL Network (a network of 15 national and multinational lymphoma study groups) in 13 European countries and in Israel, and financially supported by the MAH.

The MAH was not involved in the study design and the conduct of the study, however the study is the main basis for the proposed extension of indication, proposed to encompass the use of ibrutinib together with ASCT maintenance (Arm A+I) or without ASCT (Arm I).

<div style=\"page-break-after: always\"></div>

Figure 1 Study MCL3003: Schematic Overview of the Study Design

<!-- image -->

## Methods

## Study participants

Key Inclusion criteria (according to protocol version 1.9)

- -Histologically confirmed diagnosis of MCL according to WHO classification 2008
- -Previously untreated MCL
- -Suitable for high-dose treatment including high-dose Ara-C
- -Stage II-IV (Ann Arbor)

-

Age ≥ 18 years and ≤ 65 years

- -ECOG/WHO performance status ≤ 2
- -Absolute neutrophil count (ANC) &gt;1000 cells/uL
- -Platelets &gt;100,000 cells/uL
- -Transaminases (AST and ALT) &lt;3 x upper limit of normal (ULN) and total bilirubin &lt;2x ULN unless due to known Gilbert-Meulengracht-Syndrome
- -Creatinine &lt;2 mg/dL or calculated creatinine clearance &gt;50 mL/min
- -Written informed consent form according to ICH/EU GCP and national regulations

Key Exclusion criteria (according to protocol version 1.9)

- -Major surgery within 4 weeks prior to randomization.
- -History of stroke or intracranial hemorrhage within 6 months prior to randomization.
- -Requires anticoagulation with warfarin or equivalent vitamin K antagonists
- -Requires treatment with strong CYP3A4/5 inhibitors.
- -Known CNS involvement of MCL
- -Previous lymphoma therapy with radiation, cytostatic drugs, anti-CD20 antibody or interferon except prephase therapy outlined in this trial protocol

<div style=\"page-break-after: always\"></div>

- -Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of Screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the New York Heart Association Functional Classification or LVEF below LLN )
- -Pulmonary (chronic lung disease with hypoxemia)
- -Severe, not sufficiently controlled diabetes mellitus
- -Prior organ, bone marrow or peripheral blood stem cell transplantation

## Treatments

Table 1 Definition of Treatment Arms in Study MCL3003

| Arm   | Treatment Regimen (21-day cycles)                                                                                                                                                                    | Group        |
|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|
| A     | Alternating 3 cycles R-CHOP (Cycles 1, 3, and 5)/3 cycles R-DHAP (Cycles 2, 4, and 6) induction followed by high-dose therapy (THAM or BEAM) and ASCT                                                | Control      |
| A+I   | Alternating 3 cycles R-CHOP+ibrutinib (Cycles 1, 3, and 5)/3 cycles R- DHAP (Cycles 2, 4, and 6) induction, followed by high-dose therapy (THAM or BEAM) and ASCT, and 2 years ibrutinib maintenance | Experimental |
| I     | Alternating 3 cycles R-CHOP+ibrutinib (Cycles 1, 3, and 5)/3 cycles R- DHAP (Cycles 2, 4, and 6) induction, followed by 2 years ibrutinib maintenance                                                | Experimental |

## R-CHOP

Rituximab 375 mg/m 2  IV (D0 or 1), cyclophosphamide 750 mg/m 2  IV (D1), doxorubicin 50 mg/m 2  IV (D1), vincristine 1,4 mg/m 2  (max 2 mg) IV (D1), predniso(lo)ne 100 mg oral (D1 to D5)

## R-DHAP

Rituximab 375 mg/m 2  IV (D0 or 1), dexamethasone 40 mg oral (D1 to D4), Ara-C 2x 2 g/m 2  q12h IV (D2), cisplatin 100 mg/m 2  (alternatively oxaliplatin 130 mg/m 2 ) IV (D1). G-CSF 5 μ g/kg SC was mandatory in R-DHAP from D6 daily until recovery of WBC &gt;2.5 G/l (alternatively pegfilgrastim could be applied once at D6)

## High-dose therapy THAM or BEAM

Each site decided before trial activation which ASCT conditioning regimen (THAM or BEAM) would be chosen for all patients.

THAM= total body irradiation (TBI) 10 Gy (D -7 to -5), Ara-C 2x 1,5 g/m 2  q12h IV (D -4 to -3), melphalan 140 mg/m 2  IV (D -2)

BEAM= BCNU 300 mg/m 2  IV (D -7), etoposide 2x 100 mg/m 2  q12h IV (D -6 to -3), Ara-C 2x 200 mg/m 2  q12h IV (D -6 to -3), melphalan 140 mg/m 2  IV (D -2)

## Ibrutinib

Induction :

<div style=\"page-break-after: always\"></div>

560 mg oral (D1 to D19) in combination with R-CHOP cycle 1, 3, and 5.

## Maintenance :

560 mg oral (daily) for 2 years. According to the protocol version 1.9, ibrutinib maintenance should start after regeneration of peripheral blood count after the end of the last cycle of induction therapy (earliest maintenance start at week 18) or ASCT (earliest maintenance start at week 22).

## Rituximab maintenance

As evidence supporting rituximab maintenance treatment was not yet established at the start of the study, rituximab maintenance was not considered a study treatment in Study MCL3003. However, in the original protocol (protocol version 1.1, dated 18 December 2015) it was stated that 'if the recently completely recruited LyMa trial proves a benefit of rituximab maintenance after an ASCT, rituximab maintenance will be added to all 3 study arms depending on national guidelines '.

Since the final results from the LyMa trial (Le Gouill 2017) demonstrated prolonged OS for the rituximab maintenance group after ASCT in patients with previously untreated MCL, this approach has been included in national treatment guidelines in the EU. Thus, following the implementation in the national guidelines for a participating country, rituximab maintenance was to be administered to participants as per the recommendations of the site's study group, and the decision on rituximab maintenance had to be consistent for all 3 study arms to avoid treatment-related bias.

## Objectives and Outcomes/endpoints

Study MCL3003 was designed to establish 1 of the 3 treatment arms as the future standard of care (per the academic study sponsor's original protocol) based on the primary endpoint Failure-free survival (FFS).

More specifically, the sponsor´s intention was to investigate whether adding ibrutinib to the current standard treatment for younger patients with MCL eligible for transplant (which includes induction immunochemotherapy followed by ASCT), would lead to superior outcomes. In addition, the study was designed to determine whether the current standard despite the short- and long-term toxicity remains superior to the same regimen in which ibrutinib is added in induction and maintenance treatment but without ASCT. Finally, the study evaluated whether the addition of ibrutinib to the current standard is superior to the same regimen but without ASCT.

Table 2 Primary and Secondary Efficacy Objectives and Endpoints for Study MCL3003

| Objectives                                                                                                                                                                                                                                                                               | Endpoints                                                                                                      |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|
| Primary                                                                                                                                                                                                                                                                                  |                                                                                                                |
| To establish 1 of 3 treatment arms, - R-CHOP/R-DHAP followed by ASCT (control Arm A ), - R-CHOP+ibrutinib /R-DHAP followed by ASCT and followed by ibrutinib maintenance (experimental Arm A+I ), and - R-CHOP+ibrutinib /R-DHAP followed by ibrutinib maintenance (experimental Arm I ) | FFS (the time from randomization to stable disease at EoI, PD, or death from any cause, whichever comes first) |

<div style=\"page-break-after: always\"></div>

| Objectives                                                                                                                              | Endpoints                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|-----------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| as future standard based on the comparison of FFS assessed by central medical EU MCL Network case evaluation of investigator assessment |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Secondary                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| To compare the efficacy of the 3 treatment arms in terms of secondary efficacy endpoints                                                | OS (the time from randomization to death) PFS (the time to progression or death from any cause) calculated from: o randomization o EoI in patients with CR or PR at EoI o the staging 4 to 6 weeks after the EoI assessment (ie, at month 6 evaluation [pASCT]) a in participants with CR or PR at this point CRR and ORR during the study, b response rate and CRR at EoI and 4 to 6 weeks after EoI, ie, at Month 6 evaluation (pASCT) PR to CR conversion rate during follow-up after EoI (for participants with PR at the EoI) |

a  For comparability of efficacy across the 3 arms, participants in Arm I had an evaluation 4 to 6 weeks after EoI, to align with the evaluation 3 to 5 weeks after ASCT for Arm A and Arm A+I (the pASCT timepoint). Hereafter, 'pASCT' will be used to refer to this timepoint for all 3 arms.

b  These endpoints reflect the best response rates and were not pre-specified in the protocol but were included in the SAP as supportive secondary endpoints.

In case of either stable disease at the end of induction immunochemotherapy (EoI) or progressive disease at any time (proven by CT scan), study treatment had to be stopped, but the participant was expected to remain in the study for further follow-up. Any salvage therapy according to institutional standard could be used after stopping study treatment upon the discretion of the treating physician.

EOI evaluation was performed 3 weeks after completion of the last cycle of chemotherapy.

## Sample size

SAP version 5 states that up to 870 patients from up to 250 international sites were planned to be enrolled. The maximal trial duration would be up to 10 years with up to 5 years of recruitment. The trial may stop earlier based on the result of pre-planned interim analyses.

## Randomisation and Blinding (masking)

After verification of eligibility (registration checklist) patient registration and randomisation were planned to be performed via EDC system. Participants planned to be randomized into the 3 treatment groups.

<div style=\"page-break-after: always\"></div>

allocation ratio was done 1:1:1 unless one treatment group would have been closed; allocation ratio would then be changed to 1:1. Randomisation was stratified according to prespecified regional study groups and Mantle Cell Lymphoma International Prognostic Index (MIPI) risk groups at study entry.

The investigational product was to be labelled and handled as open-label material.

## Statistical methods

## Sample size and timing of interim analyses

The following assumptions were used to estimate the sample size and the trial duration:

- Randomization period up to 5 years
- Additional follow-up period up to 5 years
- Randomization rate 174 per year
- Allocation ratio 1:1:1
- Drop-out rate 5% of randomized patients
- Three pairwise log-rank tests for FFS with local one-sided significance level 0.05/3; overall significance level 5%
- FFS curve for control arm A as estimated from the experimental arm of the preceding MCL Younger trial of the European MCL Network (clinical cut-off date April 7, 2013, section 15.1.4 (CTP\\_Version 1.1\\_18. Dec 2015)
- Power 95% to detect a FFS superiority of A vs. I (hazard ratio 0.60, 5-year FFS: 64.8% vs. 48.5%)
- Power 90% to detect a FFS superiority of A+I vs. A and of A+I vs. I (hazard ratio 0.60, 5-year FFS: 77.1% vs. 64.8%)
- Regular interim analyses to allow early stopping for efficacy or futility by truncated sequential probability ratio tests truncated at 230 events for A vs. I and at 190 events for A+I vs. A and A+I vs. I

Regular pre-planned interim analyses with respect to the primary outcome FFS were planned to be performed for each pairwise comparison to allow early stopping for efficacy or futility. The multiple testing correction for interim analyses was performed using truncated sequential probability ratio tests (Whitehead 1985). For the truncated sequential probability ratio test, the number of interim analyses or the number of events at each interim analysis did not have to be specified in advance. However, regular interim analyses in an approximately half-yearly schedule triggered by the regular meetings of the European MCL Network that took place twice a year were planned. The stopping boundaries were calculated based on the number of events achieved at the time of each interim analysis in line with tSPRT methodology using the Planning and Evaluation of Sequential Trials (PEST) Version 3 software (PEST 1993). The Christmas tree adjustment was used to adjust for the discrete nature of interim analyses.

Based on the truncated sequential probability ratio test, it was concluded that a maximum of 230 events would be needed for the one-sided comparison A vs. I and a maximum of 190 events for comparisons A+I vs. A and A+I vs. I. The planned sample size was approximately 870 participants.

The truncated sequential probability ratio test was also performed for the post-hoc two-sided analyses stated in SAP version 5. It was concluded that the comparison of I vs. A would require at maximum 230 events. Corresponding fixed-sample test (without interim analyses) would require 218 events. The

<div style=\"page-break-after: always\"></div>

comparison A+I vs. A and A+I vs. I would require maximum number of events of 190. Corresponding fixed-sample test (without interim analyses) would require 178 events.

SAP version 5 states that up to 870 patients from up to 250 international sites were planned to be enrolled. The maximal trial duration would be up to 10 years with up to 5 years of recruitment. The trial may stop earlier based on the result of pre-planned interim analyses.

## Endpoints

The analysis of the primary objective were to be performed according to the intention to treat. Thus, all randomised patients were planned to be included in the primary analysis irrespective of eligibility and evaluated according to the treatment arms they were randomly allocated to. No exclusion or censoring was planned to be done in case of protocol violations.

However, it was not possible to adhere to the initially defined primary analysis population according to ITT. The applicant describes the circumstances as follows in the clinical overview:

' Per the European General Data Protection Regulation (GDPR), a study participant must provide explicit permission for the participant's data to be included in a dossier for global HA submissions. As the results from Study MCL3003 were not originally intended by the study sponsor to be included in a dossier for global HA submissions, and due to the timing of the GDPR regulation becoming effective (25 May 2018), such explicit permission was not required to be requested within the original study ICF.

Therefore, the ICF was updated in 2023 and of the 870 participants randomized to the study (ITT analysis set: Arm A+I: 292; Arm I: 290; Arm A: 288), 809 participants (272, 268, and 269 for Arm A+I, Arm I and Arm A, respectively) have either provided explicit permission in the ICF for their data to be included in a dossier for global HA submissions or were deceased. These 809 participants (93% of the ITT analysis set) are referred to throughout the submission documents as the FAS. '

Consequently, post-hoc SAP version 5 (dated 5 September 2024) states that all analyses prepared by the applicant would contain all randomized participants who had provided explicit consent for their data to be used by the applicant for health authority submissions and participants who are deceased (Full Analysis Set). The safety analysis set would include all participant of the FAS who received at least 1 dose of study intervention.

## Analysis methods for primary efficacy endpoint

The primary endpoint FFS, was defined according to protocol, as the time from randomisation to stable disease at end of induction immuno-chemotherapy, progressive disease, or death from any cause, whichever came first. The primary endpoint was FFS assessed by central medical EU MCL Network case evaluation of investigator assessment. Three pairwise one-sided statistical hypothesis tests (A vs. I, A+I vs. A, and A+I vs. I) were planned to be performed using the log-rank statistic for FFS.

The hypotheses of these three log-rank tests are described as follows:

- FFS comparison Control arm A (R-CHOP/R-DHAP followed by ASCT) vs. Experimental arm I (RCHOP+ibrutinib/R-DHAP followed by ibrutinib maintenance)
- o H0: A is not superior to I
- o H1: A is superior to I
- FFS comparison Experimental arm A+I (R-CHOP+ibrutinib/R-DHAP followed by ASCT and ibrutinib maintenance) vs. Control arm A (R-CHOP/R-DHAP followed by ASCT)
- o H0: A+I is not superior to A

<div style=\"page-break-after: always\"></div>

- o H1: A+I is superior to A
- FFS comparison Experimental arm A+I (R-CHOP+ibrutinib/R-DHAP followed by ASCT and ibrutinib maintenance) vs. Experimental arm I (R-CHOP+ibrutinib/R-DHAP followed by ibrutinib maintenance)
- o H0: A+I is not superior to I
- o H1: A+I is superior to I

For each pairwise test, the local one-sided significance level was planned to be 0.05/3 =0,0167 such that a global significance level of 5% would be maintained (Bonferroni-correction for multiple testing).

The formal decision for the new standard would be taken based on the results for the three pairwise statistical tests. According to protocol, for the primary analysis, p-values and hazard ratios for the treatment effects would be calculated correcting for the sequential design.

Post-hoc SAP version 5 (dated 5 September 2024) specified additional post-hoc analyses to support regulatory assessment of the proposed indication. The following hypotheses were planned to be performed to support the initial primary analyses that were specified in the protocol.

FFS two-sided comparison based on log-rank test of hypotheses I vs. A; A+I vs A and A+I vs I with alpha at 0.05/3 (0.0167) for each comparison.

- FFS one-sided comparison based on log-rank test of hypotheses I vs. A; A+I vs A and A+I vs I with alpha at 0.025/3 (0.0083) for each comparison.

Post-hoc SAP version 5 state the following as primary estimator:

- Median unbiased estimator (MUE) of hazard ratio with one-sided 98.33% CI was planned to be the primary estimator (correcting for sequential analyses) according to the prespecified primary analysis in the protocol. Overrunning analyses would incorporate data collected after the formal decision of each sequential test. Kaplan-Meier method would be used to estimate the distribution of FFS for each treatment group.
- One-sided unstratified log-rank test for statistical significance at the 1.667% level (after Bonferroni correction for pairwise treatment group comparison) would be conducted, correcting for sequential analyses. Post hoc analysis based on the two-sided log-rank test for statistical significance at the 1.667% level (one-sided log-rank test for statistical significance at the 0.83% level) would also be conducted.
- Unstratified Cox's regression model with study treatment (Treatment groups) as the sole explanatory variable would be performed to provide hazard ratio with one-sided 98.33% CIs.

## Censoring rules, handling of missing data and Intercurrent events

According to protocol, patients alive without failure at latest contact were planned to be censored at the latest tumour assessment date. Patients without any lymphoma restaging during or at end of induction were planned to be censored at the date of randomisation.

According to SAP version 5, derivation of FFS would use the following data: date of randomisation, end of induction response, date of first progression, date of death, date of end of induction staging, last date without progression. Patients with stable disease at the end of induction therapy or with progressive disease or death at any time from any cause have an FFS event. If two or more FFS events occurred, the earlier event would count for FFS evaluation. In patients with complete or partial response at the end of induction therapy and without progression or death, FFS would be censored at

<div style=\"page-break-after: always\"></div>

the last adequate disease assessment date. Patients without any lymphoma disease evaluation during or at the end of induction were planned to be censored one day after randomization.

As the TRIANGLE protocol was written prior to the adoption of (ICHE9[R1] 2019), estimands were not defined and explicitly pre-specified in the protocol. However, because this is currently expected by regulators and other stakeholders, estimands were defined explicitly in the SAP for the primary endpoint and the key secondary endpoints of PFS and OS. Intercurrent event Treatment discontinuation due to AE or reasons other than AE or worsening of disease would be handled using treatment policy. Use of subsequent anticancer therapy would be handled with both treatment policy and hypothetical strategy in which participants would not use any subsequent anti-cancer therapies, as they would not have been available.

## Sensitivity analyses

The protocol stated that after the decision of the confirmatory statistical test, secondary efficacy endpoints would be compared between the three treatment groups. As secondary sensitivity analysis for the primary analyses of FFS, a modified intention-to-treat cohort would be used including randomised patients with confirmed MCL who started induction immuno-chemotherapy according to the randomly allocated treatment arm.

## According to post-hoc SAP version 5, the following was stated

## Sensitivity estimator 1

- A stratified Cox regression model with study treatment as the sole explanatory variable, with the MIPI risk group as stratification factor, was planned to be performed for FFS.

In case stratified log-rank test and stratified Cox regression model causes any convergence issue due to small number of events, stratified log-rank and stratified Cox regression model would be conducted by combining the stratum level with convergence issue.

## Sensitivity estimator 2

- A stratified Cox regression model with study treatment as the sole explanatory variable, with Rituximab maintenance status (Yes or No) as stratification factor, was planned to be performed for FFS.

Of note, as per protocol, study group was specified as one of the stratification factors in the randomization of the study. Due to the large number of categories in study group stratification factor, Rituximab maintenance status is used as a substitute stratification factor in this sensitivity analysis

- An unstratified Cox's regression model with study treatment (Treatment groups) as the sole explanatory variable was planned to be performed to analyse FFS by investigator.

## Subgroup analyses

According to the protocol, subgroup analyses would be performed according to MIPI, Ki-67 index, remission status (CR vs. PR) at end of induction immuno-chemotherapy, and remission status 3 months after end of induction immuno-chemotherapy. For subgroup analyses, statistical tests would be done in multivariable regression models on the interaction term of treatment group and the subgroup indicator including the main effects treatment group and subgroup indicator.

Sex, MIPI risk group, Ki-67 index, Cytology (MCL), p53 expression and Rituximab maintenance are defined as subgroups in post-hoc SAP. The subgroup analyses were planned to be performed using the multivariate Cox regression model that include treatment group and subgroup indicator as main effects and treatment-by-subgroup interaction in the model.

<div style=\"page-break-after: always\"></div>

## Changes from protocol specified analyses

The following post-hoc analyses were stated in the SAP version 5

- Estimands were specified for FFS, PFS and OS
- PFS calculated from randomisation will be considered as the primary PFS endpoint and the other 2 will be considered supportive.
- Additional analyses of the 2-sided tests at an overall 5% significance level (individual 1.67% significance level) and 1-sided test at an overall 2.5% significance level (individual 0.833% significance level) based on the log-rank test statistic were not pre-specified in the protocol. These analyses were specified in the SAP to support the primary analysis.
- FFS stratified by MIPI; FFS stratified by Rituximab status; FFS by investigator assessment were specified in SAP version 5 as sensitivity analyses.
- FFS; censored at the last disease assessment showing evidence of neither stable disease at EoI therapy nor evidence of PD before subsequent anticancer therapy.\\\\

## Results

## Participant flow

Figure 2 Consort diagram of the Treatment disposition of participants in study MCL3003

<!-- image -->

Table 3 Treatment Disposition FAS Study MCL3003

<div style=\"page-break-after: always\"></div>

|                                           | A+I          | I            | A           | Total       |
|-------------------------------------------|--------------|--------------|-------------|-------------|
| Analysis set: Full                        | 272          | 268          | 269         | 809         |
| Subjects randomized but not treated       | 0            | 0            | 1 (0.4%)    | 1 (0.1%)    |
| Subjects who received study treatment     | 272 (100.0%) | 268 (100.0%) | 268 (99.6%) | 808 (99.9%) |
| Subjects who completed treatment          | 132 (48.5%)  | 180 (67.2%)  | 234 (87.0%) | 546 (67.5%) |
| Subjects who are still on treatment       | 0            | 0            | 0           | 0           |
| Subjects who discontinued study treatment | 140 (51.5%)  | 88 (32.8%)   | 34 (12.6%)  | 262 (32.4%) |
| Adverse event                             | 106 (39.0%)  | 57 (21.3%)   | 6 (2.2%)    | 169 (20.9%) |
| Asservation failure                       | 0            | 0            | 4 (1.5%)    | 4 (0.5%)    |
| Death                                     | 0            | 1 (0.4%)     | 0           | 1 (0.1%)    |
| Investigator or sponsor decision          | 0            | 1 (0.4%)     | 0           | 1 (0.1%)    |
| Non compliance                            | 0            | 1 (0.4%)     | 0           | 1 (0.1%)    |
| Other a                                   | 10 (3.7%)    | 3 (1.1%)     | 6 (2.2%)    | 19 (2.3%)   |
| Progressive disease                       | 14 (5.1%)    | 17 (6.3%)    | 12 (4.5%)   | 43 (5.3%)   |
| Stable disease at end of induction        | 1 (0.4%)     | 1 (0.4%)     | 2 (0.7%)    | 4 (0.5%)    |
| Subject refuses treatment                 | 4 (1.5%)     | 5 (1.9%)     | 2 (0.7%)    | 11 (1.4%)   |
| Unknown                                   | 1 (0.4%)     | 0            | 0           | 1 (0.1%)    |
| Withdrawal of consent                     | 4 (1.5%)     | 2 (0.7%)     | 2 (0.7%)    | 8 (1.0%)    |

Key: ASCT=autologous stem cell transplant, A=ASCT, A+I=ASCT+Ibrutinib, I=Ibrutinib, MCL=Mantle Cell Lymphoma.

a Other includes eg, non-MCL diagnosis at baseline and errors.

Note: Percentages are calculated with the number of subjects in the full analysis set in each treatment group as the denominators.

Table 4 Subject Disposition FAS Study MCL3003

|                                  | A+I         |             | A           | Total       |
|----------------------------------|-------------|-------------|-------------|-------------|
| Analysis set: Full               | 272         | 268         | 269         | 809         |
| Completed                        | 34 (12.5%)  | 33 (12.3%)  | 60 (22.3%)  | 127 (15.7%) |
| Still ongoing                    | 230 (84.6%) | 229 (85.4%) | 206 (76.6%) | 665 (82.2%) |
| Discontinued study participation | 8 (2.9%)    | 6 (2.2%)    | 3 (1.1%)    | 17 (2.1%)   |
| Reasonfordiscontinuation         |             |             |             |             |
| Withdrawalofconsent              | 8 (2.9%)    | 6 (2.2%)    | 3 (1.1%)    | 17 (2.1%)   |
| Losttofollow-up                  | 0           | 0           | 0           | 0           |
| Other reason                     | 0           | 0           | 0           | 0           |

Key: ASCT=autologous stem cell transplant, A=ASCT, A+I=ASCT+Ibrutinib,I=Ibrutinib.

Note: Percentages are calculated with the number of subjects in the full analysis set in each treatment group as the denominators.

## Recruitment

Study Period : 25 July 2016 (date first participant signed informed consent) to 09 May 2024 (CCO and date of last observation recorded as part of the database for this CSR).

Number of Study Centers and Countries/Territories: This study was conducted at 165 sites that enrolled participants in 13 European countries and in Israel: Czech Republic (4 sites), Germany (49 sites), Italy (31 sites), Portugal (1 site), the Netherlands (22 sites), Belgium (5 sites), Denmark (6

<div style=\"page-break-after: always\"></div>

sites), Finland (1 site), Norway (4 sites), Sweden (8 sites), Poland (7 sites), Spain (14 sites), Switzerland (8 sites), and Israel (5 sites).

## Conduct of the study

## Protocol amendments

Changes in the conduct of the study were implemented by 7 protocol amendments.

Table 5 A selection of the substantial amendments of the study protocol

| Protocol amendment Protocol version and date   | Substantial / non- substantial   | Description of changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|------------------------------------------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 01 1.2 12 May 2016                             | Substantial                      | General editorial amendments throughout Revisions to: • THAM dose: study day of administration • Schedule of treatments and assessments: corrections and clarifications • Clinical safety; addition of sub-section interstitial lung disease • Myeloablative treatment • Interruption of ibrutinib therapy if patients experience specific gastrointestinal events • Assessments completed in cases of progressive disease during study treatment • SAE reporting timeline • Quality complaint reporting timeline • EoT assessment updated to EoI assessment for |
| 02 1.3 07 February 2017                        | Substantial                      | General editorial amendments throughout Revisions to: • Inclusion criteria: specifically, approved contraceptive methods • Pharmacokinetics of ibrutinib; supportive data from in vitro studies • Treatment related lymphocytosis • Clinical safety; updated the safety data profile to present data from 1,944 subjects rather than 1,637, addition of reported events of hypertension, secondary primary malignancies and non-melanoma skin cancer                                                                                                             |

<div style=\"page-break-after: always\"></div>

| Protocol amendment Protocol version and date   | Substantial / non- substantial   | Description of changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|------------------------------------------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                |                                  | • Risk-benefit assessment • Interruption of R-CHOP/R-DHAP/ ibrutinib therapy in the event of insufficient blood level recovery, persistent Grade >2 AEs, hematological or treatment associated toxicity • Timing of scheduled assessments to allow scheduled assessments and treatments to be performed within a timeframe of ±4 days except for the last intake of ibrutinib and the first day of the following R-DHAP which should be at least 3 days to ensure an adequate drug washout                                                                                                                                                            |
| 03 1.4 24 May 2018                             | Substantial                      | • SAE reporting criteria General editorial amendments throughout Revisions to: • Inclusion criteria: specifically approved contraceptive methods up to 12 months following rituximab therapy • Exclusion criteria: positive test results for HBV, hepatitis B and C infections • Clinical safety; updated safety data pool, addition of reported events of bleeding-related events, infections, and cardiac arrhythmias • Interruption of ibrutinib therapy if patients experience specific cardiac events. Associated study drug disposition and compliance. • Stem cell mobilization and harvest • Survival follow-up assessment of salvage therapy |
| 04 1.6 19 November 2019                        | Substantial                      | General editorial amendments throughout Revisions to: • Study flow chart and schedule of assessments; follow- up assessments • Ibrutinib maintenance therapy: ibrutinib maintenance therapy could be resumed at full dose even if dose reduced during induction • Tumor and response assessments; bone marrow biopsies • Timing of baseline examinations                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

| Protocol amendment Protocol version and date   | Substantial / non- substantial   | Description of changes                                                                                                                                                                                                                                                          |
|------------------------------------------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                |                                  | • Assessments completed during observation, without treatment • eCRF reporting                                                                                                                                                                                                  |
| 05 1.7 10 August 2020                          | Substantial                      | General editorial amendments throughout Revisions to: • Clinical safety; updated safety data pool, addition of reported events of leukostasis, hypertension, cerebrovascular accidents • Blood sample collections                                                               |
| 06 1.8 10 June 2021                            | Substantial                      | General editorial amendments throughout Revisions to: • Non-clinical data on ibrutinib • Pharmacokinetics of ibrutinib; use of CYP3A inhibitors in subjects with hematological malignancies • Clinical safety; infections, cardiac arrhythmias, rash, cerebrovascular accidents |
| 07 1.9 12 April 2023                           | Substantial                      | General editorial amendments throughout Revisions to: • Management of cardiac toxicity during ibrutinib therapy with instructions to withhold ibrutinib therapy in the event of new or worsening Grade 2 cardiac failure or cardiac arrhythmias.                                |

With regard to COVID-19-related changes in study conduct, the sponsor provided guidance on how to manage study visits in view of COVID-19-related restrictions considering the 'Guidance on the Management of Clinical Trials during the COVID-19 pandemic' Version No. 1 dated 20/03/2020 by the EMA and the European Commission. To maintain data quality and integrity, the following actions were also taken (i) remote monitoring visits were implemented whenever local COVID-19 restrictions prevented in-person monitoring visits, (ii) safety analyses of COVID-19-related TEAEs and deaths were included, and (iii) AEs were coded using MedDRA version 26.1, which includes specific terms for COVID-19 related AEs.

## Protocol deviations

A summary of major protocol deviations, defined as any deviation that directly impacted participants rights, safety, or wellbeing, or the integrity and/or results of the clinical study, is provided in table below.

Table 6 Summary of Subjects with Major Protocol Deviations, FAS, Study MCL3003

<div style=\"page-break-after: always\"></div>

|                                                 | A+I       | I          | A         | Total     |
|-------------------------------------------------|-----------|------------|-----------|-----------|
| Analysis set: Full                              | 272       | 268        | 269       | 809       |
| Subjects with major protocol deviations         | 23 (8.5%) | 28 (10.4%) | 11 (4.1%) | 62 (7.7%) |
| Developed withdrawal criteria but not withdrawn | 0         | 0          | 0         | 0         |
| Entered butdid notsatisfycriteria               | 18 (6.6%) | 12 (4.5%)  | 8 (3.0%)  | 38 (4.7%) |
| Receivedadisallowedconcomitant treatment        | 1 (0.4%)  | 5 (1.9%)   | 1 (0.4%)  | 7 (0.9%)  |
| Received wrong treatment or incorrect dose      | 4 (1.5%)  | 8 (3.0%)   | 1 (0.4%)  | 13 (1.6%) |
| Other                                           | 2 (0.7%)  | 4 (1.5%)   | 2 (0.7%)  | 8 (1.0%)  |

Key: ASCT=autologous stem cell transplant, A=ASCT, A+I=ASCT+Ibrutinib, I=Ibrutinib.

Note: Subjects may appear in more than one category.

## Baseline data

Demographics and Baseline Characteristics

Table 7 Demographics and Baseline Characteristics, FAS, Study MCL3003

|                           | A+I         | I           | A           | Total       |
|---------------------------|-------------|-------------|-------------|-------------|
| Analysis set: Full        | 272         | 268         | 269         | 809         |
| Age , years               |             |             |             |             |
| N                         | 272         | 268         | 269         | 809         |
| Median                    | 57.0        | 57.0        | 57.0        | 57.0        |
| Range                     | (36; 68)    | (27; 65)    | (31; 65)    | (27; 68)    |
| 26-50                     | 52 (19.1%)  | 58 (21.6%)  | 48 (17.8%)  | 158 (19.5%) |
| 51-64                     | 206 (75.7%) | 202 (75.4%) | 204 (75.8%) | 612 (75.6%) |
| >=65                      | 14 (5.1%)   | 8 (3.0%)    | 17 (6.3%)   | 39 (4.8%)   |
| Sex                       |             |             |             |             |
| N                         | 272         | 268         | 269         | 809         |
| Female                    | 70 (25.7%)  | 54 (20.1%)  | 64 (23.8%)  | 188 (23.2%) |
| Male                      | 202 (74.3%) | 214 (79.9%) | 205 (76.2%) | 621 (76.8%) |
| Race                      |             |             |             |             |
| N                         | 272         | 268         | 269         | 809         |
| Asian                     | 1 (0.4%)    | 0           | 0           | 1 (0.1%)    |
| Black or African American | 1 (0.4%)    | 0           | 0           | 1 (0.1%)    |

<div style=\"page-break-after: always\"></div>

|                       | A+I         | I            | A           | Total       |
|-----------------------|-------------|--------------|-------------|-------------|
| White                 | 263 (96.7%) | 268 (100.0%) | 264 (98.1%) | 795 (98.3%) |
| Other                 | 7 (2.6%)    | 0            | 5 (1.9%)    | 12 (1.5%)   |
| Study Group           |             |              |             |             |
| N                     | 272         | 268          | 269         | 809         |
| Czech Republic: CLSG  | 6 (2.2%)    | 6 (2.2%)     | 4 (1.5%)    | 16 (2.0%)   |
| Nordic Lymphoma Group | 34 (12.5%)  | 34 (12.7%)   | 33 (12.3%)  | 101 (12.5%) |
| Germany, GLA/GLSG     | 91 (33.5%)  | 87 (32.5%)   | 88 (32.7%)  | 266 (32.9%) |
| Israelian Study group | 0           | 0            | 0           | 0           |
| Italy: FIL            | 66 (24.3%)  | 64 (23.9%)   | 65 (24.2%)  | 195 (24.1%) |
| Netherlands/Belgium   | 30 (11.0%)  | 31 (11.6%)   | 32 (11.9%)  | 93 (11.5%)  |
| Poland                | 10 (3.7%)   | 11 (4.1%)    | 11 (4.1%)   | 32 (4.0%)   |
| Portugal              | 2 (0.7%)    | 1 (0.4%)     | 1 (0.4%)    | 4 (0.5%)    |
| Spain                 | 23 (8.5%)   | 23 (8.6%)    | 24 (8.9%)   | 70 (8.7%)   |
| Switzerland           | 10 (3.7%)   | 11 (4.1%)    | 11 (4.1%)   | 32 (4.0%)   |

ASCT=autologous stem cell transplant, A=ASCT, A+I=ASCT+Ibrutinib, I=Ibrutinib, SD=standard deviation, Q1=first quartile, Q3=third quartile.

Note: N's for each parameter reflect non-missing values.

Note: Baseline results include values collected outside of the 28-day screening window.

Note: Percentages are calculated with the number of subjects in each treatment group with available data as denominator.

Table 8 Baseline Disease Characteristics, FAS, Study MCL3003

|                    | A+I         | I           | A           | Total       |
|--------------------|-------------|-------------|-------------|-------------|
| Analysis set: Full | 272         | 268         | 269         | 809         |
| MIPI Risk Group a  |             |             |             |             |
| N                  | 272         | 268         | 269         | 809         |
| Low risk           | 155 (57.0%) | 152 (56.7%) | 153 (56.9%) | 460 (56.9%) |
| Intermediate risk  | 76 (27.9%)  | 76 (28.4%)  | 75 (27.9%)  | 227 (28.1%) |
| High risk          | 41 (15.1%)  | 40 (14.9%)  | 41 (15.2%)  | 122 (15.1%) |

<div style=\"page-break-after: always\"></div>

|                         | A+I         | I           | A           | Total       |
|-------------------------|-------------|-------------|-------------|-------------|
| ECOG Performance Status |             |             |             |             |
| N                       | 272         | 267         | 266         | 805         |
| 0                       | 199 (73.2%) | 187 (70.0%) | 191 (71.8%) | 577 (71.7%) |
| 1                       | 71 (26.1%)  | 75 (28.1%)  | 71 (26.7%)  | 217 (27.0%) |
| 2                       | 2 (0.7%)    | 5 (1.9%)    | 4 (1.5%)    | 11 (1.4%)   |
| Ki-67                   |             |             |             |             |
| N                       | 244         | 239         | 235         | 718         |
| <30%                    | 168 (68.9%) | 161 (67.4%) | 157 (66.8%) | 486 (67.7%) |
| >=30%                   | 76 (31.1%)  | 78 (32.6%)  | 78 (33.2%)  | 232 (32.3%) |
| Not done                | 28          | 29          | 34          | 91          |
| p53 expression          |             |             |             |             |
| N                       | 161         | 177         | 170         | 508         |
| <=50%                   | 138 (85.7%) | 149 (84.2%) | 149 (87.6%) | 436 (85.8%) |
| >50%                    | 23 (14.3%)  | 28 (15.8%)  | 21 (12.4%)  | 72 (14.2%)  |
| Not done                | 111         | 91          | 99          | 301         |
| Cytology (MCL)          |             |             |             |             |
| N                       | 244         | 246         | 238         | 728         |
| Blastoid/Pleomorphic    | 32 (13.1%)  | 29 (11.8%)  | 27 (11.3%)  | 88 (12.1%)  |
| Classic/Small cell      | 212 (86.9%) | 217 (88.2%) | 211 (88.7%) | 640 (87.9%) |
| Not done                | 28          | 22          | 31          | 81          |
| Rituximab maintenance   |             |             |             |             |
| N                       | 272         | 268         | 269         | 809         |
| Yes                     | 163 (59.9%) | 160 (59.7%) | 168 (62.5%) | 491 (60.7%) |
| No                      | 109 (40.1%) | 108 (40.3%) | 101 (37.5%) | 318 (39.3%) |
| Diagnosis               |             |             |             |             |
| N                       | 272         | 268         | 269         | 809         |
| MCL                     | 269 (98.9%) | 266 (99.3%) | 267 (99.3%) | 802 (99.1%) |

<div style=\"page-break-after: always\"></div>

|                         | A+I         | I           | A           | Total       |
|-------------------------|-------------|-------------|-------------|-------------|
| Other                   | 3 (1.1%)    | 2 (0.7%)    | 2 (0.7%)    | 7 (0.9%)    |
| Ann Arbor stage         |             |             |             |             |
| N                       | 272         | 268         | 267         | 807         |
| I                       | 0           | 0           | 1 (0.4%)    | 1 (0.1%)    |
| II                      | 11 (4.0%)   | 16 (6.0%)   | 8 (3.0%)    | 35 (4.3%)   |
| III                     | 21 (7.7%)   | 26 (9.7%)   | 22 (8.2%)   | 69 (8.6%)   |
| IV                      | 240 (88.2%) | 226 (84.3%) | 236 (88.4%) | 702 (87.0%) |
| Bone marrow involvement |             |             |             |             |
| N                       | 266         | 261         | 261         | 788         |
| Yes                     | 203 (76.3%) | 200 (76.6%) | 209 (80.1%) | 612 (77.7%) |
| No                      | 57 (21.4%)  | 57 (21.8%)  | 49 (18.8%)  | 163 (20.7%) |
| Unknown                 | 6 (2.3%)    | 4 (1.5%)    | 3 (1.1%)    | 13 (1.6%)   |

Key: ASCT=autologous stem cell transplant, A=ASCT, A+I=ASCT+Ibrutinib, I=Ibrutinib, MIPI=Mantle Cell Lymphoma International Prognostic Index, ECOG=Eastern Cooperative Oncology Group, a Patients were stratified by mantle cell lymphoma international prognostic index (MIPI) score (low risk [&lt;5.7] vs. intermediate risk [&gt;=5.7 and &lt;6.2] vs. high risk [&gt;=6.2) in MCL3003.

Note: Baseline results include values collected outside of the 28-day screening window.

Note: Percentages are calculated with the number of subjects in each treatment group with available data as denominator.

## Comparison of Baseline data FAS vs ITT Population

Table 9 Baseline Demographic and Disease Characteristics for FAS vs ITT Population

<div style=\"page-break-after: always\"></div>

| Variable                                               | ArmA                                                      | ArmA                                            | Arm A+I                                      | Arm A+I                                          | ArmI                                          | ArmI                                              |
|--------------------------------------------------------|-----------------------------------------------------------|-------------------------------------------------|----------------------------------------------|--------------------------------------------------|-----------------------------------------------|---------------------------------------------------|
|                                                        | ITI, N=288                                                | FAS, N=269                                      | ITT, N=292                                   | FAS, N=272                                       | ITT, N=290                                    | FAS, N=268                                        |
| Age (years)*, Median (IQR)                             | 57 (52 -61)                                               | 57 (53 -61)                                     | 57 (52 -61)                                  | 57 (52 -61)                                      | 57.5 (52 -61)                                 | 57 (52 - 61)                                      |
| Sex, Male n (%)                                        | 218 (76%)                                                 | 205 (76%)                                       | 216 (74%)                                    | 202 (74%)                                        | 228 (79%)                                     | 214 (80%)                                         |
| Race                                                   |                                                           |                                                 |                                              |                                                  |                                               |                                                   |
| White or Caucasian n (%) Other n (%)                   | 283 (98%) 5 (2%)                                          | 264 (98%) 5 (2%)                                | 283 (97%) 9 (3%)                             | 263 (97%) 7 (3%)                                 | 290 (100%) 0 (0%)                             | 268 (100%) 0 (0%)                                 |
| Amn Arbor Stage                                        |                                                           |                                                 |                                              |                                                  |                                               |                                                   |
| In (%) IIn (%) Ⅲn (%) IVn (%) B-symptoms,Present n (%) | (%0) 0 11/285 (4%) 24/285 (8%) 250/285 (88%) 72/285 (25%) | 1/267 (0%) 8/267 (3%) 22/267 (8%) 236/267 (88%) | 0 (0%) 12/290 (4%) 21/290 (7%) 257/290 (89%) | 0/272 (0%) 11/272 (4%) 21/272 (8%) 240/272 (88%) | 0 (0%) 18/289 (6%) 29/289 (10%) 242/289 (84%) | 0/268 (0%) 16/268 (6%) 26/268 (10%) 226/268 (84%) |
| ECOG                                                   |                                                           |                                                 |                                              |                                                  |                                               |                                                   |
| 0n (%)                                                 | 213 (74%)                                                 | 191 (72%) 71 (27%)                              | 213 (73%) 77 (26%)                           | 199 (73%) 71 (26%)                               | 208 (72%) 77 (27%)                            | 187 (70%) 75 (28%)                                |
| 1 n (%) 2 n (%)                                        | 70 (24%)                                                  |                                                 |                                              | 2 (1%)                                           | 5 (2%)                                        |                                                   |
| LDH, >ULNn (%)                                         | 5 (2%)                                                    | 4 (2%)                                          | 2 (1%) 120 (41%)                             | 105 (39%)                                        | 105 (36%) 7.4 (5.77 - 11.92)                  | 5 (2%)                                            |
| Leukocytes (WBC, G/L), Median (IQR)                    | 7.34 (5.50 -10.91)                                        | 7.4 (5.7- 12.1)                                 | 7.09 (5.28 - 11.11)                          |                                                  |                                               | 7.8 (6.0- 12.0)                                   |
|                                                        | 123 (43%)                                                 | 114 (43%)                                       |                                              | 7.0 (5.2 - 11.0)                                 | 168 (58%)                                     | 93 (35%)                                          |
| MIPI score Low n (%)                                   | 168 (58%) 79 (27%)                                        | 153 (57%) 75 (28%)                              | 168 (58%) 80 (27%)                           | 155 (57%) 76 (28%)                               | 77 (27%)                                      | 152 (57%) 76 (28%)                                |
|                                                        | 41 (14%)                                                  | 78/235 (33%)                                    | 44 (15%)                                     |                                                  | 45 (16%)                                      |                                                   |
| Intermediate n (%) High n (%)                          |                                                           | 41 (15%)                                        |                                              | 41 (15%)                                         |                                               | 40 (15%)                                          |
| Ki-67 index, ≥30% n (%)                                |                                                           |                                                 |                                              |                                                  |                                               |                                                   |
| p53 expression, >50% n (%)                             | 81/249 (33%)                                              | 21/170 (12%)                                    | 81/262 (31%)                                 | 76/244 (31%)                                     | 82/259 (32%)                                  | 78/239 (33%)                                      |
|                                                        |                                                           |                                                 | 25/175 (14%)                                 |                                                  |                                               |                                                   |
|                                                        | 21/183 (11%)                                              |                                                 |                                              | 23/161 (14%)                                     | 31/189 (16%)                                  | 28/177 (16%)                                      |

ECOG=Eastem Cooperative Oncology Group; IQR=interquartile range; LDH=lactate dehydrogenase; MCL=mantle cell lymphoma; MIPI=Mantle Cell Lymphoma Intermational Prognostic Index; ULN=upper limit of normal

*Notes for ITT population: 1 patient aged 68 years and 1 patient aged 66 years were randomized in Arm A+I.

ECOG=Eastem Cooperative Oncology Group;IQR=interquartile range;LDH=lactate dehydrogenase; MCL=mantle cell lymphoma; MIPI=Mantle Cell Lymphoma IntemationalPrognosticIndex; ULN=upperlimit of normal

*Notes for ITT population: 1 patient aged 68 years and 1 patient aged 66 years were randomized in Arm A+I.

## Concomitant therapy

The most common concomitant medications received were: Immunostimulants (Arm A+I: 96.7%, Arm I: 95.8%, Arm A:95.9%), Antibacterials for systemic use (Arm A+I: 96.4%, Arm I: 93.6%; Arm A: 97.0%), and Antiemetics (Arm A+I: 91.6.%, Arm I: 90.2%, Arm A: 88.1%).

Concomitant medications with a difference ≥10% between any arm included: Antivirals for systemic use (higher in Arm A+I (90.2%) and Arm A (81.3%) compared with Arm I (67.9%)), Antimycotics for systemic use (higher in Arm A+I (66.9%) and Arm A (66.0%) compared with Arm I (42.6%)).

The use of antithrombotic agents (including factor X inhibitors and platelet aggregation inhibitors other than heparin) was common and similar between the treatment arms (54.5%, 46.8%, and 51.5% in Arm A+I, Arm I and Arm A, respectively). No participant in the ibrutinib-containing arms received a vitamin K antagonist.

The percentage of participants who received any type of transfusion (blood products) during the study was 26.5%, 18.1%, and 20.5% in participants from Arm A+I, Arm I, and Arm A, respectively.

## Numbers analysed

## Table 10 Data sets analysed

|                                | Arm A+I   | ArmI   |   Arm A |   Total |
|--------------------------------|-----------|--------|---------|---------|
| Randomized (Dreyling 2024 [a]) | 292       | 290    |     288 |     870 |
| FAS                            | 272       | 268    |     269 |     809 |
| Safety Analysis Set            | 275*      | 265*   |     268 |     808 |

FAS: all randomized participants who have provided explicit consent for their data to be included by the Applicant for global HA submissions and participants who are deceased.

*Three participants who were randomly assigned to Arm I, received ASCT, therefore are considered as part of Arm A+I for safety analysis and reporting.

<div style=\"page-break-after: always\"></div>

## Outcomes and estimation

## Primary endpoint FFS

The presented primary analysis of study MCL3003 is based on the FAS (n=809) with CCO date of 09 May 2024 and a median time on study for all participants of 54.9 months. In the table below, both the one-sided Primary analysis (as pre-specified in the original protocol) and the two-sided Additional analyses are presented.

<div style=\"page-break-after: always\"></div>

Table 11 Summary of FFS, FAS, Study MCL3003

|                                                   | A+I N=272                          | I N=268                            | A N=269                            | A+I vs A         | A vs I           | I vs A b   | A+I vs I         |
|---------------------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------|------------------|------------|------------------|
| Primary Analysis a                                |                                    |                                    |                                    |                  |                  |            |                  |
| FFS Events                                        | 61 (22.4%)                         | 61 (22.8%)                         | 87 (32.3%)                         |                  |                  |            |                  |
| SD at EoI                                         | 1 (0.4%)                           | 1 (0.4%)                           | 5 (1.9%)                           |                  |                  |            |                  |
| Failure-free Survival (months)                    |                                    |                                    |                                    |                  |                  |            |                  |
| Median (95% CI)                                   | NE (NE, NE)                        | NE (NE, NE)                        | NE (NE, NE)                        |                  |                  |            |                  |
| 48-month FFS rate (95% CI)                        | 0.819 (0.767, 0.861)               | 0.818 (0.765, 0.860)               | 0.703 (0.643, 0.755)               |                  |                  |            |                  |
| 54-month FFS rate (95% CI) 60-month FFS rate (95% | 0.803 (0.748, 0.848) 0.743 (0.676, | 0.807 (0.753, 0.851) 0.754 (0.688, | 0.687 (0.626, 0.741) 0.646 (0.578, |                  |                  |            |                  |
| MUE HR (1-sided 98.33% CI)                        |                                    |                                    |                                    | 0.644 (0, 0.934) | 1.546 (0, 2.206) | -          | 0.948 (0, 1.417) |
| p-value (1-sided)                                 |                                    |                                    |                                    | 0.0065           | 0.9883           | -          | 0.3912           |

<div style=\"page-break-after: always\"></div>

| Cox HR (1-sided 98.33%   | 0.633 (0,     | 1.565 (0,     | -             | 0.983 (0,     |
|--------------------------|---------------|---------------|---------------|---------------|
| CI)                      | 0.904)        | 2.233)        |               | 1.445)        |
| p-value (1-sided)        | 0.0029        | 0.9966        | -             | 0.4612        |
| Additional Analyses b    |               |               |               |               |
| MUE HR (2-sided 98.33%   | 0.640 (0.430, | 0.640 (0.430, | 0.646 (0.434, | 1.059 (0.663, |
| CI)                      | 0.963)        | -             | 0.974)        | 1.802)        |
| p-value (2-sided)        | 0.0091        | -             | 0.0112        | 0.7782        |
| Cox HR (2-sided 98.33%   | 0.633 (0.425, | 0.633 (0.425, | 0.639 (0.428, | 0.983 (0.637, |
| CI)                      | 0.945)        | -             | 0.953)        | 1.516)        |
| p-value (2-sided)        | 0.0058        | -             | 0.0068        | 0.9224        |

a  Primary analyses based on 1-sided 1.67% (5%/3) significance level using the tSPRT boundary-based approach.  b  Additional analyses based on 2-sided 1.67% (5%/3) significance level using the tSPRT boundary-based approach.

Table 12 Details on FFS events, FAS, Study MCL3003

|                              | A+I         |             | A           |
|------------------------------|-------------|-------------|-------------|
| Analysis set: Full           | 272         | 268         | 269         |
| FFS Events                   | 61 (22.4%)  | 61 (22.8%)  | 87 (32.3%)  |
| Stable Disease at the End of |             |             |             |
| InductionTherapy             | 1 (0.4%)    | 1 (0.4%)    | 5 (1.9%)    |
| Disease Progression          | 40 (14.7%)  | 49 (18.3%)  | 60 (22.3%)  |
| Death                        | 20 (7.4%)   | 11 (4.1%)   | 22 (8.2%)   |
| Censored                     | 211 (77.6%) | 207 (77.2%) | 182 (67.7%) |

<div style=\"page-break-after: always\"></div>

<!-- image -->

Key: ASCT=autologous stem cell transplant, A=ASCT, A+I=ASCT+Ibrutinib, I=Ibrutinib.

Figure 3 Kaplan-Meier Curves of FFS, FAS, Study MCL3003

Table 13 Reasons for censoring in each treatment arm in the FFS analysi s

| TEFFFS01AMCL: Failure-freeSurvival,Reason for Censoring by Central Medical MCL Network;Full AnalysisSet (Study54179060MCL3003)   | TEFFFS01AMCL: Failure-freeSurvival,Reason for Censoring by Central Medical MCL Network;Full AnalysisSet (Study54179060MCL3003)   | TEFFFS01AMCL: Failure-freeSurvival,Reason for Censoring by Central Medical MCL Network;Full AnalysisSet (Study54179060MCL3003)   | TEFFFS01AMCL: Failure-freeSurvival,Reason for Censoring by Central Medical MCL Network;Full AnalysisSet (Study54179060MCL3003)   |
|----------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                  | A+I                                                                                                                              |                                                                                                                                  | A                                                                                                                                |
| Analysis set: Full                                                                                                               | 272                                                                                                                              | 268                                                                                                                              | 269                                                                                                                              |
| Censored                                                                                                                         | 211                                                                                                                              | 207                                                                                                                              | 182                                                                                                                              |
| Reason for Censoring                                                                                                             |                                                                                                                                  |                                                                                                                                  |                                                                                                                                  |
| Nopostbaselinediseaseassessment                                                                                                  | 5 (2.4%)                                                                                                                         | 4 (1.9%)                                                                                                                         | 6 (3.3%)                                                                                                                         |
| Study cut-off                                                                                                                    | 201 (95.3%)                                                                                                                      | 199 (96.1%)                                                                                                                      | 176 (96.7%)                                                                                                                      |
| Withdrewconsent                                                                                                                  | 5 (2.4%)                                                                                                                         | 4 (1.9%)                                                                                                                         | 0                                                                                                                                |

Key:ASCT=autologous stem cell transplant,A=ASCT,A+I=ASCT+Ibrutinib,I=Ibrutinib

Note:Percentagesarecalculatedwith thenumberofcensoredsubjectsasdenominator.

## Sensitivity and Supplementary analyses of FFS

Table 14 Overview of Sensitivity and Supplementary Analyses for FFS in Study MCL3003

<div style=\"page-break-after: always\"></div>

| A+I vs A   | I vs A   | A+I vs I   |
|------------|----------|------------|

## SENSITIVITY ANALYSES

| 1: Cox regression model, stratified by MIPI risk group       | 1: Cox regression model, stratified by MIPI risk group       | 1: Cox regression model, stratified by MIPI risk group       | 1: Cox regression model, stratified by MIPI risk group       |
|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|
| Median (months)                                              | Median (months)                                              | Median (months)                                              | Median (months)                                              |
| (95% CI)                                                     | NE (NE, NE)                                                  | NE (NE, NE)                                                  | NE (NE, NE)                                                  |
| Cox HR (98.33% CI)                                           | 0.626 (0.420, 0.935)                                         | 0.627 (0.420, 0.936)                                         | 0.993 (0.644, 1.532)                                         |
| p-value (2-sided)                                            | 0.0048                                                       | 0.0049                                                       | 0.9693                                                       |
| 2: Cox regression model, stratified by rituximab maintenance | 2: Cox regression model, stratified by rituximab maintenance | 2: Cox regression model, stratified by rituximab maintenance | 2: Cox regression model, stratified by rituximab maintenance |
| Median (months)                                              | Median (months)                                              | Median (months)                                              | Median (months)                                              |
| (95% CI)                                                     | NE (NE, NE)                                                  | NE (NE, NE)                                                  | NE (NE, NE)                                                  |
| Cox HR (98.33% CI)                                           | 0.587 (0.393, 0.876)                                         | 0.587 (0.393, 0.878)                                         | 1.016 (0.659, 1.568)                                         |
| p-value (2-sided)                                            | 0.0013                                                       | 0.0013                                                       | 0.9284                                                       |
| 3: FFS per investigator assessment                           | 3: FFS per investigator assessment                           | 3: FFS per investigator assessment                           | 3: FFS per investigator assessment                           |
| Median (months) (95% CI)                                     | NE (NE, NE)                                                  | NE (NE, NE)                                                  | NE (75.14, NE)                                               |
| Cox HR (98.33% CI)                                           | 0.633 (0.424, 0.945)                                         | 0.641 (0.430, 0.956)                                         | 0.975 (0.631, 1.508)                                         |
| p-value (2-sided)                                            | 0.0059                                                       | 0.0072                                                       | 0.8900                                                       |

## SUPPLEMENTARY ANALYSIS

## 1: Applying hypothetical strategy to handling of use of subsequent anticancer therapies

Median (months) (95% CI)

NE (NE, NE)

NE (NE, NE)

NE (NE, NE)

<div style=\"page-break-after: always\"></div>

|                    | A+I vs A      | I vs A        | A+I vs I      |
|--------------------|---------------|---------------|---------------|
| Cox HR (98.33% CI) | 0.642 (0.429, | 0.623 (0.414, | 1.022 (0.658, |
| p-value (2-sided)  | 0.961) 0.0080 | 0.936) 0.0050 | 1.588) 0.9071 |

Source Table 9 SCE

## FFS comparison for FAS vs ITT Population

Table 15 Pairwise FFS Testing in ITT Population (Dreyling Lancet Publication) and FAS

|          | ITT (n=870)                                                                                                                         | FAS (n=809)                                |
|----------|-------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------|
| HR       | (1-sided 98.3% CI) 1-sided p-value                                                                                                  | MUE HR (1-sided 98.33% CI) 1-sided p-value |
| A+I vs A | 0.52 (0.00, 0.86) p-value: 0.0008 0.644 (0, p-value:                                                                                | 0.934) 0.0065                              |
| A vs I   | 1.77 (0.00, 3.76) p-value: 0.9979                                                                                                   | 1.546 (0, 2.206) p-value: 0.9883           |
| A+I vs I | Pairwise comparison for the superiority test of Arm A+I vs Arm I still ongoing at the time of 22 May 2022 CCO, to be reported later | 0.948 (0, 1.417) p-value: 0.3912           |

CCO=clinical cutoff; CI=confidence interval; FAS=full analysis set; FFS=failure-free survival; HR=hazard ratio; ITT=intent-to-treat; MUE=median unbiased estimate(or). Note: based on median follow-up of 31 months for the ITT analysis set (Dreyling 2024]) and 54.9 months for the FAS.

## Secondary endpoints

Overall survival

<div style=\"page-break-after: always\"></div>

<!-- image -->

Key: ASCT=autologous stem cell transplant, A=ASCT, A+I=ASCT+Ibrutinib, I=Ibrutinib.

Figure 4 Kaplan-Meier Curves of OS, FAS, Study MCL3003

Table 16 Summary of OS, FAS, Study MCL3003

|                                         | A+I N=272            | I N=268              | A N=269              | A+I vs A                    | I vs A                      | A+I vs I                    |
|-----------------------------------------|----------------------|----------------------|----------------------|-----------------------------|-----------------------------|-----------------------------|
| Death                                   | 34 (12.5%)           | 33 (12.3%)           | 60 (22.3%)           |                             |                             |                             |
| Censored                                | 238 (87.5%)          | 235 (87.7%)          | 209 (77.7%)          |                             |                             |                             |
| OverallSurvival(months) Median (95% CI) | NE (NE, NE)          | NE (NE, NE)          | NE (NE, NE)          |                             |                             |                             |
| 48-month survivalrate(95%CI)            | 0.875 (0.828, 0.909) | 0.896 (0.852, 0.928) | 0.796 (0.741, 0.840) |                             |                             |                             |
| 54-month survivalrate(95%CI)            | 0.875 (0.828, 0.909) | 0.873 (0.824, 0.910) | 0.779 (0.722, 0.826) |                             |                             |                             |
| 60-month survival rate (95%CI)          | 0.867 (0.818, 0.904) | 0.856 (0.800, 0.897) | 0.753 (0.690, 0.805) |                             |                             |                             |
| Cox HR (95% CI) p-value(2-sided)        |                      |                      |                      | 0.542 (0.356, 0.826) 0.0038 | 0.522 (0.341, 0.799) 0.0023 | 1.040 (0.644, 1.679) 0.8721 |

## Progression-free survival

<div style=\"page-break-after: always\"></div>

<!-- image -->

Key:ASCT=autologous stem cell transplant,A=ASCT,A+I=ASCT+Ibrutinib,I=Ibrutinib.

Figure 5 Kaplan-Meier Curves of PFS, FAS, Study MCL3003

Table 17 Summary of PFS, FAS, Study MCL3003

<!-- image -->

|                                                                                                           | N=272 A+I                                                                                                 | N=268 I                                                                                                   | N=269 A                                                                                                   | A+I vs A                                                                                                  | A vs I                                                                                                    | I vs A                                                                                                    | A+I vs I                                                                                                  |
|-----------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| Primary Analysis                                                                                          |                                                                                                           |                                                                                                           |                                                                                                           |                                                                                                           |                                                                                                           |                                                                                                           |                                                                                                           |
| PFS Events                                                                                                | 62 (22.8%)                                                                                                | 60 (22.4%)                                                                                                | 87 (32.3%)                                                                                                |                                                                                                           |                                                                                                           |                                                                                                           |                                                                                                           |
| Disease Progression                                                                                       | 42 (15.4%)                                                                                                | 49 (18.3%)                                                                                                | 63 (23.4%)                                                                                                |                                                                                                           |                                                                                                           |                                                                                                           |                                                                                                           |
| Death                                                                                                     | 20 (7.4%)                                                                                                 | 11 (4.1%)                                                                                                 | 24 (8.9%)                                                                                                 |                                                                                                           |                                                                                                           |                                                                                                           |                                                                                                           |
| Progression-freeSurvival(months) Median (95%CI)                                                           | NE (NE, NE)                                                                                               | NE (NE, NE)                                                                                               | NE (77.44, NE)                                                                                            |                                                                                                           |                                                                                                           |                                                                                                           |                                                                                                           |
| 48-month PFS rate (95% CI)                                                                                | 0.817 (0.765, 0.859)                                                                                      | 0.824 (0.772, 0.865)                                                                                      | 0.710 (0.651, 0.761)                                                                                      |                                                                                                           |                                                                                                           |                                                                                                           |                                                                                                           |
| 54-month PFS rate (95% CI)                                                                                | 0.802 (0.747, 0.846)                                                                                      | 0.813 (0.759, 0.856)                                                                                      | 0.694 (0.633, 0.747)                                                                                      |                                                                                                           |                                                                                                           |                                                                                                           |                                                                                                           |
| 60-month PFS rate (95% CI)                                                                                | 0.741 (0.675, 0.797)                                                                                      | 0.760 (0.696, 0.813)                                                                                      | 0.655 (0.587, 0.714)                                                                                      |                                                                                                           |                                                                                                           |                                                                                                           |                                                                                                           |
| MUE HR (1-sided 98.33% CI) p-value (1-sided)                                                              |                                                                                                           |                                                                                                           |                                                                                                           | 0.661 (0, 0.953) 0.0084                                                                                   | 1.561 (0, 2.229) 0.9903                                                                                   |                                                                                                           | 1.009 (0, 1.492) 0.5187                                                                                   |
| Cox HR (1-sided 98.33% CI)                                                                                |                                                                                                           |                                                                                                           |                                                                                                           | 0.651 (0, 0.928)                                                                                          | 1.580 (0, 2.258)                                                                                          |                                                                                                           | 1.021 (0, 1.501)                                                                                          |
| p-value (1-sided)                                                                                         |                                                                                                           |                                                                                                           |                                                                                                           | 0.0047                                                                                                    | 0.9970                                                                                                    |                                                                                                           | 0.5449                                                                                                    |
| Additional Analysesh                                                                                      |                                                                                                           |                                                                                                           |                                                                                                           |                                                                                                           |                                                                                                           |                                                                                                           |                                                                                                           |
| MUE HR (2-sided 98.33% CI)                                                                                |                                                                                                           |                                                                                                           |                                                                                                           | 0.656 (0.441, 0.981)                                                                                      |                                                                                                           | 0.640 (0.430, 0.969)                                                                                      | 1.076 (0.681, 1.803)                                                                                      |
| p-value (2-sided)                                                                                         |                                                                                                           |                                                                                                           |                                                                                                           | 0.0122                                                                                                    |                                                                                                           | 0.0103                                                                                                    | 0.7092                                                                                                    |
| Cox HR (2-sided 98.33% CI)                                                                                |                                                                                                           |                                                                                                           |                                                                                                           | 0.651 (0.437, 0.969)                                                                                      |                                                                                                           | 0.633 (0.424, 0.946)                                                                                      | 1.021 (0.662, 1.574)                                                                                      |
| p-value (2-sided)                                                                                         |                                                                                                           |                                                                                                           |                                                                                                           | 0.0093                                                                                                    |                                                                                                           | 0.0060                                                                                                    | 0.9102                                                                                                    |
| bAdditionalanalyses basedon 2-sided 1.67%(5%/3) significanceleve1 using the tSPRTboundary-based approach. | bAdditionalanalyses basedon 2-sided 1.67%(5%/3) significanceleve1 using the tSPRTboundary-based approach. | bAdditionalanalyses basedon 2-sided 1.67%(5%/3) significanceleve1 using the tSPRTboundary-based approach. | bAdditionalanalyses basedon 2-sided 1.67%(5%/3) significanceleve1 using the tSPRTboundary-based approach. | bAdditionalanalyses basedon 2-sided 1.67%(5%/3) significanceleve1 using the tSPRTboundary-based approach. | bAdditionalanalyses basedon 2-sided 1.67%(5%/3) significanceleve1 using the tSPRTboundary-based approach. | bAdditionalanalyses basedon 2-sided 1.67%(5%/3) significanceleve1 using the tSPRTboundary-based approach. | bAdditionalanalyses basedon 2-sided 1.67%(5%/3) significanceleve1 using the tSPRTboundary-based approach. |

## CR, ORR and PR to CR Conversion Rate

Table 18 CR and ORR Rate, FAS, Study MCL3003

<div style=\"page-break-after: always\"></div>

| Analysis set: Full                                                         | A+I 272     | I 268       | A 269       | A+I vs A                    | I vs A                      | A+I vs I                    |
|----------------------------------------------------------------------------|-------------|-------------|-------------|-----------------------------|-----------------------------|-----------------------------|
| Complete Response Ratea                                                    |             |             |             |                             |                             |                             |
| CompleteResponseRate,n (%) Relative risk (2-sided 95% CI)c p-valued        | 196 (72.1%) | 180 (67.2%) | 174 (64.7%) | 1.114 (0.993, 1.250) 0.0788 | 1.038 (0.919, 1.173) 0.5851 | 1.073 (0.959, 1.200) 0.2250 |
| Overall Response Rateb                                                     |             |             |             |                             |                             |                             |
| Overall Response Rate (CR, PR), n (%) Relativerisk(2-sided90%CI)c p-valued | 260 (95.6%) | 258 (96.3%) | 248 (92.2%) | 1.037 (0.993, 1.083) 0.1085 | 1.044 (1.001, 1.089) 0.0627 | 0.993 (0.959,1.028) 0.8284  |
| Best Overall Response, n (%)                                               |             |             |             |                             |                             |                             |
| CompleteResponse(CR)                                                       | 196 (72.1%) | 180 (67.2%) | 174 (64.7%) |                             |                             |                             |
| Partial Response (PR)                                                      | 64 (23.5%)  | 78 (29.1%)  | 74 (27.5%)  |                             |                             |                             |
| Stable Disease (SD)                                                        | 1 (0.4%)    | 1 (0.4%)    | 3 (1.1%)    |                             |                             |                             |
| Progressive Disease (PD)                                                   | 4 (1.5%)    | 3 (1.1%)    | 11 (4.1%)   |                             |                             |                             |
| NotEvaluable(NE)                                                           | 7 (2.6%)    | 6 (2.2%)    | 7 (2.6%)    |                             |                             |                             |

b ORR is defined as the proportion of subjects with a best response of CR or PR.

aCRRisdefined as theproportion of subjectswho achieveabestresponse ofCR.

cRelative Risk &gt;1 favors I vs.A, A+I vs.A, or A+I vs. I.

dp-value isfrom theFisher'sexact test.

Note:Subjects with missing post-randomization data and non-evaluableresponses are considered non-responders.

Note:Percentages arecalculatedwith thenumberof subjectsinthefull analysisset ineach treatmentgroupas the denominators.

Table 19 PR and CR Conversion Rate during Follow-up after End of Induction, FAS, Study MCL3003

|                             | A+I        | I          | A          | A+I vs.A I vs. A   | A+I vs. I     |               |
|-----------------------------|------------|------------|------------|--------------------|---------------|---------------|
| Analysis set: Full          | 272        | 268        | 269        |                    |               |               |
| SubjectswithPRatEOI         | 145        | 138        | 150        |                    |               |               |
| PRtoCRconversionrate, n (%) | 81 (55.9%) | 60 (43.5%) | 76 (50.7%) |                    |               |               |
| Relative risk (Two-sided    |            |            |            | 1.103 (0.890,      | 0.858 (0.670, | 1.285 (1.012, |
| 95% CI)a                    |            |            |            | 1.366)             | 1.099)        | 1.632)        |
| p-valueb                    |            |            |            | 0.4144             | 0.2389        | 0.0434        |

Key: + = censored observation, PR = Partial Response, CR = Complete Response, ASCT=autologous stem cell transplant, A=ASCT,A+I=ASCT+Ibrutinib,I=Ibrutinib,CI=confidenceinterval,EOI=End ofInduction.

aRelativeRisk&gt;1 favors I vs.A,A+I vs.A, or A+I vs.I.

bp-valueisfromtheFisher'sexacttest.

Note: Subjects with missing post-randomization data and non-evaluable responses are considered non-responders.

Note: Percentages are calculated with the number of subjects in the full analysis set in each treatment group with PR at EOI as the denominators.

## Ancillary analyses on primary endpoint FFS

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                       |                       |                 |                 | A               | A               |
|-----------------------|-----------------------|-----------------|-----------------|-----------------|-----------------|
| Group                 | Hazard Ratio (95% Cl) | EVT/N           | Median (suow)   | EVT/N           | Median (suow)   |
| All Subjects          | 0.639 (0.461,0.886)   | 61/268          | NE              | 87/269          | NE              |
| Sex                   |                       |                 |                 |                 |                 |
| Male                  | 0.619 (0.431, 0.889)  | 50/214          | NE              | 71/205          | NE              |
| Female                | 0.705 (0.327,1.520)   | 11/54           | NE              | 16/64           | NE              |
| MIPIrisk group        |                       |                 |                 |                 |                 |
| Low risk              | 0.762 (0.471, 1.234)  | 30/152          | NE              | 37/153          | NE              |
| Intermediate risk     | 0.352 (0.188,0.661)   | 14/76           | NE              | 32/75           | 75.14           |
| High risk             | 0.882 (0.454,1.713)   | 17/40           | NE              | 18/41           | NE              |
| Ki-67 index           |                       |                 |                 |                 |                 |
| %0>                   | 0.645 (0.398,1.045)   | 28/161          | NE              | 40/157          | NE              |
| ≥30%                  | 0.631 (0.386,1.031)   | 28/78           | NE              | 37/78           | NE              |
| Not done              | 0.517 (0.177,1.512)   | 5/29            | NE              | 10/34           | NE              |
| Cytology (MCL)        |                       |                 |                 |                 |                 |
| BlastoidorPleomorphic | 1.101 (0.509,2.383)   | 14/29           | 64.95           | 12/27           | 59.50           |
| Classic or Small cell | 0.513 (0.349,0.756)   | 41/217          | NE              | 69/211          | NE              |
| Not done              | 1.312 (0.423, 4.074)  | 6/22            | NE              | 6/31            | NE              |
| p53expression         |                       |                 |                 |                 |                 |
| ≤50%                  | 0.731 (0.455, 1.175)  | 31/149          | NE              | 38/149          | NE              |
| >50%                  | 0.403 (0.184,0.882)   | 11/28           | NE              | 15/21           | 11.99           |
| Not done              | 0.566 (0.323,0.992)   | 19/91           | NE              | 34/99           | NE              |
| Rituximabmaintenance  |                       |                 |                 |                 |                 |
| Yes                   | 0.810 (0.489, 1.342)  | 27/160          | NE              | 34/168          | NE              |
| No                    | 0.469 (0.305,0.723)   | 34/108          | NE              | 53/101          | 45.34           |
|                       |                       | 2.5 4           |                 |                 |                 |
| Favor 1 Favor A       | Favor 1 Favor A       | Favor 1 Favor A | Favor 1 Favor A | Favor 1 Favor A | Favor 1 Favor A |

Key: ASCT=autologous stem cell transplant, A=ASCT, A+I=ASCT+Ibrutinib, I=Ibrutinib, MIPI=MCL International Prognostic Index.

Figure 6 Forest Plot of Subgroup Analyses on FFS (I vs. A) ; FAS, Study MCL3003

## Summary of main study

<div style=\"page-break-after: always\"></div>

The following table summarises the efficacy results from the main study supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 20 Summary of Efficacy for trial MCL3003

<!-- image -->

| Title: Phase 3 Study - Autologous transplantation after a rituximab/ibrutinib/ara-c containing induction in generalized mantle cell lymphoma -a randomized European MCL network trial   | Title: Phase 3 Study - Autologous transplantation after a rituximab/ibrutinib/ara-c containing induction in generalized mantle cell lymphoma -a randomized European MCL network trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Title: Phase 3 Study - Autologous transplantation after a rituximab/ibrutinib/ara-c containing induction in generalized mantle cell lymphoma -a randomized European MCL network trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Title: Phase 3 Study - Autologous transplantation after a rituximab/ibrutinib/ara-c containing induction in generalized mantle cell lymphoma -a randomized European MCL network trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Title: Phase 3 Study - Autologous transplantation after a rituximab/ibrutinib/ara-c containing induction in generalized mantle cell lymphoma -a randomized European MCL network trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                        | 54179060MCL3003 MCL3003 - TRIANGLE Eudra-CT-Number: 2014-001363-12 ClinicalTrials.gov ID NCT02858258                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 54179060MCL3003 MCL3003 - TRIANGLE Eudra-CT-Number: 2014-001363-12 ClinicalTrials.gov ID NCT02858258                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 54179060MCL3003 MCL3003 - TRIANGLE Eudra-CT-Number: 2014-001363-12 ClinicalTrials.gov ID NCT02858258                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 54179060MCL3003 MCL3003 - TRIANGLE Eudra-CT-Number: 2014-001363-12 ClinicalTrials.gov ID NCT02858258                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Design                                                                                                                                                                                  | Randomized, 3-arm, parallel-group, open-label, international multicenter Phase 3 study conducted by the Klinikum der Universität München, Germany, on behalf of the European MCL Network at multiple sites in Europe and in Israel in participants with previously untreated MCL eligible for ASCT to compare 3 alternating courses of R-CHOP/R-DHAP followed by ASCT (control Arm A) versus the combination of R-CHOP+ibrutinib/R-DHAP followed by ASCT and ibrutinib maintenance (experimental Arm A+I) or R-CHOP+ibrutinib/R-DHAP followed by ibrutinib maintenance without ASCT (experimental Arm I). The planned total sample size was up to 870 participants allocated to 1 of 3 treatment arms at a 1:1:1 ratio with randomization stratified by study group and MIPI risk group at study entry. As evidence supporting rituximab maintenance treatment was not yet established at the start of the study, rituximab maintenance was not considered a study treatment in Study MCL3003. However, upon its implementation in national treatment guidelines, rituximab maintenance therapy was to be administered to participants as per the recommendations of the site's study group as the decision on rituximab maintenance had to be identical for all 3 | Randomized, 3-arm, parallel-group, open-label, international multicenter Phase 3 study conducted by the Klinikum der Universität München, Germany, on behalf of the European MCL Network at multiple sites in Europe and in Israel in participants with previously untreated MCL eligible for ASCT to compare 3 alternating courses of R-CHOP/R-DHAP followed by ASCT (control Arm A) versus the combination of R-CHOP+ibrutinib/R-DHAP followed by ASCT and ibrutinib maintenance (experimental Arm A+I) or R-CHOP+ibrutinib/R-DHAP followed by ibrutinib maintenance without ASCT (experimental Arm I). The planned total sample size was up to 870 participants allocated to 1 of 3 treatment arms at a 1:1:1 ratio with randomization stratified by study group and MIPI risk group at study entry. As evidence supporting rituximab maintenance treatment was not yet established at the start of the study, rituximab maintenance was not considered a study treatment in Study MCL3003. However, upon its implementation in national treatment guidelines, rituximab maintenance therapy was to be administered to participants as per the recommendations of the site's study group as the decision on rituximab maintenance had to be identical for all 3 | Randomized, 3-arm, parallel-group, open-label, international multicenter Phase 3 study conducted by the Klinikum der Universität München, Germany, on behalf of the European MCL Network at multiple sites in Europe and in Israel in participants with previously untreated MCL eligible for ASCT to compare 3 alternating courses of R-CHOP/R-DHAP followed by ASCT (control Arm A) versus the combination of R-CHOP+ibrutinib/R-DHAP followed by ASCT and ibrutinib maintenance (experimental Arm A+I) or R-CHOP+ibrutinib/R-DHAP followed by ibrutinib maintenance without ASCT (experimental Arm I). The planned total sample size was up to 870 participants allocated to 1 of 3 treatment arms at a 1:1:1 ratio with randomization stratified by study group and MIPI risk group at study entry. As evidence supporting rituximab maintenance treatment was not yet established at the start of the study, rituximab maintenance was not considered a study treatment in Study MCL3003. However, upon its implementation in national treatment guidelines, rituximab maintenance therapy was to be administered to participants as per the recommendations of the site's study group as the decision on rituximab maintenance had to be identical for all 3 | Randomized, 3-arm, parallel-group, open-label, international multicenter Phase 3 study conducted by the Klinikum der Universität München, Germany, on behalf of the European MCL Network at multiple sites in Europe and in Israel in participants with previously untreated MCL eligible for ASCT to compare 3 alternating courses of R-CHOP/R-DHAP followed by ASCT (control Arm A) versus the combination of R-CHOP+ibrutinib/R-DHAP followed by ASCT and ibrutinib maintenance (experimental Arm A+I) or R-CHOP+ibrutinib/R-DHAP followed by ibrutinib maintenance without ASCT (experimental Arm I). The planned total sample size was up to 870 participants allocated to 1 of 3 treatment arms at a 1:1:1 ratio with randomization stratified by study group and MIPI risk group at study entry. As evidence supporting rituximab maintenance treatment was not yet established at the start of the study, rituximab maintenance was not considered a study treatment in Study MCL3003. However, upon its implementation in national treatment guidelines, rituximab maintenance therapy was to be administered to participants as per the recommendations of the site's study group as the decision on rituximab maintenance had to be identical for all 3 |
| Design                                                                                                                                                                                  | Duration of main phase:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Duration of main phase:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 18 weeks induction therapy, +/- 6 weeks ASCT, +/- 2 years ibrutinib-maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 18 weeks induction therapy, +/- 6 weeks ASCT, +/- 2 years ibrutinib-maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Design                                                                                                                                                                                  | Duration of Run-in phase:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Duration of Run-in phase:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | N.A.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | N.A.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Hypothesis                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Hypothesis                                                                                                                                                                              | FFS comparison                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Null Hypothesis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Null Hypothesis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Alternative Hypothesis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Hypothesis                                                                                                                                                                              | A versus I                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | A is not superior to I                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | A is not superior to I                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | A is superior to I                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Hypothesis                                                                                                                                                                              | A+I versus A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | A+I is not superior to                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | A+I is not superior to                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | A+I is superior to A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Hypothesis                                                                                                                                                                              | A+I versus I                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | A+I is not superior to I                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | A+I is not superior to I                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | A+I is superior to I                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

| Treatments groups         | Arm A+I (Experimental)   | Arm A+I (Experimental)          | Ibrutinib 560 mg daily (Days 1-19) in combination with R-CHOP for three 21-day cycles (Cycles 1, 3, 5) alternating with three 21- day cycles of R-DHAP (Cycles 2, 4, 6) as induction therapy followed by high-dose chemotherapy and ASCT followed by 2 years Ibrutinib 560 mg daily (n=292 randomized patients).   |
|---------------------------|--------------------------|---------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Treatments groups         | Arm I (Experimental)     | Arm I (Experimental)            | Ibrutinib 560 mg daily (Days 1-19) in combination with R-CHOP for three 21-day cycles (Cycles 1, 3, 5) alternating with three 21- day cycles of R-DHAP (Cycles 2, 4, 6) as induction therapy followed by 2 years Ibrutinib 560 mg daily without ASCT (n=290 randomized patients).                                  |
| Treatments groups         | Arm A (Control)          | Arm A (Control)                 | R-CHOP for three 21-day cycles (Cycles 1, 3, 5) alternating with three 21-day cycles of R-DHAP (Cycles 2, 4, 6) as induction therapy followed by high-dose chemotherapy and ASCT (n=288 randomized patients).                                                                                                      |
| Endpoints and definitions | Primary endpoint         | Failure Free Survival (FFS)     | Time from randomization to stable disease at EoI, progressive disease, or death from any cause, whichever comes first.                                                                                                                                                                                             |
| Endpoints and definitions | Major Secondary endpoint | Overall Survival (OS)           | Time from randomization to death.                                                                                                                                                                                                                                                                                  |
| Endpoints and definitions | Major Secondary endpoint | Progression Free Survival (PFS) | Time to progression or death from any cause. PFS from randomization was considered as the primary PFS endpoint.                                                                                                                                                                                                    |
| Endpoints and definitions | Major Secondary endpoint | Overall Response Rate (ORR)     | The proportion of participants with a best overall response of CR or PR during the study.                                                                                                                                                                                                                          |
| Endpoints and definitions | Major Secondary endpoint | Complete Response (CR) Rate     | The proportion of participants with a best overall response of CR during the study.                                                                                                                                                                                                                                |
| Database lock             | CCO date of 09 May 2024  | CCO date of 09 May 2024         | CCO date of 09 May 2024                                                                                                                                                                                                                                                                                            |
| Results and Analysis      | Results and Analysis     | Results and Analysis            | Results and Analysis                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

| Analysis description                            | Primary Analysis - FFS                                                                                                                                                                                                                                                                                                                                                                                                 | Primary Analysis - FFS                                                                                                                                                                                                                                                                                                                                                                                                 | Primary Analysis - FFS                                                                                                                                                                                                                                                                                                                                                                                                 | Primary Analysis - FFS                                                                                                                                                                                                                                                                                                                                                                                                 | Primary Analysis - FFS                                                                                                                                                                                                                                                                                                                                                                                                 |
|-------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Analysis population and time point description  | Patients with previously untreated MCL who are eligible for ASCT (n=870 randomized patients). Due to European GDPR, the efficacy analyses were conducted based on 809 patients (272 patients in Arm A+I, 268 patients in Arm I and 269 patients in Arm A) in the full analysis set (FAS)/modified intention-to-treat (mITT) population. Efficacy results are based on a median follow-up time on study of 54.9 months. | Patients with previously untreated MCL who are eligible for ASCT (n=870 randomized patients). Due to European GDPR, the efficacy analyses were conducted based on 809 patients (272 patients in Arm A+I, 268 patients in Arm I and 269 patients in Arm A) in the full analysis set (FAS)/modified intention-to-treat (mITT) population. Efficacy results are based on a median follow-up time on study of 54.9 months. | Patients with previously untreated MCL who are eligible for ASCT (n=870 randomized patients). Due to European GDPR, the efficacy analyses were conducted based on 809 patients (272 patients in Arm A+I, 268 patients in Arm I and 269 patients in Arm A) in the full analysis set (FAS)/modified intention-to-treat (mITT) population. Efficacy results are based on a median follow-up time on study of 54.9 months. | Patients with previously untreated MCL who are eligible for ASCT (n=870 randomized patients). Due to European GDPR, the efficacy analyses were conducted based on 809 patients (272 patients in Arm A+I, 268 patients in Arm I and 269 patients in Arm A) in the full analysis set (FAS)/modified intention-to-treat (mITT) population. Efficacy results are based on a median follow-up time on study of 54.9 months. | Patients with previously untreated MCL who are eligible for ASCT (n=870 randomized patients). Due to European GDPR, the efficacy analyses were conducted based on 809 patients (272 patients in Arm A+I, 268 patients in Arm I and 269 patients in Arm A) in the full analysis set (FAS)/modified intention-to-treat (mITT) population. Efficacy results are based on a median follow-up time on study of 54.9 months. |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                        | Arm A+I                                                                                                                                                                                                                                                                                                                                                                                                                | Arm I                                                                                                                                                                                                                                                                                                                                                                                                                  | Arm I                                                                                                                                                                                                                                                                                                                                                                                                                  | Arm A                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Descriptive statistics and estimate variability | Number of subject                                                                                                                                                                                                                                                                                                                                                                                                      | N=272                                                                                                                                                                                                                                                                                                                                                                                                                  | N=268                                                                                                                                                                                                                                                                                                                                                                                                                  | N=268                                                                                                                                                                                                                                                                                                                                                                                                                  | N=269                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Descriptive statistics and estimate variability | FFS Number of Events (%)                                                                                                                                                                                                                                                                                                                                                                                               | 61 (22.4%)                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                        | 87 (32.3%)                                                                                                                                                                                                                                                                                                                                                                                                             |
| Descriptive statistics and estimate variability | Stable Disease at the end of induction                                                                                                                                                                                                                                                                                                                                                                                 | 1 (0.4%)                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                        | 5 (1.9%)                                                                                                                                                                                                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability | Disease progression                                                                                                                                                                                                                                                                                                                                                                                                    | 40 (14.7%)                                                                                                                                                                                                                                                                                                                                                                                                             | 49 (18.3%)                                                                                                                                                                                                                                                                                                                                                                                                             | 49 (18.3%)                                                                                                                                                                                                                                                                                                                                                                                                             | 60 (22.3%)                                                                                                                                                                                                                                                                                                                                                                                                             |
| Descriptive statistics and estimate variability | Death events                                                                                                                                                                                                                                                                                                                                                                                                           | 20 (7.4%)                                                                                                                                                                                                                                                                                                                                                                                                              | 11 (4.1%)                                                                                                                                                                                                                                                                                                                                                                                                              | 11 (4.1%)                                                                                                                                                                                                                                                                                                                                                                                                              | 22 (8.2%)                                                                                                                                                                                                                                                                                                                                                                                                              |
| Effect estimate per comparison                  | Primary endpoint FFS* Arm I vs Arm A                                                                                                                                                                                                                                                                                                                                                                                   | Primary endpoint FFS* Arm I vs Arm A                                                                                                                                                                                                                                                                                                                                                                                   | Primary endpoint FFS* Arm I vs Arm A                                                                                                                                                                                                                                                                                                                                                                                   | IMBRUVICA vs ASCT Arms                                                                                                                                                                                                                                                                                                                                                                                                 | IMBRUVICA vs ASCT Arms                                                                                                                                                                                                                                                                                                                                                                                                 |
| Effect estimate per comparison                  |                                                                                                                                                                                                                                                                                                                                                                                                                        | HR (98.33% CI)                                                                                                                                                                                                                                                                                                                                                                                                         | HR (98.33% CI)                                                                                                                                                                                                                                                                                                                                                                                                         | 0.639 (0.428, 0.953)                                                                                                                                                                                                                                                                                                                                                                                                   | 0.639 (0.428, 0.953)                                                                                                                                                                                                                                                                                                                                                                                                   |
| Effect estimate per comparison                  |                                                                                                                                                                                                                                                                                                                                                                                                                        | P-value                                                                                                                                                                                                                                                                                                                                                                                                                | P-value                                                                                                                                                                                                                                                                                                                                                                                                                | 0.0068                                                                                                                                                                                                                                                                                                                                                                                                                 | 0.0068                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Effect estimate per comparison                  |                                                                                                                                                                                                                                                                                                                                                                                                                        | Arm A+I vs Arm A                                                                                                                                                                                                                                                                                                                                                                                                       | Arm A+I vs Arm A                                                                                                                                                                                                                                                                                                                                                                                                       | IMBRUVICA + ASCT vs ASCT Arms                                                                                                                                                                                                                                                                                                                                                                                          | IMBRUVICA + ASCT vs ASCT Arms                                                                                                                                                                                                                                                                                                                                                                                          |
| Effect estimate per comparison                  |                                                                                                                                                                                                                                                                                                                                                                                                                        | HR (98.33% CI)                                                                                                                                                                                                                                                                                                                                                                                                         | HR (98.33% CI)                                                                                                                                                                                                                                                                                                                                                                                                         | 0.633 (0.425, 0.945)                                                                                                                                                                                                                                                                                                                                                                                                   | 0.633 (0.425, 0.945)                                                                                                                                                                                                                                                                                                                                                                                                   |
| Effect estimate per comparison                  |                                                                                                                                                                                                                                                                                                                                                                                                                        | P-value                                                                                                                                                                                                                                                                                                                                                                                                                | P-value                                                                                                                                                                                                                                                                                                                                                                                                                | 0.0058                                                                                                                                                                                                                                                                                                                                                                                                                 | 0.0058                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Effect estimate per comparison                  |                                                                                                                                                                                                                                                                                                                                                                                                                        | Arm A+I vs Arm I                                                                                                                                                                                                                                                                                                                                                                                                       | Arm A+I vs Arm I                                                                                                                                                                                                                                                                                                                                                                                                       | IMBRUVICA + ASCT vs IMBRUVICA Arms                                                                                                                                                                                                                                                                                                                                                                                     | IMBRUVICA + ASCT vs IMBRUVICA Arms                                                                                                                                                                                                                                                                                                                                                                                     |
| Effect estimate per comparison                  |                                                                                                                                                                                                                                                                                                                                                                                                                        | HR (98.33% CI)                                                                                                                                                                                                                                                                                                                                                                                                         | HR (98.33% CI)                                                                                                                                                                                                                                                                                                                                                                                                         | 0.983 (0.637, 1.516)                                                                                                                                                                                                                                                                                                                                                                                                   | 0.983 (0.637, 1.516)                                                                                                                                                                                                                                                                                                                                                                                                   |
| Effect estimate per comparison                  |                                                                                                                                                                                                                                                                                                                                                                                                                        | P-value                                                                                                                                                                                                                                                                                                                                                                                                                | P-value                                                                                                                                                                                                                                                                                                                                                                                                                | 0.9224                                                                                                                                                                                                                                                                                                                                                                                                                 | 0.9224                                                                                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| Notes                                           | *Based on Cox Regression Model   | *Based on Cox Regression Model   | *Based on Cox Regression Model   | *Based on Cox Regression Model     | *Based on Cox Regression Model     |
|-------------------------------------------------|----------------------------------|----------------------------------|----------------------------------|------------------------------------|------------------------------------|
| Analysis description                            | Major Secondary Analysis - OS    | Major Secondary Analysis - OS    | Major Secondary Analysis - OS    | Major Secondary Analysis - OS      | Major Secondary Analysis - OS      |
| Descriptive statistics and estimate variability | Treatment group                  | Arm A+I                          | Arm I                            | Arm I                              | Arm A                              |
| Descriptive statistics and estimate variability | Number of subject                | N=272                            | N=268                            | N=268                              | N=269                              |
| Descriptive statistics and estimate variability | OS Number of deaths (%)          | 34 (12.5%)                       |                                  |                                    | 60 (22.3%)                         |
| Effect estimate per comparison                  | Major Secondary endpoint - OS    | Arm I vs Arm A                   | Arm I vs Arm A                   | IMBRUVICA vs ASCT Arms             | IMBRUVICA vs ASCT Arms             |
| Effect estimate per comparison                  | Major Secondary endpoint - OS    | HR (95% CI)                      | HR (95% CI)                      | 0.522 (0.341, 0.799)               | 0.522 (0.341, 0.799)               |
| Effect estimate per comparison                  | Major Secondary endpoint - OS    | P-value                          | P-value                          |                                    |                                    |
| Effect estimate per comparison                  | Major Secondary endpoint - OS    | Arm A+I vs Arm A                 | Arm A+I vs Arm A                 | IMBRUVICA + ASCT vs ASCT Arms      | IMBRUVICA + ASCT vs ASCT Arms      |
| Effect estimate per comparison                  | Major Secondary endpoint - OS    | HR (95% CI)                      | HR (95% CI)                      | 0.542 (0.356, 0.826)               | 0.542 (0.356, 0.826)               |
| Effect estimate per comparison                  | Major Secondary endpoint - OS    | P-value                          | P-value                          | 0.0038                             | 0.0038                             |
| Effect estimate per comparison                  | Major Secondary endpoint - OS    | Arm A+I vs Arm I                 | Arm A+I vs Arm I                 | IMBRUVICA + ASCT vs IMBRUVICA Arms | IMBRUVICA + ASCT vs IMBRUVICA Arms |
| Effect estimate per comparison                  | Major Secondary endpoint - OS    | HR (95% CI)                      | HR (95% CI)                      | 1.040 (0.644, 1.679)               | 1.040 (0.644, 1.679)               |
| Effect estimate per comparison                  | Major Secondary endpoint - OS    | P-value                          | P-value                          | 0.8721                             | 0.8721                             |
| Notes                                           | Notes                            | Notes                            | Notes                            | Notes                              | Notes                              |
| Analysis description                            | Major Secondary Analysis - PFS   | Major Secondary Analysis - PFS   | Major Secondary Analysis - PFS   | Major Secondary Analysis - PFS     | Major Secondary Analysis - PFS     |
| Descriptive statistics and estimate variability | Treatment group                  | Arm A+I                          | Arm I                            | Arm I                              | Arm A                              |
| Descriptive statistics and estimate variability | Number of subject                | N=272                            | N=268                            | N=268                              | N=269                              |
| Descriptive statistics and estimate variability | Number of Events (%)             | 62 (22.8%)                       | 60 (22.4%)                       | 60 (22.4%)                         | 87 (32.3%)                         |
| Descriptive statistics and estimate variability | Disease progression              | 42 (15.4%)                       | 49 (18.3%)                       | 49 (18.3%)                         | 63 (23.4%)                         |
| Descriptive statistics and estimate variability | Death events                     | 20 (7.4%)                        | 11 (4.1%)                        | 11 (4.1%)                          | 24 (8.9%)                          |

<div style=\"page-break-after: always\"></div>

| Effect estimate per comparison                  | Major Secondary endpoint -PFS*                   | Arm I vs Arm A                                   | Arm I vs Arm A                                   | IMBRUVICA vs ASCT Arms                           | IMBRUVICA vs ASCT Arms                           |
|-------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|
|                                                 |                                                  | HR (98.33% CI)                                   | HR (98.33% CI)                                   | 0.633 (0.424, 0.946)                             | 0.633 (0.424, 0.946)                             |
|                                                 |                                                  | P-value                                          | P-value                                          | 0.0060                                           | 0.0060                                           |
|                                                 |                                                  | Arm A+I vs Arm A                                 | Arm A+I vs Arm A                                 | IMBRUVICA + ASCT vs ASCT Arms                    | IMBRUVICA + ASCT vs ASCT Arms                    |
|                                                 |                                                  | HR (98.33% CI)                                   | HR (98.33% CI)                                   | 0.651 (0.437, 0.969)                             | 0.651 (0.437, 0.969)                             |
|                                                 |                                                  | P-value                                          | P-value                                          | 0.0093                                           | 0.0093                                           |
|                                                 |                                                  | Arm A+I vs Arm I                                 | Arm A+I vs Arm I                                 | IMBRUVICA + ASCT vs IMBRUVICA Arms               | IMBRUVICA + ASCT vs IMBRUVICA Arms               |
|                                                 |                                                  | HR (98.33% CI)                                   | HR (98.33% CI)                                   | 1.021 (0.662, 1.574)                             | 1.021 (0.662, 1.574)                             |
|                                                 |                                                  | P-value                                          | P-value                                          | 0.9102                                           | 0.9102                                           |
| Notes                                           | *Based on Cox Regression Model                   | *Based on Cox Regression Model                   | *Based on Cox Regression Model                   | *Based on Cox Regression Model                   | *Based on Cox Regression Model                   |
| Analysis description                            | Major Secondary Analysis - Overall Response Rate | Major Secondary Analysis - Overall Response Rate | Major Secondary Analysis - Overall Response Rate | Major Secondary Analysis - Overall Response Rate | Major Secondary Analysis - Overall Response Rate |
| Descriptive statistics and estimate variability | Treatment group                                  | Arm A+I                                          | Arm I                                            | Arm I                                            | Arm A                                            |
|                                                 | Number of subject                                | N=272                                            | N=268                                            | N=268                                            | N=269                                            |
|                                                 | ORR                                              | 260 (95.6%)                                      | 258 (96.3%)                                      | 258 (96.3%)                                      | 248 (92.2%)                                      |
| Effect estimate per comparison                  | Major Secondary endpoint -ORR                    | Arm I vs Arm A                                   | Arm I vs Arm A                                   | IMBRUVICA vs ASCT Arms                           | IMBRUVICA vs ASCT Arms                           |
|                                                 |                                                  | Relative risk (2-sided 95% CI)                   | Relative risk (2-sided 95% CI)                   | 1.044 (1.001, 1.089)                             | 1.044 (1.001, 1.089)                             |
|                                                 |                                                  | P-value                                          | P-value                                          | 0.0627                                           | 0.0627                                           |
|                                                 |                                                  | Arm A+I vs Arm A                                 | Arm A+I vs Arm A                                 | IMBRUVICA + ASCT vs ASCT Arms                    | IMBRUVICA + ASCT vs ASCT Arms                    |
|                                                 |                                                  | Relative risk (2-sided 95% CI)                   | Relative risk (2-sided 95% CI)                   | 1.037 (0.993, 1.083)                             | 1.037 (0.993, 1.083)                             |
|                                                 |                                                  | P-value                                          | P-value                                          | 0.1085                                           | 0.1085                                           |

Arm A+I vs Arm I

IMBRUVICA Arms vs IMBRUVICA + ASCT

Relative risk (2-sided 95% CI)

0.993 (0.959, 1.028)

P-value

0.8284

Notes

## Analysis description

## Major Secondary Analysis - Complete Response Rate

Descriptive statistics and estimate variability

Treatment group Arm A+I

Arm I

Arm A

Number of subject  N=272

N=268

N=269

CR rate

196 (72.1%)

180 (67.2%)

174 (64.7%)

Effect estimate per comparison

## Major Secondary endpoint - CR rate

## Arm I vs Arm A

## IMBRUVICA vs ASCT Arms

Relative risk (2-sided 95% CI)

1.038 (0.919, 1.173)

P-value

0.5851

Arm A+I vs Arm A

IMBRUVICA + ASCT vs ASCT Arms

Relative risk (2-sided 95% CI)

1.114 (0.993, 1.250)

P-value

0.0788

Arm A+I vs Arm I

IMBRUVICA + ASCT vs IMBRUVICA Arms

Relative risk (2-sided 95% CI)

1.073 (0.959, 1.200)

P-value

0.2250

Notes

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

## 2.4.3. Discussion on clinical efficacy

Study MCL3003 (TRIANGLE) is a randomised, 3-arm, open-label, multicenter Phase 3 study.

Transplant-eligible patients ≤ 65 years with newly diagnosed MCL Stage II-IV were stratified according to MIPI risk groups and Study groups, and randomised to:

- Alternating 3 cycles R-CHOP (Cycles 1, 3, and 5)/3 cycles R-DHAP (Cycles 2, 4, and 6) induction followed by ASCT (Arm A)
- Alternating 3 cycles R-CHOP+ibrutinib (Cycles 1, 3, and 5)/3 cycles R-DHAP (Cycles 2, 4, and 6) induction, followed by ASCT, and 2 years ibrutinib maintenance (Arm A+I)
- Alternating 3 cycles R-CHOP+ibrutinib (Cycles 1, 3, and 5)/3 cycles R-DHAP (Cycles 2, 4, and 6) induction, followed by 2 years ibrutinib maintenance (Arm I)

Since the final results from the LyMa trial (Le Gouill 2017) demonstrated prolonged OS for the rituximab maintenance group after ASCT in patients with previously untreated MCL, this approach was added to all 3 treatment arms depending on implementation in the national treatment guidelines for each study site during the study.

## Endpoints

The primary endpoint FFS was defined as the time from randomisation to SD at the end of induction immunochemotherapy (EoI), PD, or death from any cause, whichever comes first. Not achieving PR or better at EoI was considered treatment failure and an FFS event. FFS, as defined above, is considered an appropriate primary endpoint based on the treatment paradigm for transplant-eligible MCL patients at the time of the study initiation. Response assessment was performed based on CT scans and bone marrow examinations using of the Revised Response Criteria for Malignant Lymphoma (Cheson 2007).

<div style=\"page-break-after: always\"></div>

The primary endpoint was FFS assessed by central medical European MCL Network case evaluation of investigator assessment per protocol criteria.

The secondary efficacy endpoints (OS, PFS, CRR, ORR, and PR to CR conversion rate) were analysed in a descriptive way without correction for multiple testing.

## Sample size

Overall, the sample size calculations seem to have been well thought out.

## Randomisation and blinding

The randomisation process seems to have been adequately planned. Randomization was performed via EDC system and done in accordance with pre-specified distribution in the number of subjects in each treatment group and pre-specified ratio. The study was not blinded.

## Analysis sets

Initially, analysis of the primary objective was planned to be performed according to the ITT. However, the initial ICF did not explicitly request permission for participants data to be included in a dossier for global HA submissions as per the subsequently applicable GDPR.

Study participants were therefore required to re-consent to provide this permission during study conduct. It is understood that the applicant and sponsor did not systematically select which subjects would re-consent. All efforts were made to re-consent all subjects. It is deemed unlikely that selection bias occurred in regard to the re-consenting process. The exception to this is for patients that died and therefore reconsent did not apply, they were differentially selected dependent on outcome. It is deemed unlikely that these patients could have had an impact on the overall conclusion. The resulting population is termed the FAS.

The applicant did not manage to re-consent 61 of the 870 randomized participants (ITT). Data for these 61 participants are therefore not included in the analyses nor presented in the CSR. As a result, the analysis population (FAS) prepared by the Applicant is limited to the 809 participants (93% of ITT) who either provided explicit consent for their data to be included in a dossier for global HA submissions or were deceased.

Reasons for why re-consent could not be obtained include 'withdrawal of consent prior HA submission', 'lost to follow-up', 'refusal of consent' as well as 'other' reasons, including the inability to contact or reach participants.

## Primary efficacy endpoint

In the pre-specified analyses section of the protocol, the sponsor chose to perform three pairwise statistical tests one-sided at 5% significance level , because only differences observed in the direction indicated by the respective alternative hypothesis would result in consequences for the decision in

<div style=\"page-break-after: always\"></div>

favour of a treatment arm. Thus, the following pairwise one-sided tests were planned by the sponsor: A+I superior to A; A superior to I; A+I superior to I

Considering the hypothesis testing of e.g A vs I was one-sided to detect superiority of A vs. I, superiority of I vs A couldn't be concluded.

Consequently, the MAH prepared a separate SAP (version 5 dated 5 September 2024) with post-hoc analyses to supplement the original pre-specified analyses and thereby provide a comprehensive evaluation of the study data in support of the regulatory submission. First version of the SAP is dated 16 sept 2022.

The CSR therefore includes not only the results of original pre-specified (one-sided tests at 0.05/3 significance level for each test), but also post-hoc analyses based on 2-sided alpha at 5% significance level (i.e., two-sided test at 1.667% significance level for each pairwise test) and one-sided post-hoc analyses based on 2.5% significance level (i.e., one-sided test at 0.83% significance level for each pairwise test).

## Timing of analysis

Sequential statistical design was applied in this study. Pre-planned interim analyses were performed during the study on the ITT population, as specified in the original protocol from the academic sponsor, in approximately half-yearly intervals for each pairwise comparison (1-sided overall 5% significance level) to allow early stopping for efficacy or futility using the truncated sequential probability ratio test (tSPRT) boundary-based approach. Cut-offs for superiority and futility were based on Z values and not p-values. The crossing boundaries were calculated at each interim analysis, for each pairwise comparison. Statistical monitoring would continue until next interim analysis if crossing boundary had not been reached.

To address the advice given by the MPA in 2024, the MAH was asked to re-run the interim analyses retrospectively based on the FAS population, to conclude a read-out that was based on the reconsented subjects (i.e. FAS population) with not only the pre-specified 1-sided overall 5% significance level, but also applying a two-sided 5% significance level. Results from the retrospective interim analyses on the FAS population, at the 1-sided overall 5% significance level as pre-specified in the original protocol, were aligned with the conclusions drawn by the sponsor based on the ITT analysis set (Dreyling 2024), albeit at different interim analyses for A+I vs A and A+I vs I, which happened at IA7 (dated 24 oct 2021) and IA11 (dated 09 May 2024) respectively. When a more stringent two-sided overall 5% significance level was applied, superiority boundary was crossed at IA8 (dated 22 May 2022) for comparison I vs A and futility stop at IA9 (dated 01 May 2023) for comparison A+I vs I.

As for comparison of A+I vs A, - which was part of the original scope - neither superiority nor futility could be concluded at the time of the CCO for primary analysis (IA11 dated 09 May 2024), meaning that the study should have continued to be followed up for this comparison. However, the final indication claim does not include the A+I combination regimen therefore this issue is not further pursued.

Furthermore, the applicant provided, the number of FFS events when boundaries were crossed for each hypothesis test. For the 2-sided tests at a 1.67% significance level, boundaries were crossed at IA8 for I vs. A, with a total of 106 events (69 events in Arm A and 37 events in Arm I). Based on the truncated sequential probability ratio test, it was estimated that a maximum of 230 events would be needed for the comparison A vs. I. Corresponding fixed-sample test (without interim analyses) would

<div style=\"page-break-after: always\"></div>

require 218 events. It is noted that the actual number of events did not exceed estimated maximum number of events, which is acceptable.

## Analysis methods for primary efficacy endpoint

The statistical method section is overall sparce in the initial protocol. The protocol states: for p-values and hazard ratios for the primary analysis, the treatment effects would be calculated correcting for the sequential design . Statistical monitoring of log-rank test for FFS is mentioned, but no details on whether this test would be unstratified or stratified by variables used during randomisation or any other stratification strata of interest.

Post-hoc SAP version 5 however, details the derivation of the primary endpoint FFS as well as the statistical methods that were planned to be used as primary estimator. One-sided unstratified log-rank test with alpha at 1,67% as well as supplementary analyses based on two-sided log-rank test with alpha at 0,83% at each tail were stated as a primary estimator. Median unbiased estimator (MUE) of hazard ratio with one-sided CI at 98,33% as well as unstratified Cox's regression model with study treatment as the sole explanatory to provide hazard ratio with one-sided 98,33% CI were also specified as primary estimator.

Analyses presented in the CSR seem to have been done in accordance with post-hoc SAP version 5. Hazards ratio from unstratified Cox-regression model and two-sided p-values from unstratified logrank test based on 5% significance level (divided equally between each hypothesis) are presented. For the primary efficacy analysis, the FFS results were derived from both the tSPRT method and the Cox proportional hazard model. The overall conclusion between tSPRT method reflect the overall conclusion from the Cox proportional hazard model for comparison I vs. A, which is acceptable.

Stratification factors (MIPI risk group and Rituximab maintenance status) have been included in separate models respectively, however, there does not seem to be any analysis that include both stratification factors in one model. Nevertheless, a comparison between models without stratification factors [HR 0.639 CI 0.428 - 0.953] and model with stratification factors MIPI [HR 0.627 CI 0.420 0.936] and Rituximab Maintenance Status [HR 0.587 CI 0.393 - 0.878] for Arm I vs. A show similar results in the HR. It can be concluded that a model that includes both stratification factors Rituximab maintenance status and MIPI risk group would yield similar results and was therefore not requested.

## Multiplicity

Multiplicity was planned to be controlled at 5% significant level for the whole study. It is questionable whether the type-1 error was maintained at 5% in this study. There are several points that may have contributed to the loss of type-I error i.e one-sided hypotheses that were pre-specified in the initial version of the protocol, the main analysis model that were not clearly defined in the protocol as well as the multiple interim analyses.

The protocol mentions that the tSPRT method and the Christmas tree adjustment were applied. The truncated sequential probability ratio test (tSPRT) was used for adjustment for the repeated (interim) analyses within each treatment comparison and Bonferroni approach was used for multiplicity adjustment for the three pairwise treatment comparisons. The applicant further details that the tSPRT framework is specifically designed to handle the analysis of data collected at varied intervals while effectively controlling the error rate by employing a well-defined boundary-based approach for multiple

<div style=\"page-break-after: always\"></div>

analyses. The applicant has provided more details regarding the tSPRT method and references to a well-known published book (Whitehead, 1997), which is acknowledged.

All secondary objectives were planned to be analysed in a descriptive way without correction for multiple testing.

## Intercurrent events

It is understood that treatment policy was the primary strategy for handling of intercurrent events and hypothetical strategy was used as supportive, which is acceptable. Results applying hypothetical strategy to handling of use of subsequent anticancer therapies are presented.

## Sensitivity analyses

Sensitivity analyses were performed as specified in the post-hoc SAP. A stratified Cox regression model defined as sensitivity estimator 2 seem to have taken stratification variables used during randomization into account, though stratification factor Study group was substituted by Rituximab maintenance status due to the large number of categories in variable Study group. The sample CRF indicates that an external code list was made for Study group stratification factor.

## Study conduct

The MAH has submitted 8 protocol versions. None of the presented substantial amendments are considered to have a major impact on the overall efficacy conclusions.

Out of 809 participants in the FAS, 62 (7.7%) had major protocol deviations. It is noted that 5 patients (1.9%) in Arm I received disallowed concomitant treatment. This is not considered to have a major impact on the overall efficacy conclusions.

## Efficacy data and additional analyses

The median time on study was 54.9 months (range: 0-91). In the FAS, 82.2% participants remained ongoing in the study at the time of CCO.

Median study treatment duration was 29.21 months (range: 0-39.3) for Arm A+I and 28.45 months (range: 0.2-35.5) for Arm I versus 5.16 months (range: 0.2-12.7) for Arm A.

All participants had either discontinued (32.4%) or completed (67.5%) study treatment at CCO.

Baseline characteristics of the FAS are considered reflective of the target population and were overall balanced across the treatment arms. Median age was 57.0 years (range: 27 to 68 years) and 76.8% of the participants were male which is consistent with the described sex-distribution pattern for MCL. Most participants had an ECOG score of 0 (71.7%) or 1 (27.0%).

The distribution of poor prognostic factors such as blastoid/pleomorphic histology, increased p53 expression, and elevated Ki-67 proliferation index was similar across the treatment arms.

The proportion of participants receiving rituximab maintenance treatment was balanced across the 3 treatment arms: 59.9% in Arm A+I, 59.7% in Arm I, and 62.5% in Arm A.

A comparison of the baseline demographic and disease characteristics of the FAS (n=809) and ITT populations (n=870, Dreyling et al 2024) demonstrated consistency between the 2 populations. As a comparable and relatively large number of participants were included in the FAS across all treatment

<div style=\"page-break-after: always\"></div>

arms (overall 809/870; 93%), the use of the FAS is not considered to have introduced a significant bias. Thus, the conclusions of the study results based on FAS are considered to adequately reflect those of the ITT population.

## Pre-planned and additional analyses of primary endpoint FFS in the primary analysis

At the CCO date, 61 FFS events (22.4%) in Arm A+I, 61 FFS events (22.8%) in Arm I, and 87 FFS events (32.3%) in Arm A) were reported. Although the FFS data is not fully mature, the rather extensive duration of follow-up substitutes for this (median 54.9 months).

The proportion of censored patients in the FFS analysis at CCO date was 77.6% in Arm A+I, 77.2% in Arm I, and 67.7% in Arm A. There is no concern that informative censoring could have had major impact on the FFS analysis. EMA censoring rules were applied in study MCL3003.

Of note, FFS analyses were performed on the FAS using both:

1. One-sided test with a significance level of 1.67% (5%/3) for each of the 3 hypotheses to maintain an overall one-sided 5% significance level, as pre-specified in the original study protocol by the academic sponsor, with Bonferroni-correction for multiple testing.
2. -Arm A+I vs Arm A: Improvement in FFS was demonstrated for participants in Arm A+I vs Arm A, HR unstratified Cox regression (1-sided 98.33% CI) 0.633 (0, 0.904), p-value (1-sided) 0.0029.
3. -Arm A vs Arm I : Arm A failed to show superiority in FFS compared with Arm I, HR unstratified Cox regression (1-sided 98.33% CI) 1.565 (0, 2.233), p-value (1-sided) 0.9966.
4. -Arm A+I vs Arm I : No meaningful differences in FFS were observed for participants in Arm A+I vs Arm I, HR unstratified Cox regression (1-sided 98.33% CI) 0.983 (0, 1.445), p-value (1sided) 0.4612.

MUE HR estimates (with adjustment for interim analyses) were numerically similar to the corresponding Cox estimates across all three analyses.

2. Additional post-hoc analyses using two-sided 5% significance level (ie, a 2-sided 1.67% level for each of the 3 tests).
2. -An improvement in FFS was observed for participants in Arm A+I vs Arm A , HR unstratified Cox regression (2-sided 98.33% CI) of 0.633 (0.425, 0.945), 2-sided p-value: 0.0058, which is in line with the results from the originally pre-specified 1-sided test of Arm A+I vs Arm A. However, as outlined above, the retrospective interim analyses on the FAS (using two-sided overall 5% significance level) showed that neither the superiority boundary nor the futility boundary for Arm A+I vs Arm A was crossed at the time of the CCO for primary analysis.
3. -An improvement in FFS was observed for participants in Arm I vs Arm A , HR unstratified Cox regression (2-sided 98.33% CI) of 0.639 (0.428, 0.953), 2-sided p-value: 0.0068. Of note, this two-sided test provides results for superiority testing of Arm I vs Arm A, as compared to results provided for the one-sided comparison of Arm A vs Arm I as pre-specified in the

<div style=\"page-break-after: always\"></div>

original protocol, which only tested one-sided for the opposite direction, i.e., superiority of A vs I.

- -No difference was observed in FFS for participants in Arm A+I vs Arm I , HR unstratified Cox regression (2-sided 98.33% CI) of 0.983 (0.637, 1.516), 2-sided p-value: 0.9224, which is in line with the results from the originally pre-specified 1-sided test of Arm A+I vs Arm I.

MUE HR estimates (with adjustment for interim analyses) were numerically similar to the corresponding Cox estimates across all three analyses.

The presented FFS sensitivity analyses, i.e., FFS stratified by MIPI, Rituximab status, and Investigator assessment were overall consistent with primary FFS results.

In addition, FFS supplementary analysis, censoring participants who started a subsequent anticancer therapy prior to SD at EoI or PD (1, 3, and 2 participants in Arm A+I, Arm I and Arm A, respectively), were consistent with the primary FFS results.

Moreover, to assess a potential impact of the ITT data that were not included in the FAS, FFS results for the FAS (based on the primary analysis CCO date of 09 May 2024, median follow-up 54.9 months) were compared with FFS results from the ITT population (based on a CCO date of 22 May 2022, median follow-up 31 months, as published by the sponsor, Dreyling 2024). This comparative review of the FFS results for the FAS and ITT population indicates that the efficacy results obtained with the FAS are overall consistent with the results obtained with the ITT population.

The FFS results were generally consistent across relevant subgroups. Notably, subgroup analyses are hampered by exploratory nature and small sample size.

Regarding rituximab maintenance, this approach was similarly implemented in each study arm and therefore does not incur bias with respect to the efficacy demonstration. With regards to potential heterogeneity of between-arm treatment effects depending on whether rituximab was given, subgroup analyses show overlapping confidence limits and no indication of substantially different effect sizes.

In SmPC section 5.1, a footnote was added under the Efficacy results table to specify that ' The FFS results are not controlled for type 1 error, as these analyses are derived from post-hoc analyses conducted for registrational purposes '.

## Secondary endpoints

OS results were consistent with the observed results for the primary endpoint FFS. There was no indication of a detrimental effect when substituting ibrutinib for ASCT, or when adding ibrutinib to ASCT. At the time of CCO, 60 participants (22.3%) in Arm A had died, vs 34 participants (12.5%) in Arm A+I and 33 participants (12.3%) in Arm I.

Similar to the FFS results, the Kaplan Meier curves for OS showed a separation between the 2 ibrutinib containing arms and the control arm. Improvement in OS was observed for participants in Arm A+I vs Arm A (Cox regression HR [95% CI] of 0.542 [0.356, 0.826] 2-sided nominal p-value=0.0038) as well as for participants in Arm I vs Arm A (Cox regression HR [95% CI] of 0.522 [0.341, 0.799]; 2-sided

<div style=\"page-break-after: always\"></div>

nominal p value=0.0023). As for FFS, no difference in survival was demonstrated for the comparison of Arm A+I and Arm I (HR [95% CI]: 1.040 [0.644, 1.679], 2-sided nominal p value: 0.8721).

The early increase in fatal events observed in Arm A and Arm A+I in comparison to Arm I, and the corresponding initial decline in the Kaplan-Meier OS curve for the two ASCT-containing treatment arms, were to a large extent attributed to the toxicity associated with high-dose therapy.

No increase in OS events, including relapse-related events, was observed after the completion of the maintenance period in Arm I compared to Arm A and Arm A+I.

As could be expected, subsequent anticancer therapy differed between Arm A and the ibrutinibcontaining treatment arms. In Arm A, most participants received subsequent anticancer therapy at disease progression with a BTK inhibitor (i.e., 49/59 receiving subsequent anticancer therapy), while most participants in Arm A+I and Arm I received different combination regimens of antineoplastic agents following progression after ibrutinib-based treatments.

PFS results were consistent with the observed results for the primary endpoint FFS, which is expected since the only difference between these 2 endpoints is that not achieving at least PR, but instead only stable disease at EoI is considered as treatment failure and an event for FFS, whereas it is not considered an event for PFS.

Overall response rates were similar across the 3 treatment arms: 95.6% for Arm A+I, 96.3% for Arm I, and 92.2% for Arm A. The CR rate was 72.1% for Arm A+I, 67.2% for Arm I, and 64.7%, for Arm A. The ORR and CR rates are of interest for prescribers and these data are presented in SmPC section 5.1.

The published results from study MCL3003 (Dreyling, Lancet 2024) have led to the adoption of the treatment strategy in MCL3003 as alternative treatment approaches for newly diagnosed young MCL patients &lt; 66 years, in the NCCN GL 2025. In addition, the treatment strategy of Arm I is presented as the new standard of care in younger MCL patients, based on results from study MCL3003 (Dreyling, ASH December 2024). Thus, the published results from study MCL3003 appear to have triggered practice changing initiatives in the lymphoma community. European MCL Network recently presented an abstract in which they propose the

## Additional expert consultation

NA

## Assessment of paediatric data on clinical efficacy

NA

## 2.4.4. Conclusions on the clinical efficacy

Data demonstrate a clinically meaningful improvement of efficacy in the ibrutinib-containing treatment arms, compared to the standard ASCT regimen without ibrutinib. There was no demonstrable added benefit of including ASCT in the ibrutinib-containing regimen.

Thus, data support an extension of indication as: 'IMBRUVICA in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (IMBRUVICA + R-CHOP) alternating with a R-DHAP (or R-DHAOx) without IMBRUVICA, followed by IMBRUVICA monotherapy, is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who would be

<div style=\"page-break-after: always\"></div>

eligible for autologous stem cell transplantation (ASCT).'

## 2.5. Clinical safety

## Introduction

Ibrutinib has been authorised for use in the EU since 2014 and approved in several indications. The safety profile previously established include diarrhoea, neutropenia, musculoskeletal pain, haemorrhage (e.g., bruising), rash, nausea, thrombocytopenia, arthralgia, and upper respiratory tract infection. Neutropenia, lymphocytosis, thrombocytopenia, hypertension, and pneumonia constitute the most common grade 3/4 adverse reactions (≥5%).

The safety specification according to the latest approved RMP version 22.1, include `Haemorrhage´, `Hepatotoxicity (including hepatic failure)´, `Atrial fibrillation´, `Ventricular tachyarrhythmias´,

`Hypertension´, `Ischemic stroke´, `Cardiac failure´, and `Infections (including viral reactivation)´ as important identified risks and `PML´, `Cardiac arrhythmia (excluding atrial fibrillation and ventricular tachyarrhythmias)´, and `Other malignancies (excluding non-melanoma skin cancer)´ as important potential risks.

The key safety data in support of this application derive from the primary analysis of Study MCL3003 (TRIANGLE) with a data cutoff date of 09 May 2024.

## Patient exposure

The dose of ibrutinib used in the study was 560 mg daily which is the approved dose as single agent for the treatment of patients with relapsed/refractory MCL. Standard doses and schedules were administered for R-CHOP/R-DHAP. Rituximab maintenance was not considered a study treatment in the TRIANGLE study as evidence supporting rituximab maintenance treatment (Le Gouill 2017) was not yet established at the start of the study. However, upon its implementation in the national guidelines for a participating country, rituximab maintenance was to be administered to participants, as per the recommendation of the site´s study group.

Table 21 Duration of Study Treatment; Safety Analysis Set (Study 54179060MCL3003)

|                                                | A+I           |               | A            |
|------------------------------------------------|---------------|---------------|--------------|
| Analysisset:Safety                             | 275           | 265           | 268          |
| Totaltreatmentduration (maximumnumberofmonths) |               |               |              |
| N                                              | 275           | 265           | 268          |
| Mean (SD)                                      | 22.44(10.753) | 24.42 (8.688) | 5.22 (1.546) |
| Median                                         | 29.21         | 28.45         | 5.16         |
| Q1, Q3                                         | 12.91,30.85   | 23.62,29.34   | 4.75, 5.78   |
| Range                                          | (0.0; 39.3)   | (0.2; 35.5)   | (0.2; 12.7)  |

Key:ASCT=autologousstem cell transplant,A=ASCT,A+I=ASCT+Ibrutinib,I=Ibrutinib,SD=standard deviation,Q1=first quartile,Q3=thirdquartile Note:Durationfrom thefirstdoseofanystudytreatment to thelastdoseofanystudytreatment,where studytreatmentreferstoIbrutinibR-CHOPR-DHAP,BEAM TEAM,THAMorPBSCT.

Table 22 Extent of Exposure for Ibrutinib during Induction Therapy; Safety Analysis Set (Study 54179060MCL3003)

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                          | A+I               |                   |
|------------------------------------------|-------------------|-------------------|
| Analysis set: Safety                     | 275               | 265               |
| Total number of cycles                   |                   |                   |
| N                                        | 273               | 265               |
| 1 cycle                                  | 7 (2.6%)          | 7 (2.6%)          |
| 2 cycles                                 | 12 (4.4%)         | 5 (1.9%)          |
| >=3 cycles                               | 254 (93.0%)       | 253 (95.5%)       |
| Mean (SD)                                | 2.9 (0.41)        | 2.9 (0.35)        |
| Median                                   | 3.0               | 3.0               |
| Q1,Q3                                    | 3.0, 3.0          | 3.0, 3.0          |
| Range                                    | (1; 5)            | (1;4)             |
| Total dose administered (mg)             |                   |                   |
| N                                        | 273               | 265               |
| Mean (SD)                                | 29880.0 (6120.86) | 30392.2 (5297.81) |
| Median                                   | 31920.0           | 31920.0           |
| Q1,Q3                                    | 29680,31920       | 30800, 31920      |
| Range                                    | (560; 76720)      | (2800; 48720)     |
| Dose intensity per protocol (mg/day)b    |                   |                   |
| N                                        | 273               | 265               |
| Mean (SD)                                | 524.2 (107.38)    | 533.2 (92.94)     |
| Median                                   | 560.0             | 560.0             |
| Q1, Q3                                   | 520.7,560.0       | 540.4, 560.0      |
| Range                                    | (10; 1346)        | (49; 855)         |
| Relative dose intensity per protocol (%) |                   |                   |
| N                                        | 273               | 265               |
| Mean (SD)                                | 93.6 (19.18)      | 95.2 (16.60)      |
| Median                                   | 100.0             | 100.0             |
| Q1, Q3                                   | 93.0, 100.0       | 96.5, 100.0       |
| Range                                    | (2; 240)          | (9; 153)          |

Key: ASCT=autologous stem cell transplant, A=ASCT, A+I=ASCT+Ibrutinib,I=Ibrutinib, SD=standard deviation, Q1=first quartile, Q3=third quartile.

- b Dose intensity per protocol is calculated as the ratio of total dose administered and planmed total treatment duration per protocol (mg/day).
- Treatment duration is calculated as (date oflast dose of Ibrutinib -date of first dose ofIbrutinib +1)/30.4375.

* Relative dose intensity per protocol is calculated as the ratio of dose intensity per protocol and 560 mg.

Note: Percentages are calculated with the number of subjects in each treatment group with available data as denominator.

Table 23 Extent of Exposure for Ibrutinib during Maintenance Period; Safety Analysis Set (Study 54179060MCL3003)

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                           | A+I                  |                      |
|-------------------------------------------|----------------------|----------------------|
| Analysis set: Safety                      | 275                  | 265                  |
| Total treatment duration (months)         |                      |                      |
| N                                         | 230                  | 245                  |
| Mean (SD)                                 | 18.3 (7.91)          | 21.3 (6.24)          |
| Median                                    | 23.2                 | 24.0                 |
| Q1, Q3                                    | 11.4, 24.0           | 22.2, 24.1           |
| Range                                     | (0;29)               | (0;29)               |
| 0 -<6 months                              | 27 (11.7%)           | 14 (5.7%)            |
| 6-<12 months                              | 33 (14.3%)           | 12 (4.9%)            |
| 12 -<18 months                            | 15 (6.5%)            | 17 (6.9%)            |
| >= 18 months                              | 155 (67.4%)          | 202 (82.4%)          |
| Total dose administered (mg)              |                      |                      |
| N                                         | 230                  | 245                  |
| Mean (SD)                                 | 276316.2 (135622.74) | 337144.0 (110712.67) |
| Median                                    | 316750.0             | 389200.0             |
| Q1,Q3                                     | 179060.0, 397600.0   | 304920.0, 408800.0   |
| Range                                     | (1680; 451360)       | (3360; 482720)       |
| Dose intensity (mg/day)b                  |                      |                      |
| N                                         | 230                  | 245                  |
| Mean (SD)                                 | 483.9 (96.74)        | 520.2 (70.32)        |
| Median                                    | 537.8                | 555.2                |
| Q1,Q3                                     | 424.0, 560.0         | 515.5,560.0          |
| Range                                     | (98; 560)            | (231; 561)           |
| Relative dose intensity (%)c              |                      |                      |
| N                                         | 230                  | 245                  |
| Mean (SD)                                 | 86.4 (17.28)         | 92.9 (12.56)         |
| Median                                    | 96.0                 | 99.1                 |
| Q1,Q3                                     | 75.7, 100.0          | 92.1, 100.0          |
| Range                                     | (18; 100)            | (41; 100)            |
| Dose intensity per protocol (mg/day)d     |                      |                      |
| N                                         | 230                  | 245                  |
| Mean (SD)                                 | 378.5 (185.78)       | 461.8 (151.66)       |
| Median                                    | 433.9                | 533.2                |
| Q1, Q3                                    | 245.3, 544.7         | 417.7, 560.0         |
| Range                                     | (2; 618)             | (5; 661)             |
|                                           | A+I                  |                      |
| Relative dose intensity per protocol (%)* |                      |                      |
| N                                         | 230                  | 245                  |
| Mean (SD)                                 | 67.6 (33.18)         | 82.5 (27.08)         |
| Median                                    | 77.5                 | 95.2                 |
| Q1,Q3                                     | 43.8, 97.3           | 74.6, 100.0          |
| Range                                     | (0; 110)             | (1; 118)             |

Key: ASCT=autologous stem cell transplant, A=ASCT, A+I=ASCT+Ibrutinib, I=Ibrutinib, SD=standard deviation, Q1=first quartile, Q3=third quartile.

b Dose intensity is calculated as the ratio of total dose administered and total treatment duration (mg/day).

Treatment duration is calculated as (date of last dose of Ibrutinib - date of first dose of Ibrutinib +1)/30.4375.

*Relative dose intensity is calculated as the ratio of dose intensity and 560 mg.

• Relative dose intensity per protocol is calculated as the ratio of dose intensity per protocol and 560 mg.

d Dose intensity per protocol is calculated as the ratio of total dose administered and planned total treatment duration per protocol (mg/day).

Note: Percentages are calculated with the number of subjects in each treatment group with available data as denominator.

## Methodology for ADR Determination

## Protocol Definition of an AE

Treatment-emergent AEs were defined as AEs that started or worsened in severity after the first dose of study treatment up to 30 days following the last dose of study treatment or until the start of subsequent anti-cancer therapy, if earlier, and also included any AE that was considered study treatment related regardless of the start date of the event. The last individual study specific medication in Arm A is the ASCT, in Arm A+I and Arm I it is the last dose of Ibrutinib-Maintenance.

## ADR Term Selection

The following steps were used to determine ADR terms for the labelling pool(s):

- Step Ia . TEAE data from Arm A+I and Arm I from the Study MCL3003 were compared to the TEAEs from Arm A. TEAE preferred terms (including grouped terms) that met the following criteria were identified:
- -TEAE reported in ≥10% of participants in Arm A+I and/or Arm I and reported at a &gt;5% higher incidence compared to Arm A.

<div style=\"page-break-after: always\"></div>

- Step Ib . Serious TEAE data from Arm A+I and Arm I from Study MCL3003 were compared to the serious TEAEs from Arm A. Serious TEAE preferred terms (including grouped terms) that met the following criteria were identified:
- -Serious TEAEs reported in ≥2% of participants in any of the two ibrutinib -containing arms, Arm A+I and Arm I and reported at a &gt;2% higher incidence when any of the two arms, Arm A+I and Arm I is compared to Arm A.
- Step II . Medical review of potential ADRs identified in Steps Ia and Ib was conducted. In addition, a review of all ADRs from the current SmPC and any events from Study MCL3003 were conducted, to identify additional ADRs that are biologically plausible based on the current biological and clinical knowledge of ibrutinib therapy (e.g., mechanism of action, pharmacological profile or well-established ADR for ibrutinib from other clinical trials or post marketing spontaneous reports, consistent trending across multiple studies).
- Step III . A final list of ADRs as identified in Steps I and II above was compiled and applied to the safety population in Study MCL3003 to establish ADR frequency rates for proposed labelling.

Table 24 Incidence of Treatment-emergent Adverse Drug Reaction (ADR) by Toxicity Grade, System Organ Class and ADR Term (EUPI, rounded) - MCL3003; Safety Population

|                                                     |                                   | A+I(N=275)             | A+I(N=275)   | A+I(N=275)                   | I(N=265)               | I(N=265)       | I(N=265)      |
|-----------------------------------------------------|-----------------------------------|------------------------|--------------|------------------------------|------------------------|----------------|---------------|
| System Organ Class                                  | Adverse Drug Reactions            | Frequency (All Grades) |              | All Grades (%) Grade >=3 (%) | Frequency (All Grades) | All Grades (%) | Grade >=3 (%) |
| Blood and lymphatic system disorders                | Thrombocytopenia*                 | Very common            | 78           | 72                           | Very common            | 69             | 61            |
|                                                     | Neutropenia*                      | Very common            | 76           | 75                           | Very common            | 63             | 60            |
|                                                     | Febrile neutropenia               | Very common            | 36           | 36                           | Very common            | 14             | 14            |
|                                                     | Leukocytosis                      | Common                 | 7            | 3                            | Common                 | 3              | <1            |
|                                                     | Lymphocytosis*                    | Common                 | 4            | 1                            |                        | 0              | 0             |
| Cardiac disorders                                   | Atrial fibrillation               | Common                 | 8            | 5                            | Common                 | 10             | 4             |
|                                                     | Cardiac failure*                  | Common                 | 2            | 1                            | Common                 | 2              | 0             |
|                                                     | Ventricular tachyarhythmia*       | Uncommon               | <            | <1                           |                        | 0              | 0             |
| Eye disorders                                       | Vision blurred                    | Uncommon               | <1           | 0                            | Uncommon               | <              | 0             |
|                                                     | Eye haemorrhage                   |                        | 0            | 0                            | Uncommon               | <1             | 0             |
| Gastrointestinal disorders                          | Nausea                            | Very common            | 41           | 8                            | Very common            | 32             | 4             |
|                                                     | Diarrhoea                         | Very common            | 38           | 7                            | Very common            | 28             | 5             |
|                                                     | Vomiting                          | Very common            | 22           | 4                            | Very common            | 18             | 4             |
|                                                     | Stomatitis*                       | Very common            | 21           | 10                           | Very common            | 11             | 2             |
|                                                     | Constipation                      | Very common            | 21           | 0                            | Very common            | 17             | <1            |
|                                                     | Dyspepsia                         | Common                 | 7            | 0                            | Common                 | 8              | 0             |
| Generaldisorders and administration site conditions | Pyrexia                           | Very common            | 35           | 3                            | Very common            | 22             | 2             |
|                                                     | Oedema peripheral                 | Common                 | 5            | <1                           | Common                 | 5              | 0             |
| Hepatobiliary disorders                             | Hepatic failure*                  | Uncommon               | <1           | <1                           |                        | 0              | 0             |
| Immune system disorders                             | Interstitial lung disease*        | Common                 | 3            | 1                            | Common                 | 5              | <1            |
| Infections and infestations                         | Pneumonia*#                       | Very common            | 26           | 15                           | Very common            | 16             | 9             |
|                                                     | Skin infection*                   | Very common            | 13           | 2                            | Very common            | 12             | 3             |
|                                                     | Upper respiratory tract infection | Very common            | 11           | 1                            | Common                 | 6              | <1            |
|                                                     | Sepsis*#                          | Common                 | 10           | 9                            | Common                 | 2              | 2             |
|                                                     | Urinary tract infection           | Common                 | 6            | 1                            | Common                 | 6              | <1            |
|                                                     | Sinusitis*                        | Common                 | 4            | 1                            | Common                 | 6              | <1            |
|                                                     | Aspergillus infections*           | Uncommon               | <1           | 1                            | Uncommon               | 1              | <1            |
|                                                     | Pneumocystis infections*          | Uncommon               | <            | <1                           |                        | 0              | 0             |
| Investigations                                      | Hypokalaemia                      | Very common            | 23           | 9                            | Very common            | 14             | 6             |
|                                                     | Blood creatinine increased        | Very common            | 15           | <1                           | Very common            | 16             | 1             |
|                                                     | Hypomagnesaemia                   | Very common            | 11           | 2                            | Common                 | 7              | <1            |
| Metabolism and nutrition disorders                  | Hyperuricaemia                    | Common                 | 5            | 2                            | Common                 | 8              | 3             |
|                                                     | Tumour lysis syndrome*            | Uncommon               | <1           | <1                           | Common                 | 3              | 3             |

<div style=\"page-break-after: always\"></div>

|                                                                    |                            | A+I(N=275)             | A+I(N=275)     | A+I(N=275)    | I (N=265)              | I (N=265)      | I (N=265)     |
|--------------------------------------------------------------------|----------------------------|------------------------|----------------|---------------|------------------------|----------------|---------------|
| System Organ Class                                                 | Adverse Drug Reactions     | Frequency (All Grades) | All Grades (%) | Grade >=3 (%) | Frequency (All Grades) | All Grades (%) | Grade >=3 (%) |
| Musculoskeletaland connective tissue disorders                     | Musculoskeletal pain*      | Very common            | 23             | 3             | Very common            | 19             | 2             |
|                                                                    | Muscle spasms              | Common                 | 10             | <1            | Common                 | 9              | 1             |
|                                                                    | Arthralgia                 | Common                 | 8              | 0             | Common                 | 8              | <1            |
| Neoplasms benign,malignant and unspecified (incl cysts and polyps) | Non-Melanomaskincancer*    | Common                 | 1              | 0             | Common                 | 1              | <1            |
|                                                                    | Basal cell carcinoma       | Uncommon               | &1             | 0             | Common                 | 1              | <1            |
|                                                                    | Squamouscellcarcinoma      | Uncommon               | <1             | 0             |                        | 0              | 0             |
| Nervous system disorders                                           | Peripheral neuropathy-*    | Very common            | 36             | 4             | Very common            | 35             | 3             |
|                                                                    | Headache                   | Very common            | 11             | 0             | Very common            | 11             | 1             |
|                                                                    | Dizziness                  | Common                 | 5              | 0             | Common                 | 6              | <1            |
|                                                                    | Transient ischaemic attack |                        | 0              | 0             | Uncommon               | 1              | 0             |
| Renal and urinary disorders                                        | Acute kidney injury        | Very common            | 11             | 4             | Very common            | 11             | 5             |
| Skin and subcutaneous tissue disorders                             | Rash*                      | Very common            | 33             | 4             | Very common            | 23             | 2             |
|                                                                    | Erythema                   | Common                 | 4              | <1            | Common                 | 5              | 0             |
|                                                                    | Onychoclasis               | Common                 | 1              | 0             | Common                 | 2              | 0             |
|                                                                    | Urticaria                  | Common                 | 1              | <1            | Uncommon               | <1             | 0             |
|                                                                    | NeutrophilicDermatoses*    | Uncommon               | 1              | 0             |                        | 0              | 0             |
|                                                                    | Angioedema                 |                        | 0              | 0             | Uncommon               | <1             | 0             |
|                                                                    | Cutaneous vasculitis       |                        | 0              | 0             | Uncommon               | <1             | 0             |
|                                                                    | Panniculitis*              |                        | 0              | 0             | Uncommon               | <1             | 0             |
| Vascular disorders                                                 | Haemomhage*                | Very common            | 13             | <1            | Very common            | 14             | 2             |
|                                                                    | Bruising                   | Common                 | 4              | 0             | Common                 | 8              | <1            |
|                                                                    | Epistaxis Petechiae        | Common Common          | 8              | <1            | Common                 | 6              | 1             |
|                                                                    |                            | Common                 | 2              | <1            | Common                 | 3              | 0             |
|                                                                    | Hypertension*              |                        | 10             | 4             | Very common            | 14             | 5             |

* Terms required grouping

Frequencies are defined as: very common (&gt;=1/10), common (&gt;=1/100 to &lt;1/10), uncommon (&gt;=1/1000 to &lt;1/100), rare (&gt;=1/10000 to &lt;1/1000), very rare (&lt;1/10000).

#Includesevents withfataloutcome.

MedDRA is in version 26.1

Use EU ADR strategy.

## Adverse events

## Overall summary of TEAEs

Table 25 Overall Summary of Treatment-emergent Adverse Events; Safety Analysis Set (Study 4179060MCL3003)

|                                                                                                   | A+I         | 1           | A           |
|---------------------------------------------------------------------------------------------------|-------------|-------------|-------------|
| Analysis set: Safety                                                                              | 275         | 265         | 268         |
| Subjects with 1 or more:                                                                          |             |             |             |
| Treatment-emergent adverse events                                                                 | 273 (99.3%) | 263 (99.2%) | 267 (99.6%) |
| Grade >= 3                                                                                        | 268 (97.5%) | 247 (93.2%) | 250 (93.3%) |
| Ibrutinib-related a                                                                               | 233 (84.7%) | 212 (80.0%) | NA          |
| Treatment-emergent serious adverse events                                                         | 186 (67.6%) | 171 (64.5%) | 123 (45.9%) |
| Grade >= 3                                                                                        | 158 (57.5%) | 146 (55.1%) | 105 (39.2%) |
| Ibrutinib-related                                                                                 | 69 (25.1%)  | 50 (18.9%)  | NA.         |
| Treatment-emergent adverse events leading to death b                                              | 15 (5.5%)   | 6 (2.3%)    | 11 (4.1%)   |
| Treatment-emergent adverse events leading to death within 30 days of last dose of study treatment | 6 (2.2%)    | 4 (1.5%)    | 5 (1.9%)    |
| Treatment-emergent adverse events leading to Ibrutinib discontinuation                            | 105 (38.2%) | 61 (23.0%)  | NA          |
| Treatment-emergent adverse events leading to Ibrutinib dose reduction                             | 54 (19.6%)  | 43 (16.2%)  | NA          |
| COVID-19 Treatment-emergent adverse events                                                        | 49 (17.8%)  | 52 (19.6%)  | 5 (1.9%)    |
| COVID-19 Treatment-emergent serious adverse events                                                | 21 (7.6%)   | 23 (8.7%)   | 4 (1.5%)    |
| COVID-19 Treatment-emergent adverse events with outcome of death                                  | 5 (1.8%)    | 4 (1.5%)    | 2 (0.7%)    |

Key: ASCT=autologous stem cell transplant, A=ASCT, A+I=ASCT+Ibrutinib, I=Ibrutinib, COVID-19=Coronavirus Disease 20i9, TEAE=treatment-emergent adverse event, EOT=end of treatment, SMQ=Standardized MedDRA Queries.

* Relatedness is based on investigator assessment. The causal relationship of an adverse event to study treatment is only collected for Ibrutinib.

b Adverse events leading to death are based on AE outcome of Fatal. This includes patients with fatal TEAEs and date of death &gt;30 days after EOT if the respective TEAE started within 30 days after E0T.

Note: There was no Grade 1/2 reporting required after the safety run-in phase.

Note: Percentages are calculated with the number of subjects in safety analysis set as denominator.

Adverse events are coded using MedDRA Version 26.1.

<div style=\"page-break-after: always\"></div>

Table 26 Overall Summary of Treatment-emergent Adverse Events - MCL3003 Induction; Safety Population

|                                                                                                   | A+I         | I           | A           |
|---------------------------------------------------------------------------------------------------|-------------|-------------|-------------|
| Analysis set: Safety Population                                                                   | 275         | 265         | 268         |
| Subjects with 1 or more:                                                                          |             |             |             |
| Treatment-emergent adverse events                                                                 | 272 (98.9%) | 259 (97.7%) | 262 (97.8%) |
| Grade >= 3                                                                                        | 241 (87.6%) | 228 (86.0%) | 220 (82.1%) |
| Ibrutinib-related =                                                                               | 150 (54.5%) | 148 (55.8%) | NA          |
| Treatment-emergent serious adverse events                                                         | 118 (42.9%) | 119 (44.9%) | 110 (41.0%) |
| Grade >= 3                                                                                        | -92 (33.5%) | 90 (34.0%)  | 89 (33.2%)  |
| Ibrutinib-related *                                                                               | L28 (10.2%) | 22 (8.3%)   | NA          |
| Treatment-emergent adverse events leading to death b                                              | 2 (0.7%)    | 1 (0.4%)    | 3 (1.1%)    |
| Treatment-emergent adverse events leading to death within 30 days of last dose of study treatment | 1 (0.4%)    | 1 (0.4%)    | 0           |
| Treatment-emergent adverse events leading to Ibrutinib discontinuation                            | 18 (6.5%)   | 13 (4.9%)   | NA          |
| Treatment-emergent adverse events leading to Ibrutinib dose reduction                             | 4 (1.5%)    | 10 (3.8%)   | NA          |
| COVID-19 Treatment-emergent adverse events                                                        | 5 (1.8%)    | 3 (1.1%)    | 3 (1.1%)    |
| COVID-19 Treatment-emergent serious adverse events                                                | 4 (1.5%)    | 2 (0.8%)    | 2 (0.7%)    |
| COVID-19 Treatment-emergent adverse events with outcome of death                                  | 1 (0.4%)    | 1 (0.4%)    | 1 (0.4%)    |

Key: ASCT=autologous stem cell transplant, A=ASCT, A+I=ASCT+Ibrutinib, I=Ibrutinib, COVID-19=Coronavirus Disease 2019, TEAE=treatment-emergent adverse event, EOT=end of treatment, SMQ=Standardized MedDRA Queries.

Adverse events leading to death are based on AE outcome of Fatal. This includes patients with fatal TEAEs and date of death &gt;30 days after EOT if the respective TEAE started within 30 days after EOT.

* Relatedness is based on investigator assessment. The causal relationship of an adverse event to study treatment is only collected for Ibrutinib.

Note: There was no Grade 1/2 reporting required after the safety run-in phase.

Note: Percentages are calculated with the number of subjects in safety amalysis set as denominator.

Adverse events are coded using MedDRA Version 26.1.

[tsfae01ind.rtf] [PROD/jnj-54179060/triangle/dbr\\_csr/re\\_csr/tsfae0lind.sas] 25OCT2024, 13:40

## Common TEAEs

Table 27 Incidence of TEAEs Occurring in 10% or More Subjects in Any Treatment Group by System Organ Class, Preferred Term and Toxicity Grade; Safety Analysis Set (Study 54179060MCL3003)

<div style=\"page-break-after: always\"></div>

|                                                              | A+I            | A+I                 | A+I       |                       |                     |          | A                     | A                   | A                 |
|--------------------------------------------------------------|----------------|---------------------|-----------|-----------------------|---------------------|----------|-----------------------|---------------------|-------------------|
| Analysis set: Safety                                         | All Grades 275 | Grade 3/4           | Grade 5   | All Grades            | Grade 3/4           | Grade 5  | All Grades 268        | Grade 3/4           | Grade 5           |
|                                                              |                |                     |           | 265                   |                     |          |                       |                     |                   |
| Subjects with any TEAE                                       | 273 (99.3%)    | 253 (92.0%)         | 15 (5.5%) | 263 (99.2%)           | 241 (90.9%)         | 6 (2.3%) | 267 (99.6%)           | 239 (89.2%)         | 11 (4.1%)         |
| System organ class                                           |                |                     |           |                       |                     |          |                       |                     |                   |
| Preferred tem                                                |                |                     |           |                       |                     |          |                       |                     |                   |
| Blood and lymphatic system disorders                         | 240 (87.3%)    | 226 (82.2%)         | 0         | 199 (75.1%)           | 172 (64.9%)         | 0        | 221 (82.5%)           | 201 (75.0%)         | 0                 |
| Anaemia                                                      | 162 (58.9%)    | 121 (44.0%)         | 0         | 119 (44.9%)           | 57 (21.5%)          | 0        | 155 (57.8%)           | 92 (34.3%)          | 0                 |
| Neutropenia                                                  | 141 (51.3%)    | 136 (49.5%)         | 0         | 112 (42.3%)           | 104 (39.2%)         | 0        | 110 (41.0%)           | 104 (38.8%)         | 0                 |
| Thrombocytopenia                                             | 124 (45.1%)    | 109 (39.6%)         | 0         | 105 (39.6%)           | 92 (34.7%)          | 0        | 121 (45.1%)           | 114 (42.5%)         | 0                 |
| Febrile neutropenia                                          | 98 (35.6%)     | 98 (35.6%)          | 0         | 37 (14.0%)            | 37 (14.0%)          | 0        | 71 (26.5%)            | 71 (26.5%)          | 0                 |
| Leukopenia                                                   | 38 (13.8%)     | 34 (12.4%)          | 0         | 33 (12.5%)            | 25 (9.4%)           | 0        | 37 (13.8%)            | 30 (11.2%)          | 0                 |
| Infections and infestations                                  | 223 (81.1%)    | 106 (38.5%)         | 10 (3.6%) | 186 (70.2%)           | 72 (27.2%)          | 4 (1.5%) | 137 (51.1%)           | 56 (20.9%)          | 6 (2.2%)          |
| Pneumonia                                                    | 56 (20.4%)     | 28 (10.2%)          | 2 (0.7%)  | 27 (10.2%)            | 14 (5.3%)           | 0        | 14 (5.2%)             | 10 (3.7%)           | 1 (0.4%)          |
| COVID-19                                                     | 41 (14.9%)     | 7 (2.5%)            | 4 (1.5%)  | 37 (14.0%)            | 10 (3.8%)           | 2 (0.8%) | 3 (1.1%)              | 2 (0.7%)            | 1 (0.4%)          |
|                                                              | 29 (10.5%)     | 9 (3.3%)            | 0         | 6 (2.3%)              | 1 (0.4%)            | 0        | 1 (0.4%)              | 0                   | 0                 |
| Herpes zoster                                                | 29 (10.5%)     | 4 (1.5%)            | 0         | 17 (6.4%)             |                     | 0        | 10 (3.7%)             | 1 (0.4%)            | 0                 |
| Upper respiratory tract infection Gastrointestinal disorders | 216 (78.5%)    | 84 (30.5%)          | 1 (0.4%)  | 169 (63.8%)           | 1 (0.4%) 39 (14.7%) | 0        | 190 (70.9%)           | 69 (25.7%)          | 4 (1.5%)          |
| Nausea                                                       | 112 (40.7%)    | 23 (8.4%)           | 0         | 84 (31.7%)            | 11 (4.2%)           | 0        | 105 (39.2%)           | 21 (7.8%)           | 0                 |
| Dianhoea                                                     | 105 (38.2%)    | 20 (7.3%)           | 0         | 75 (28.3%)            | 14 (5.3%)           | 0        | 78 (29.1%)            | 16 (6.0%)           | 0                 |
| Vomiting                                                     | 61 (22.2%)     | 11 (4.0%)           | 0         | 49 (18.5%)            | 11 (4.2%)           | 0        | 47 (17.5%)            | 10 (3.7%)           | 0                 |
| Constipation                                                 | 57 (20.7%)     | 0                   | 0         | 44 (16.6%)            | 1 (0.4%)            | 0        | 49 (18.3%)            | 3 (1.1%)            | 0                 |
| Stomatitis                                                   | 51 (18.5%)     | 27 (9.8%)           | 0         | 24 (9.1%)             | 4 (1.5%)            | 0        | 42 (15.7%)            | 21 (7.8%)           | 0                 |
| Abdominal pain                                               | 28 (10.2%)     | 3 (1.1%)            | 0         | 13 (4.9%)             | 0                   | 0        | 22 (8.2%)             | 4 (1.5%)            | 0                 |
| General disorders andadministration site                     |                |                     |           |                       |                     |          |                       |                     |                   |
| conditions                                                   | 191 (69.5%)    | 60 (21.8%)          | 0         | 144 (54.3%)           | 27 (10.2%)          | 0        | 175 (65.3%)           | 50 (18.7%)          | 1 (0.4%)          |
| Pyrexia                                                      | 96 (34.9%)     | 8 (2.9%)            | 0         | 57 (21.5%)            | 5 (1.9%)            | 0        | 89 (33.2%)            | 12 (4.5%)           | 0                 |
| Mucosalinflammation                                          | 86 (31.3%)     | 43 (15.6%)          | 0         | 22 (8.3%)             | 5 (1.9%)            | 0        | 74 (27.6%)            | 35 (13.1%)          | 0                 |
| Fatigue                                                      | 65 (23.6%)     | 6 (2.2%)            | 0         | 46 (17.4%)            | 6 (2.3%)            | 0        | 31 (11.6%)            | 4 (1.5%)            | 0                 |
| Asthenia                                                     | 32 (11.6%)     | 3 (1.1%)            | 0         | 24 (9.1%)             | 3 (1.1%)            | 0        | 26 (9.7%)             | 3 (1.1%)            | 0                 |
| Investigations                                               | 182 (66.2%)    | 136 (49.5%)         | 0         | 153 (57.7%)           | 115 (43.4%)         | 0        | 155 (57.8%)           | 113 (42.2%)         | 0                 |
| Platelet coumt decreased                                     | 100 (36.4%)    | 98 (35.6%)          | 0         | 87 (32.8%)            | 78 (29.4%)          | 0        | 91 (34.0%)            | 89 (33.2%)          | 0                 |
| Neutrophil countdecreased                                    | 89 (32.4%)     | 86 (31.3%)          | 0         | 68 (25.7%)            | 64 (24.2%)          | 0        | 65 (24.3%)            | 62 (23.1%)          | 0                 |
| White blood cell count decreased                             | 45 (16.4%)     | 38 (13.8%)          | 0         | 24 (9.1%)             | 17 (6.4%)           | 0        | 38 (14.2%)            | 36 (13.4%)          | 0                 |
| Blood creatinine increased                                   | 40 (14.5%)     | 2 (0.7%)            | 0         | 42 (15.8%)            | 3 (1.1%)            | 0        | 32 (11.9%)            | 2 (0.7%)            | 0 0               |
| Gamma-glutamyltransferase increased                          | 28 (10.2%)     | 15 (5.5%)           | 0         | 12 (4.5%)             | 6 (2.3%)            | 0        | 18 (6.7%)             | 11 (4.1%)           |                   |
| Nervous system disorders                                     | 138 (50.2%)    | 19 (6.9%)           | 0         | 135 (50.9%)           | 25 (9.4%)           | 0        | 104 (38.8%)           | 14 (5.2%) 0         | 0                 |
| Polymeuropathy                                               | 35 (12.7%)     | 5 (1.8%)            | 0         | 21 (7.9%)             | 2 (0.8%)            | 0        | 10 (3.7%)             |                     | 0                 |
| Headache                                                     | 31 (11.3%)     | 0                   | 0         | 29 (10.9%)            | 3 (1.1%)            | 0        | 28 (10.4%)            | 2 (0.7%)            | 0                 |
| Peripheral sensory neuropathy                                | 22 (8.0%)      | 1 (0.4%)            | 0         | 28 (10.6%)            | 3 (1.1%)            | 0        | 14 (5.2%)             | 0                   | 0                 |
|                                                              |                | A+I                 |           |                       | 1                   |          |                       | A                   |                   |
|                                                              | All Grades     | Grade 3/4           | Grade 5   | All Grades            |                     | Grade 5  | All Grades            | Grade 3/4           | Grade 5           |
|                                                              |                |                     |           |                       | Grade 3/4           |          |                       |                     |                   |
| Paraesthesia                                                 | 20 (7.3%)      | 1 (0.4%)            | 0         | 28 (10.6%)            | 2 (0.8%)            | 0        | 14 (5.2%)             | 0                   | 0                 |
| Skin and subcutaneoustissue disorders                        | 124 (45.1%)    | 17 (6.2%)           | 0         | 91 (34.3%)            | 4 (1.5%)            | 0        | 51 (19.0%)            | 2 (0.7%)            | 0                 |
| Rash                                                         | 49 (17.8%)     | 7 (2.5%)            | 0         | 36 (13.6%)            | 3 (1.1%)            | 0        | 15 (5.6%)             | 1 (0.4%)            | 0                 |
| Respiratory,thoracic andmediastinal disorders                | 119 (43.3%)    | 25 (9.1%)           | 1 (0.4%)  | 83 (31.3%)            | 10 (3.8%)           | 0        | 63 (23.5%)            | 17 (6.3%)           | 2 (0.7%)          |
| Cough                                                        | 43 (15.6%)     | 2 (0.7%)            | 0         | 33 (12.5%)            | 0                   | 0        | 12 (4.5%)             | 0                   | 0                 |
| Metabolism and nutrition disorders                           | 113 (41.1%)    | 48 (17.5%)          | 0         | 89 (33.6%)            | 43 (16.2%)          | 0        | 96 (35.8%)            | 40 (14.9%)          | 0                 |
| Hypokalaemia                                                 | 64 (23.3%)     | 25 (9.1%)           | 0         | 37 (14.0%)            | 17 (6.4%)           | 0        | 43 (16.0%)            | 12 (4.5%)           | 0                 |
| Hypomagnesaemia                                              | 30 (10.9%)     | 5 (1.8%)            | 0         | 18 (6.8%)             |                     | 0        | 14 (5.2%)             | 2 (0.7%)            | 0                 |
| Musculoskeletal andconnectivetissuedisorders                 | 99 (36.0%)     | 10 (3.6%)           | 0         | 85 (32.1%)            | 1 (0.4%) 12 (4.5%)  | 0        | 57 (21.3%)            | 6 (2.2%)            | 0                 |
| Vascular disorders                                           | 73 (26.5%)     | 21 (7.6%)           | 0         | 65 (24.5%)            | 21 (7.9%)           | 0        | 60 (22.4%)            | 16 (6.0%)           | 0                 |
| Hypertension                                                 | 23 (8.4%)      | 10 (3.6%)           | 0         |                       |                     |          | 21 (7.8%)             |                     |                   |
|                                                              | 71 (25.8%)     |                     | 0         | 33 (12.5%)            | 11 (4.2%)           | 0        |                       | 12 (4.5%) 15 (5.6%) | 0                 |
| Renal and urinary disorders Acute kidney injury              | 31 (11.3%)     | 16 (5.8%) 11 (4.0%) | 0         | 68 (25.7%) 29 (10.9%) | 21 (7.9%) 12 (4.5%) | 0 0      | 56 (20.9%) 31 (11.6%) | 7 (2.6%)            | 1 (0.4%) 1 (0.4%) |
| Cardiac disorders                                            | 53 (19.3%)     | 23 (8.4%)           | 0         | 54 (20.4%)            | 13 (4.9%)           | 1 (0.4%) | 22 (8.2%)             | 9 (3.4%)            | 0                 |
| Injury, poisoning and procedural complications               | 36 (13.1%)     | 9 (3.3%)            | 0         | 55 (20.8%)            | 12 (4.5%)           | 0        | 32 (11.9%)            | 5 (1.9%)            | 0                 |
| Psychiatric disorders                                        | 31 (11.3%)     | 1 (0.4%)            | 1 (0.4%)  | 23 (8.7%)             | 2 (0.8%)            | 0        | 20 (7.5%)             | 1 (0.4%)            | 0                 |
| Ear andlabyrinth disorders                                   | 28 (10.2%)     | 2 (0.7%)            | 0         | 39 (14.7%)            | 7 (2.6%)            | 0        | 27 (10.1%)            | 2 (0.7%)            | 0                 |

Key:ASCT=autologous stem cell transplant,A=ASCT,A+I=ASCT+Ibrutinib,I=Ibrutinib,TEAE=treatment-emergent adverse event.

Note: Adverse events are presented by decreasing frequency of system organ class and preferred term within A+I column; those with the same frequency are presented alphabetically. Note: Percentages are calculated with the number of subjects in safety analysis set as denominator.

Note: Subjects are counted only once for any given event, regardless of the number oftimes they actually experienced the event. The event experienced by the subject with the worst toxicity isused.Ifasubject hasmissing toxicity fora specific adverse event,the subjectis only counted in the All Grades column for that adverse event.

Adverse events are coded usingMedDRAVersion 26.1.

## Induction Phase

Table 28 Incidence of Treatment-emergent Adverse Events Occurring in 10% or More Subjects by Toxicity Grade, System Organ Class and Preferred Term - MCL3003 Induction; Safety Population

<div style=\"page-break-after: always\"></div>

|                                                 | A+I            | A+I         | A+I      |                |             |          | A              | A           | A        |
|-------------------------------------------------|----------------|-------------|----------|----------------|-------------|----------|----------------|-------------|----------|
| Analysis set:Safety Population                  | All Grades 275 | Grade 3/4   | Grade 5  | All Grades 265 | Grade 3/4   | Grade 5  | All Grades 268 | Grade 3/4   | Grade 5  |
| Subjects with any TEAE                          | 272 (98.9%)    | 239 (86.9%) | 2 (0.7%) | 259 (97.7%)    | 227 (85.7%) | 1 (0.4%) | 262 (97.8%)    | 217 (81.0%) | 3 (1.1%) |
| System organ class Preferred term               |                |             |          |                |             |          |                |             |          |
| Blood and lymphatic system disorders            | 198 (72.0%)    | 172 (62.5%) | 0        | 190 (71.7%)    | 162 (61.1%) | 0        | 185 (69.0%)    | 156 (58.2%) | 0        |
| Anaemia                                         | 118 (42.9%)    | 80 (29.1%)  | 0        | 114 (43.0%)    | 54 (20.4%)  | 0        | 123 (45.9%)    | 59 (22.0%)  | 0        |
| Thrombocytopenia                                | 106 (38.5%)    | 93 (33.8%)  | 0        | 101 (38.1%)    | 89 (33.6%)  | 0        | 105 (39.2%)    | 98 (36.6%)  | 0        |
| Neutropenia                                     | 95 (34.5%)     | 88 (32.0%)  | 0        | 91 (34.3%)     | 83 (31.3%)  | 0        | 94 (35.1%)     | 85 (31.7%)  | 0        |
| Febrile neutropenia                             | 33 (12.0%)     | 33 (12.0%)  | 0        | 33 (12.5%)     | 33 (12.5%)  | 0        | 26 (9.7%)      | 26 (9.7%)   | 0        |
| Leukopenia                                      | 29 (10.5%)     | 25 (9.1%)   | 0        | 30 (11.3%)     | 23 (8.7%)   | 0        | 29 (10.8%)     | 22 (8.2%)   | 0        |
| Gastrointestinal disorders                      | 166 (60.4%)    | 30 (10.9%)  | 0        | 156 (58.9%)    | 31 (11.7%)  | 0        | 145 (54.1%)    | 30 (11.2%)  | 1 (0.4%) |
| Nausea                                          | 91 (33.1%)     | 6 (2.2%)    | 0        | 79 (29.8%)     | 11 (4.2%)   | 0        | 85 (31.7%)     | 10 (3.7%)   | 0        |
| Vomiting                                        | 48 (17.5%)     | 8 (2.9%)    | 0        | 46 (17.4%)     | 9 (3.4%)    | 0        | 35 (13.1%)     | 9 (3.4%)    | 0        |
| Constipation                                    | 46 (16.7%)     | 0           | 0        | 41 (15.5%)     | 1 (0.4%)    | 0        | 44 (16.4%)     | 3 (1.1%)    | 0        |
| Diarhoea                                        | 38 (13.8%)     | 9 (3.3%)    | 0        | 58 (21.9%)     | 11 (4.2%)   | 0        | 34 (12.7%)     | 6 (2.2%)    | 0        |
| Investigations                                  | 160 (58.2%)    | 113 (41.1%) | 0        | 145 (54.7%)    | 108 (40.8%) | 0        | 139 (51.9%)    | 96 (35.8%)  | 0        |
| Platelet count decreased                        | 89 (32.4%)     | 82 (29.8%)  | 0        | 83 (31.3%)     | 75 (28.3%)  | 0        | 82 (30.6%)     | 76 (28.4%)  | 0        |
| Neutrophil count decreased                      | 62 (22.5%)     | 59 (21.5%)  | 0        | 58 (21.9%)     | 55 (20.8%)  | 0        | 56 (20.9%)     | 51 (19.0%)  | 0        |
| Blood creatinine increased                      | 35 (12.7%)     | 2 (0.7%)    | 0        | 41 (15.5%)     | 3 (1.1%)    | 0        | 32 (11.9%)     | 2 (0.7%)    | 0        |
| White blood cell count decreased                | 32 (11.6%)     | 25 (9.1%)   | 0        | 22 (8.3%)      | 16 (6.0%)   | 0        | 26 (9.7%)      | 24 (9.0%)   | 0        |
| Generaldisorders and administration             |                |             |          |                |             |          |                |             |          |
| site conditions                                 | 128 (46.5%)    | 14 (5.1%)   | 0        | 120 (45.3%)    | 20 (7.5%)   | 0        | 104 (38.8%)    | 16 (6.0%)   | 0        |
| Pyrexia                                         | 44 (16.0%)     | 3 (1.1%)    | 0        | 41 (15.5%)     | 3 (1.1%)    | 0        | 40 (14.9%)     | 5 (1.9%)    | 0        |
| Fatigue                                         | 42 (15.3%)     | 4 (1.5%)    | 0        | 37 (14.0%)     | 6 (2.3%)    | 0        | 22 (8.2%)      | 3 (1.1%)    | 0        |
| Infections and infestations                     | 109 (39.6%)    | 32 (11.6%)  | 1 (0.4%) | 100 (37.7%)    | 32 (12.1%)  | 1 (0.4%) | 79 (29.5%)     | 23 (8.6%)   | 1 (0.4%) |
| Nervous system disorders                        | 99 (36.0%)     | 8 (2.9%)    | 0        | 108 (40.8%)    | 16 (6.0%)   | 0        | 87 (32.5%)     | 8 (3.0%)    | 0        |
| Metabolism and nutritiondisorders               | 75 (27.3%)     | 30 (10.9%)  | 0        | 81 (30.6%)     | 38 (14.3%)  | 0        | 66 (24.6%)     | 19 (7.1%)   | 0        |
| Hypokalaemia                                    | 40 (14.5%)     | 16 (5.8%)   | 0        | 35 (13.2%)     | 16 (6.0%)   | 0        | 26 (9.7%)      | 4 (1.5%)    | 0        |
| Respiratory, thoracic and mediastinal disorders | 63 (22.9%)     | 8 (2.9%)    | 0        | 53 (20.0%)     | 6 (2.3%)    | 0        | 38 (14.2%)     | 9 (3.4%)    | 0        |
| Renal and urinary disorders                     | 59 (21.5%)     | 14 (5.1%)   | 0        | 54 (20.4%)     | 17 (6.4%)   | 0        | 52 (19.4%)     | 12 (4.5%)   | 0        |
| Acute kidney injury                             | 29 (10.5%)     | 11 (4.0%)   | 0        | 28 (10.6%)     | 11 (4.2%)   | 0        | 29 (10.8%)     | 7 (2.6%)    | 0        |
| Musculoskeletal and connectivetissue            |                |             |          |                |             |          |                |             |          |
| disorders                                       | 53 (19.3%)     | 4 (1.5%)    | 0        | 46 (17.4%)     | 3 (1.1%)    | 0        | 46 (17.2%)     | 4 (1.5%)    | 0        |
| Skin and subcutaneoustissue disorders           | 47 (17.1%)     | 2 (0.7%)    | 0        | 48 (18.1%)     | 3 (1.1%)    | 0        | 20 (7.5%)      | 0           | 0        |
| Vascular disorders                              | 36 (13.1%)     | 12 (4.4%)   | 0        | 40 (15.1%)     | 14 (5.3%)   | 0        | 46 (17.2%)     | 12 (4.5%)   | 0        |
| Cardiac disorders                               | 25 (9.1%)      | 12 (4.4%)   | 0        | 31 (11.7%)     | 5 (1.9%)    | 0        | 9 (3.4%)       | 4 (1.5%)    | 0        |
| Ear and labyrinth disorders                     | 23 (8.4%)      | 1 (0.4%)    | 0        | 29 (10.9%)     | 3 (1.1%)    | 0        | 22 (8.2%)      | 2 (0.7%)    | 0        |
|                                                 | A+I            | A+I         | A+I      | A+I            |             |          |                | A           | A        |
|                                                 | All Grades     | Grade 3/4   | Grade 5  | All Grades     | Grade 3/4   | Grade 5  | All Grades     | Grade 3/4   | Grade 5  |
| Injury, poisoning and procedural complications  | 21 (7.6%)      | 2 (0.7%)    | 0        | 39 (14.7%)     | 5 (1.9%)    | 0        | 28 (10.4%)     | 4 (1.5%)    | 0        |

Key:TEAE=Treatment-emergent adverse event.

Note:Percentages calculated with the number of subjects in safety population as denominator. Worst toxicity grade was used for subjects who had multiple events per system organ class or per preferred term. A subject who had event with missing toxicity grade was counted in the all grades column but not listed separately.

Adverse events are coded using MedDRA Version 26.1.

## TEAEs by severity

Table 29 Incidence of Grade 3 or Higher TEAEs Occurring in 2% or More Subjects in Any Treatment Group by System Organ Class, Preferred Term and Toxicity Grade; Safety Analysis Set (Study 54179060MCL3003)

<div style=\"page-break-after: always\"></div>

|                                                                      | A+I                 | A+I                 | A+I        |                     |                     |          | A                     | A                    | A          |
|----------------------------------------------------------------------|---------------------|---------------------|------------|---------------------|---------------------|----------|-----------------------|----------------------|------------|
| Analysis set: Safety                                                 | Grade 3 - 5 275     | Grade 3/4           | Grade 5    | Grade 3 - 5         | Grade 3/4           | Grade 5  | Grade3-5              | Grade 3/4            | Grade 5    |
|                                                                      |                     |                     |            | 265                 |                     |          | 268                   |                      |            |
| Subjects with any Grade 3 or higher TEAE                             |                     |                     |            |                     |                     |          |                       |                      | 11 (4.1%)  |
| System organ class                                                   |                     |                     |            |                     |                     |          |                       |                      |            |
| Preferred tem Blood and lymphatic system disorders                   | 226 (82.2%)         | 226 (82.2%)         | 0          | 172 (64.9%)         | 172 (64.9%)         | 0        | 201 (75.0%)           | 201 (75.0%)          | 0          |
| Neutropenia                                                          | 136 (49.5%)         | 136 (49.5%)         | 0          | 104 (39.2%)         | 104 (39.2%)         | 0        | 104 (38.8%)           | 104 (38.8%)          | 0          |
| Anaemia                                                              | 121 (44.0%)         | 121 (44.0%)         | 0          | 57 (21.5%)          | 57 (21.5%)          | 0        | 92 (34.3%)            | 92 (34.3%)           | 0          |
| Thrombocytopenia                                                     | 109 (39.6%)         | 109 (39.6%)         | 0          | 92 (34.7%)          | 92 (34.7%)          | 0        | 114 (42.5%)           | 114 (42.5%)          | 0          |
| Febrile neutropenia                                                  | 98 (35.6%)          | 98 (35.6%)          | 0          | 37 (14.0%)          | 37 (14.0%)          | 0        | 71 (26.5%)            | 71 (26.5%)           | 0          |
| Leukopenia                                                           | 34 (12.4%)          | 34 (12.4%)          | 0          | 25 (9.4%)           | 25 (9.4%)           | 0        | 30 (11.2%)            | 30 (11.2%)           | 0          |
| Leukocytosis                                                         | 9 (3.3%)            | 9 (3.3%)            | 0          | 2 (0.8%)            | 2 (0.8%)            | 0        | 2 (0.7%)              | 2 (0.7%)             | 0          |
| Lymphopenia                                                          | 3 (1.1%)            | 3 (1.1%)            | 0          | 5 (1.9%)            | 5 (1.9%)            | 0        | 8 (3.0%)              | 8 (3.0%)             | 0          |
| Investigations                                                       | 136 (49.5%)         | 136 (49.5%)         | 0          | 115 (43.4%)         | 115 (43.4%)         | 0        | 113 (42.2%)           | 113 (42.2%)          | 0          |
| Plateletcountdecreased                                               | 98 (35.6%)          | 98 (35.6%)          | 0          | 78 (29.4%)          | 78 (29.4%)          | 0        | 89 (33.2%)            | 89 (33.2%)           | 0          |
| Neutrophil count decreased                                           | 86 (31.3%)          | 86 (31.3%)          | 0          | 64 (24.2%)          | 64 (24.2%)          | 0        | 62 (23.1%)            | 62 (23.1%)           | 0          |
| White blood cell count decreased                                     | 38 (13.8%)          | 38 (13.8%)          | 0          | 17 (6.4%)           | 17 (6.4%)           | 0        | 36 (13.4%)            | 36 (13.4%)           | 0          |
| Lymphocyte count decreased                                           | 21 (7.6%)           | 21 (7.6%)           | 0          | 12 (4.5%)           | 12 (4.5%)           | 0        | 15 (5.6%)             | 15 (5.6%)            | 0          |
| Gamma-glutamyltransferase increased                                  | 15 (5.5%)           | 15 (5.5%)           | 0          | 6 (2.3%)            | 6 (2.3%)            | 0        | 11 (4.1%)             | 11 (4.1%)            | 0          |
| Alanine aminotransferase increased                                   | 8 (2.9%)            | 8 (2.9%)            | 0          | 3 (1.1%)            | 3 (1.1%)            | 0        | 6 (2.2%)              | 6 (2.2%)             | 0          |
| Infections and infestations                                          | 116 (42.2%)         | 106 (38.5%)         | 10 (3.6%)  | 76 (28.7%)          | 72 (27.2%)          | 4 (1.5%) | 62 (23.1%)            | 56 (20.9%)           | 6 (2.2%)   |
| Pneumonia                                                            | 30 (10.9%)          | 28 (10.2%)          | 2 (0.7%)   | 14 (5.3%)           | 14 (5.3%)           | 0        | 11 (4.1%)             | 10 (3.7%)            | 1 (0.4%)   |
| Sepsis                                                               | 14 (5.1%)           | 13 (4.7%)           | 1 (0.4%)   | 2 (0.8%)            | 2 (0.8%)            | 0        | 7 (2.6%)              | 4 (1.5%)             | 3 (1.1%)   |
| Device related infection                                             | 12 (4.4%)           | 12 (4.4%)           | 0          | 2 (0.8%)            | 2 (0.8%)            | 0        | 7 (2.6%)              | 7 (2.6%)             | 0          |
| COVID-19                                                             | 11 (4.0%)           | 7 (2.5%)            | 4 (1.5%)   | 12 (4.5%)           | 10 (3.8%)           | 2 (0.8%) | 3 (1.1%)              | 2 (0.7%)             | 1 (0.4%)   |
| Herpes zoster                                                        | 9 (3.3%)            | 9 (3.3%)            | 0          | 1 (0.4%)            | 1 (0.4%)            | 0        | 0                     | 0                    | 0          |
| Infection                                                            | 9 (3.3%)            | 9 (3.3%)            | 0          | 5 (1.9%)            | 5 (1.9%)            | 0        | 8 (3.0%)              | 8 (3.0%)             | 0          |
| COVID-19pneumonia                                                    | 6 (2.2%)            | 5 (1.8%)            | 1 (0.4%)   | 9 (3.4%)            | 7 (2.6%)            | 2 (0.8%) | 1 (0.4%)              | 0                    | 1 (0.4%)   |
| Gastrointestinal disorders                                           | 85 (30.9%)          | 84 (30.5%)          | 1 (0.4%)   | 39 (14.7%)          | 39 (14.7%)          | 0 0      | 73 (27.2%) 21 (7.8%)  | 69 (25.7%) 21 (7.8%) | 4 (1.5%) 0 |
| Stomatitis Nausea                                                    | 27 (9.8%)           | 27 (9.8%)           | 0          | 4 (1.5%)            | 4 (1.5%)            | 0        |                       | 21 (7.8%)            | 0          |
|                                                                      | 23 (8.4%)           | 23 (8.4%)           | 0          | 11 (4.2%)           | 11 (4.2%)           |          | 21 (7.8%)             |                      | 0          |
| Diarhoea                                                             | 20 (7.3%)           | 20 (7.3%)           | 0          | 14 (5.3%)           | 14 (5.3%)           | 0        | 16 (6.0%)             | 16 (6.0%)            |            |
| Vomiting                                                             | 11 (4.0%)           | 11 (4.0%)           | 0          | 11 (4.2%)           | 11 (4.2%)           | 0 0      | 10 (3.7%)             | 10 (3.7%) 50 (18.7%) | 0 1 (0.4%) |
| General disordersandadministrationsiteconditions Mucosalinflammation | 60 (21.8%)          | 60 (21.8%)          | 0          | 27 (10.2%)          | 27 (10.2%) 5 (1.9%) | 0        | 51 (19.0%) 35 (13.1%) | 35 (13.1%)           | 0          |
| Pyrexia                                                              | 43 (15.6%)          | 43 (15.6%)          | 0          | 5 (1.9%)            | 5 (1.9%)            | 0        | 12 (4.5%)             | 12 (4.5%)            | 0          |
| Fatigue                                                              | 8 (2.9%)            | 8 (2.9%)            | 0          | 5 (1.9%)            |                     | 0        | 4 (1.5%)              | 4 (1.5%)             | 0          |
| Metabolism andnutritiondisorders                                     | 6 (2.2%) 48 (17.5%) | 6 (2.2%) 48 (17.5%) | 0 0        | 6 (2.3%) 43 (16.2%) | 6 (2.3%) 43 (16.2%) | 0        | 40 (14.9%)            | 40 (14.9%)           | 0          |
| Hypokalaemia                                                         | 25 (9.1%)           | 25 (9.1%)           | 0          | 17 (6.4%)           | 17 (6.4%)           | 0        | 12 (4.5%)             | 12 (4.5%)            |            |
|                                                                      |                     |                     |            |                     |                     |          |                       |                      | 0          |
|                                                                      |                     |                     |            |                     | I                   |          |                       | A                    |            |
|                                                                      | Grade3-5            | A+I Grade 3/4       | Grade 5    | Grade3-5            | Grade 3/4           | Grade 5  | Grade 3 - 5           | Grade 3/4            | Grade 5    |
| Decreased appetite                                                   | 6 (2.2%)            | 6 (2.2%)            | 0          | 3 (1.1%)            | 3 (1.1%)            | 0        | 11 (4.1%)             | 11 (4.1%)            | 0          |
| Hyperglycaemia                                                       | 6 (2.2%)            | 6 (2.2%)            | 0          | 8 (3.0%)            | 8 (3.0%)            | 0        | 4 (1.5%)              | 4 (1.5%)             | 0          |
| Hyperuricaemia                                                       | 6 (2.2%)            | 6 (2.2%)            | 0          | 8 (3.0%)            | 8 (3.0%)            | 0        | 1 (0.4%)              | 1 (0.4%)             | 0          |
| Tumour lysis syndrome Respiratory,thoracic andmediastinal disorders  | 1 (0.4%) 26 (9.5%)  | 1 (0.4%) 25 (9.1%)  | 0 1 (0.4%) | 7 (2.6%) 10 (3.8%)  | 7 (2.6%) 10 (3.8%)  | 0 0      | 3 (1.1%) 19 (7.1%)    | 3 (1.1%) 17 (6.3%)   | 0 2 (0.7%) |
| Cardiac disorders                                                    | 23 (8.4%)           | 23 (8.4%)           | 0          | 14 (5.3%)           | 13 (4.9%)           | 1 (0.4%) | 9 (3.4%)              | 9 (3.4%)             | 0          |
| Atrial fibrillation                                                  | 13 (4.7%)           |                     | 0          | 10 (3.8%)           | 10 (3.8%)           | 0        |                       |                      | 0          |
|                                                                      | 21 (7.6%)           | 13 (4.7%)           | 0          | 21 (7.9%)           |                     | 0        | 5 (1.9%)              | 5 (1.9%)             | 0          |
| Vascular disorders                                                   | 10 (3.6%)           | 21 (7.6%) 10 (3.6%) |            |                     | 21 (7.9%)           |          | 16 (6.0%)             | 16 (6.0%)            |            |
| Hypertension                                                         |                     |                     | 0          | 11 (4.2%)           | 11 (4.2%)           | 0        | 12 (4.5%)             | 12 (4.5%)            | 0          |
| Nervous system disorders                                             | 19 (6.9%)           | 19 (6.9%)           | 0          | 25 (9.4%)           | 25 (9.4%)           | 0        | 14 (5.2%)             | 14 (5.2%)            | 0          |
| Syncope                                                              | 7 (2.5%)            | 7 (2.5%)            | 0          | 6 (2.3%)            | 6 (2.3%)            | 0        | 5 (1.9%)              | 5 (1.9%)             | 0          |
| Skin and subcutaneous tissue disorders                               | 17 (6.2%)           | 17 (6.2%)           | 0          | 4 (1.5%)            | 4 (1.5%)            | 0        | 2 (0.7%)              | 2 (0.7%)             | 0 0        |
| Rash Renal and urinarydisorders                                      | 7 (2.5%) 16 (5.8%)  | 7 (2.5%) 16 (5.8%)  | 0 0        | 3 (1.1%)            | 3 (1.1%) 21 (7.9%)  | 0 0      | 1 (0.4%) 16 (6.0%)    | 1 (0.4%) 15 (5.6%)   |            |
|                                                                      |                     |                     |            | 21 (7.9%)           |                     |          |                       |                      | 1 (0.4%)   |
| Acute kidney injury                                                  | 11 (4.0%)           | 11 (4.0%)           | 0          | 12 (4.5%)           | 12 (4.5%)           | 0        | 8 (3.0%)              | 7 (2.6%)             | 1 (0.4%)   |
| Musculoskeletal andconnectivetissue disorders                        | 10 (3.6%)           | 10 (3.6%)           | 0          | 12 (4.5%)           | 12 (4.5%)           | 0        | 6 (2.2%)              | 6 (2.2%)             | 0          |
| Injury, poisoning and procedural complications                       | 9 (3.3%)            | 9 (3.3%)            | 0          | 12 (4.5%)           | 12 (4.5%)           | 0        | 5 (1.9%)              | 5 (1.9%)             | 0          |
| Neoplasms benign, malignant and unspecified (incl cysts (sdiqod pue  | 7 (2.5%)            | 5 (1.8%)            | 2 (0.7%)   | 6 (2.3%)            | 5 (1.9%)            | 1 (0.4%) | 1 (0.4%)              | 0                    | 1 (0.4%) 0 |
| Immune system disorders Ear andlabyrinth disorders                   | 6 (2.2%) 2 (0.7%)   | 6 (2.2%) 2 (0.7%)   | 0 0        | 3 (1.1%) 7 (2.6%)   | 3 (1.1%) 7 (2.6%)   | 0 0      | 5 (1.9%) 2 (0.7%)     | 5 (1.9%) 2 (0.7%)    | 0          |

Key:ASCT=autologous stem cell transplant, A=ASCT,A+I=ASCT+Ibrutinib,I=Ibrutinib,TEAE=treatment-emergent adverse event.

Note: Adverse events are presented by decreasing frequency of system organ class and preferred term within A+I column; those with the same frequency are presented alphabetically. Note: Percentages are calculated with the number of subjects in safety analysis set as denominator.

Note: Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event. The event experienced by the subject with the worst toxicity is used.

Adverse events are coded using MedDRA Version 26.1.

## TEAEs related to ibrutinib

Table 30  Incidence of Treatment-emergent Adverse Events Related to Ibrutinib Occurring in 5% or More Subjects in Any Treatment Group by System Organ Class and Preferred Term; Safety Analysis Set (Study 54179060MCL3003)

<div style=\"page-break-after: always\"></div>

|                                                      | AII         | 1           | A   |
|------------------------------------------------------|-------------|-------------|-----|
| Analysis set: Safety                                 | 275         | 265         | 268 |
| Subjects with any Ibrutinib-rclated                  |             |             |     |
| TEAE                                                 | 233 (84.7%) | 212 (80.0%) | 0   |
| System organ class                                   |             |             |     |
| Preferred term                                       |             |             |     |
| Blood and lymphatie system                           |             |             |     |
| disorders                                            | 132 (48.0%) | 103 (38.9%) | 0   |
| Neutropenia                                          | 84 (30.5%)  | 61 (23.0%)  | 0   |
| Thrombocytopenia                                     | 31 (11.3%)  | 29 (10.9%)  | 0   |
| Anaemia                                              | 24 (8.7%)   | 40 (15.1%)  | 0   |
| Febrile neutropenia                                  | 19 (6.9%)   | 8 (3.0%)    | 0   |
| Infections and infestations                          | 95 (34.5%)  | 65 (24.5%)  | 0   |
| Pneumonia                                            | 24 (8.7%)   | 13 (4.9%)   | 0   |
| Herpes zoster                                        | 16 (5.8%)   | 5 (1.9%)    | 0   |
| Investigations                                       | 79 (28.7%)  | 66 (24.9%)  | 0   |
| Neutrophil count decreased                           | 39 (14.2%)  | 30 (11.3%)  | 0   |
| Platelet count decreased                             | 23 (8.4%)   | 20 (7.5%)   | 0   |
| White blood cell count decreased                     | 79 (28.7%)  | 57 (21.5%)  | 0   |
| Gastrointestinal disorders                           | 46 (16.7%)  | 35 (13.2%)  | 0   |
| Diarrhoca                                            | 30 (10.9%)  | 24 (9.1%)   | 0   |
| Nausca                                               | 12 (4.4%)   | 14 (5.3%)   | 0   |
|                                                      | A+I         |             | A   |
| Skin and subcutaneous tissue                         |             |             |     |
| disorders                                            | 50 (18.2%)  | 49 (18.5%)  | 0   |
| Rash                                                 | 19 (6.9%)   | 19 (7.2%)   | 0   |
| General disorders and administration site conditions | 45 (16.4%)  | 37 (14.0%)  | 0   |
| Musculoskcletal and connective                       |             |             |     |
| tissue disorders                                     | 42 (15.3%)  | 42 (15.8%)  | 0   |
| Muscle spasms                                        | 22 (8.0%)   | 17 (6.4%)   | 0   |
| Nervous system disorders                             | 40 (14.5%)  | 36 (13.6%)  | 0   |
| Respiratory, thoracic and mediastinal disorders      | 20 (7.3%)   | 25 (9.4%)   | 0   |
| Cardiac disorders                                    | 16 (5.8%)   | 27 (10.2%)  | 0   |
| Atrial fibrillation                                  | 11 (4.0%)   | 19 (7.2%)   | 0   |
| Vascular disorders                                   | 14 (5.1%)   | 24 (9.1%)   | 0   |
| Hypertension                                         | 2 (0.7%)    | 14 (5.3%)   | 0   |
| Metabolism and nutrition disorders                   | 11 (4.0%)   | 14 (5.3%)   | 0   |

Key: ASCTautologous stem cell transplant, A ASCT, A+I ASCT+Ibrutinib, IIbrutinib, TEAE treaiment-emergent adverse cvent.

Note: Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event.

Note: Adverse cvents are presented by decreasing frequency of system organ class and preferred term within A+I column; those

Note: Pereentages are caleulated with the number of subjects in safety analysis sct as denominator.

Adverse events are coded using MedDRA Version 26.1.

Note: The causal relationship of an adverse cvent to study treatment is only collected for Ibrutinib.

Table 31 Incidence of Grade 3 or Higher Treatment-emergent Adverse Events Related to Ibrutinib Occurring in 2% or More Subjects in Any Treatment Group by System Organ Class, Preferred Term and Toxicity Grade; Safety Analysis Set (Study 54179060MCL3003)

<div style=\"page-break-after: always\"></div>

|                                                      | IV          | IV          | IV       | 1           | 1           | 1       | A        | A         | A       |
|------------------------------------------------------|-------------|-------------|----------|-------------|-------------|---------|----------|-----------|---------|
|                                                      | Grade3-5    | Grade 3/4   | Grade 5  | Grade3-5    | Grade3/4    | Grade 5 | Grade3-5 | Grade 3/4 | Grade 5 |
| Analysis sct: Safely                                 | 275         |             |          | 265         |             |         | 268      |           |         |
| Subjcctswith anyGrade3orhighcrIbrutinib-rclated TEAE | 186 (67.6%) | 184 (66.9%) | 2 (0.7%) | 143 (54.0%) | 143 (54.0%) | 0       | 0        |           | 0       |
| System organ class Preferred term                    |             |             |          |             |             |         |          |           |         |
| Blood and lymphatic systemdisorders                  | 118 (42.9%) | 118 (42.9%) | 0        | 84 (31.7%)  | 84 (31.7%)  | 0       | 0        | 0         | 0       |
| Neutropenia                                          | 80 (29.1%)  | 80 (29.1%)  | 0        | 56 (21.1%)  | 56 (21.1%)  | 0       | 0        | 0         | 0       |
| Febrile neutropenia                                  | 19 (6.9%)   | 19 (6.9%)   | 0        | 8 (3.0%)    | 8 (3.0%)    | 0       | 0        | 0         | 0       |
| Thrombocytopenia                                     | 17 (6.2%)   | 17 (6.2%)   | 0        | 21 (7.9%)   | 21 (7.9%)   | 0       | 0        | 0         | 0       |
| Anacmia                                              | 11 (4.0%)   | 11 (4.0%)   | 0        | 17 (6.4%)   | 17 (6.4%)   | 0       | 0        | 0         | 0       |
| Leukocytosis                                         | 8 (2.9%)    | 8 (2.9%)    | 0        | 5 (1.9%)    | 5 (1.9%)    | 0       | 0        | 0         | 0       |
| Leukopenia                                           | 7 (2.5%)    | 7 (2.5%)    | 0        | 1 (0.4%)    | 1 (0.4%)    | 0       | 0        | 0         | 0       |
| Investigations                                       | 59 (21.5%)  | 59 (21.5%)  | 0        | 40 (15.1%)  | 40 (15.1%)  | 0       | 0        | 0         | 0       |
| Neutrophil count decrcased                           | 44 (16.0%)  | 44 (16.0%)  | 0        | 31 (11.7%)  | 31 (11.7%)  | 0       | 0        | 0         | 0       |
| Plateletcount decrcased                              | 24 (8.7%)   | 24 (8.7%)   | 0        | 18 (6.8%)   | 18 (6.8%)   | 0       | 0        | 0         | 0       |
| Whiteblood cell count decreased                      | 8 (2.9%)    | 8 (2.9%)    | 0        | 9 (3.4%)    | 9 (3.4%)    | 0       | 0        | 0         | 0       |
| Infections and infestations                          | 36 (13.1%)  | 35 (12.7%)  | 1 (0.4%) | 25 (9.4%)   | 25 (9.4%)   | 0       | 0        | 0         | 0       |
| Pneumonia                                            | 15 (5.5%)   | 15 (5.5%)   | 0        | 7 (2.6%)    | 7 (2.6%)    | 0       | 0        | 0         | 0       |
| Hlerpes zoster                                       | 7 (2.5%)    | 7 (2.5%)    | 0        | 1 (0.4%)    | 1 (0.4%)    | 0       | 0        | 0         | 0       |
| Gastrointestinal disorders                           | 15 (5.5%)   | 15 (5.5%)   | 0        | 11 (4.2%)   | 11 (4.2%)   | 0       | 0        | 0         | 0       |
| Diarhoea                                             | 9(3.3%)     | 9 (3.3%)    | 0        | 7 (2.6%)    | 7 (2.6%)    | 0       | 0        | 0         | 0       |
| Cardiac disorders                                    | 10 (3.6%)   | 10 (3.6%)   | 0        | 8 (3.0%)    | 8 (3.0%)    | 0       | 0        | 0         | 0       |
| Atrial fibrillation                                  | 6 (2.2%)    | 6 (2.2%)    | 0        | 8 (3.0%)    | 8 (3.0%)    | 0       | 0        | 0         | 0       |
| Nervoussystcm disorders                              | 5 (1.8%)    | 5 (1.8%)    | 0        | 6 (2.3%)    | 6 (2.3%)    | 0       | 0        | 0         | 0       |
| Vasculardisorders                                    | 4 (1.5%)    | 4 (1.5%)    | 0        | 6 (2.3%)    | 6 (2.3%)    | 0       | 0        | 0         | 0       |
| Musculoskeletalandconnectivetissue disorders         | 3 (1.1%)    | 3 (1.1%)    | 0        | 7 (2.6%)    | 7 (2.6%)    | 0       | 0        | 0         | 0       |
| Metabolismandnutritiondisorders                      | 2 (0.7%)    | 2 (0.7%)    | 0        | 7 (2.6%)    | 7 (2.6%)    | 0       | 0        | 0         | 0       |

Key:ASCTautologous stem cell transplant,AASCT,A1IASCT+Ibrutinib,IIbrutinib,TEAE-treatment-cmergent adversecvcnt.

Note: Subjects are counted only once for any given cvent, regardless of the number of times they actually experienced the event.The event experienced by the subject with theworst oxicity is used.

Note:Adversecvents arepresentedbydecreasingfrequcncy of system organ class andpreferred termwithinA+I column;thosewith the samefrequency arepresentedalphabetically. Notc:Percentages are calculatedwith the number of subjccts insafety analysissctas denominator.

Adversecvcnts are coded usingMedDRAVersion 26.1.

Notc:The causalrelationshipofan advcrsecvent tostudy drug is only collectedforIbrutinib.

## Serious adverse event and deaths

## Deaths

Table 32 Summary of Deaths During Study; Safety Analysis Set (Study 54179060MCL3003)

|                                                    | AII        | 1          | A          | Total       |
|----------------------------------------------------|------------|------------|------------|-------------|
| Analysis set: Safety                               | 275        | 265        | 268        | 808         |
| Total number of subjects who died during the study | 34 (12.4%) | 33 (12.5%) | 60 (22.4%) | 127 (15.7%) |
| Primary cause of death                             |            |            |            |             |
| Adverse event 4                                    | 15 (5.5%)  | 6 (2.3%)   | 11 (4.1%)  | 32 (4.0%)   |
| COVID-19 Rclated b                                 | 5 (1.8%)   | 4 (1.5%)   | 2 (0.7%)   | 11 (1.4%)   |
| Progressive disease                                | 9 (3.3%)   | 14 (5.3%)  | 30 (11.2%) | 53 (6.6%)   |
| Other d                                            | 9 (3.3%)   | 13 (4.9%)  | 17 (6.3%)  | 39 (4.8%)   |
| Unknown                                            | 1 (0.4%)   | 0          | 2 (0.7%)   | 3 (0.4%)    |

Key: ASCTautologous stem cell transplant, AASCT, A+IASCT+Ibrutinib, IIbrutinib, COVID-19Coronavirus Diseasc 2019, TEAE treatment-emergent adverse event, EOTcnd of treatment, SMQ Standardized MedDRA Queries.

Includes patients with fatal TEAEs and date of death &gt;30 days afiter EOT if the respective TEAE started within 30 days after EOT.

b COVID-19 TEAEs include all TEAEs with preferred terms COVID-19, COVID-19 pneumonia and Coronavirus infection.

* Other includes non-treatment-cmergent concomitant disease and malignancies, and therapy.

Note: Percentages are caleulated with the number of subjects in safety analysis set as denominators.

Table 33  Incidence of Treatment-emergent Adverse Events Leading to Death by System Organ Class and Preferred Term; Safety Analysis Set (Study 54179060MCL3003)

<div style=\"page-break-after: always\"></div>

|                                                      | A+I       |          | A         |
|------------------------------------------------------|-----------|----------|-----------|
| Analysis set: Safety                                 | 275       | 265      | 268       |
| Subjects with any TEAE leading to death              | 15 (5.5%) | 6 (2.3%) | 11 (4.1%) |
| System organ class                                   |           |          |           |
| Preferred tem                                        |           |          |           |
| Infections and infestations                          | 10 (3.6%) | 4 (1.5%) | 6 (2.2%)  |
| COVID-19                                             | 4 (1.5%)  | 2 (0.8%) | 1 (0.4%)  |
| Pneumonia                                            | 2 (0.7%)  | 0        | 1 (0.4%)  |
| COVID-19 pneumonia                                   | 1 (0.4%)  | 2 (0.8%) | 1 (0.4%)  |
| Influenza                                            | 1 (0.4%)  | 0        | 0         |
| Pneumonia viral                                      | 1 (0.4%)  | 0        | 0         |
| Sepsis                                               | 1 (0.4%)  | 0        | 3 (1.1%)  |
| Septic shock                                         | 1 (0.4%)  | 0        | 0         |
| Neoplasms benign, malignant and unspecified          |           |          |           |
| (incl cysts and polyps)                              | 2 (0.7%)  | 1 (0.4%) | 1 (0.4%)  |
| Malignant melanoma                                   | 1 (0.4%)  | 0        | 0         |
| Malignant neoplasm of thymus                         | 1 (0.4%)  | 0        | 0         |
| Oesophageal adenocarcinoma                           | 0         | 1 (0.4%) | 0         |
| Rectal adenocarcinoma                                | 0         | 0        | 1 (0.4%)  |
| Gastrointestinal disorders                           | 1 (0.4%)  | 0        | 4 (1.5%)  |
| Gastric haemorrhage                                  | 1 (0.4%)  | 0        | 1 (0.4%)  |
| Enterocolitis                                        | 0         | 0        | 1 (0.4%)  |
| Ileus paralytic                                      | 0         | 0        | 1 (0.4%)  |
| Intestinal perforation                               | 0         | 0        | 1 (0.4%)  |
| Psychiatric disorders                                | 1 (0.4%)  | 0        | 0         |
| Completed suicide                                    | 1 (0.4%)  | 0        | 0         |
| Respiratory, thoracic and mediastinal                |           |          |           |
| disorders                                            | 1 (0.4%)  | 0        | 2 (0.7%)  |
| Acute respiratory distress syndrome                  | 1 (0.4%)  | 0        | 1 (0.4%)  |
| Respiratory failure                                  | 0         | 0        | 1 (0.4%)  |
| Cardiac disorders                                    | 0         | 1 (0.4%) | 0         |
| Acute myocardial infarction                          | 0         | 1 (0.4%) | 0         |
| General disorders and administration site conditions | 0         | 0        | 1 (0.4%)  |
| Sudden death                                         | 0         | 0        | 1 (0.4%)  |
| Renal and urinary disorders                          | 0         | 0        | 1 (0.4%)  |
| Acute kidney injury                                  | 0         | 0        | 1 (0.4%)  |

Key: ASCT=autologous stem cell transplant, A=ASCT, A+I=ASCT+Ibrutinib, I=Ibrutinib, TEAE=treatment-emergent adverse event.

Note: Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event.

Note: Percentages are calculated with the number of subjects in safety analysis set as denominator.

Note: Adverse events are presented by decreasing frequency of system organ class and preferred term within A+I column; those with the same frequency are presented alphabetically.

Adverse events are coded using MedDRA Version 26.1.

## Serious Adverse Events

Table 34 Incidence of Treatment-emergent Serious Adverse Events Occurring in 2% or More Subjects in Any Treatment Group by System Organ Class, Preferred Term and Toxicity Grade; Safety Analysis Set (Study 54179060MCL3003)

<div style=\"page-break-after: always\"></div>

|                                                                     | A+I               | A+I               | A+I       |                     |                    |          | A                  | A                  | A         |
|---------------------------------------------------------------------|-------------------|-------------------|-----------|---------------------|--------------------|----------|--------------------|--------------------|-----------|
| Analysis set: Safety                                                | All Grades 275    | Grade3/4          | Grade 5   | All Grades 265      | Grade 3/4          | Grade 5  | AllGrades 268      | Grade3/4           | Grade 5   |
| Subjects with any TESAE                                             | 186 (67.6%)       | 143 (52.0%)       | 15 (5.5%) | 171 (64.5%)         | 140 (52.8%)        | 6 (2.3%) | 123 (45.9%)        | 94 (35.1%)         | 11 (4.1%) |
| System organ class                                                  |                   |                   |           |                     |                    |          |                    |                    |           |
| Preferred term                                                      |                   |                   |           |                     |                    |          |                    |                    |           |
| Infections and infestations                                         | 103 (37.5%)       | 77 (28.0%)        | 10 (3.6%) | 72 (27.2%)          | 56 (21.1%)         | 4 (1.5%) | 36 (13.4%)         | 27 (10.1%)         | 6 (2.2%)  |
| Pneumonia                                                           | 26 (9.5%)         | 20 (7.3%)         | 2 (0.7%)  | 11 (4.2%)           | 9 (3.4%)           | 0        | 8 (3.0%)           | 7 (2.6%)           | 1 (0.4%)  |
| COVID-19                                                            | 12 (4.4%)         | 4 (1.5%)          | 4 (1.5%)  | 12 (4.5%)           | 9 (3.4%)           | 2 (0.8%) | 3 (1.1%)           | 2 (0.7%)           | 1 (0.4%)  |
| Sepsis                                                              | 9 (3.3%)          | 8 (2.9%)          | 1 (0.4%)  | 2 (0.8%)            | 2 (0.8%)           | 0        | 6 (2.2%)           | 3 (1.1%)           | 3 (1.1%)  |
| COVID-19pneumonia                                                   | 8 (2.9%)          | 5 (1.8%)          | 1 (0.4%)  | 10 (3.8%)           | 7 (2.6%)           | 2 (0.8%) | 1 (0.4%)           | 0                  | 1 (0.4%)  |
| Device related infection                                            | 7 (2.5%)          | 6 (2.2%)          | 0         | 0                   | 0                  | 0        | 1 (0.4%)           | 1 (0.4%)           | 0         |
| Herpes zoster                                                       | 6 (2.2%)          | 6 (2.2%)          | 0         | 1 (0.4%)            | 1 (0.4%)           | 0        | 0                  | 0                  | 0         |
| Blood and lymphatic system                                          |                   |                   |           |                     |                    |          |                    |                    |           |
| disorders                                                           | 53 (19.3%)        | 53 (19.3%)        | 0         | 33 (12.5%)          | 33 (12.5%)         | 0        | 30 (11.2%)         | 30 (11.2%)         | 0         |
| Febrile neutropenia                                                 | 39 (14.2%)        | 39 (14.2%)        | 0         | 28 (10.6%)          | 28 (10.6%)         | 0        | 19 (7.1%)          | 19 (7.1%)          | 0         |
| Thrombocytopenia                                                    | 5 (1.8%)          | 5 (1.8%)          | 0         | 2 (0.8%)            | 2 (0.8%)           | 0        | 6 (2.2%)           | 6 (2.2%)           | 0         |
| Gastrointestinal disorders                                          | 32 (11.6%)        | 26 (9.5%)         | 1 (0.4%)  | 21 (7.9%)           | 17 (6.4%)          | 0        | 23 (8.6%)          | 16 (6.0%)          | 4 (1.5%)  |
| Diarrhoea                                                           | 7 (2.5%)          | 7 (2.5%)          | 0         | 2 (0.8%)            | 2 (0.8%)           | 0        | 3 (1.1%)           | 2 (0.7%)           | 0         |
| Vomiting                                                            | 5 (1.8%)          | 4 (1.5%)          | 0         | 9 (3.4%)            | 7 (2.6%)           | 0        | 4 (1.5%)           | 3 (1.1%)           | 0         |
| Renal and urinary disorders                                         | 26 (9.5%)         | 14 (5.1%)         | 0         | 25 (9.4%)           | 13 (4.9%)          | 0        | 20 (7.5%)          | 7 (2.6%)           | 1 (0.4%)  |
| Acute kidney injury                                                 | 15 (5.5%)         | 10 (3.6%)         | 0         | 18 (6.8%)           | 10 (3.8%)          | 0        | 14 (5.2%)          | 4 (1.5%)           | 1 (0.4%)  |
| Renal failure                                                       | 8 (2.9%)          | 4 (1.5%)          | 0         | 5 (1.9%)            | 2 (0.8%)           | 0        | 4 (1.5%)           | 2 (0.7%)           | 0         |
| Generaldisorders and administration                                 |                   |                   |           |                     |                    |          |                    |                    |           |
| site conditions                                                     | 19 (6.9%)         | 7 (2.5%)          | 0         | 18 (6.8%)           | 8 (3.0%)           | 0        | 13 (4.9%)          | 7 (2.6%)           | 1 (0.4%)  |
| Pyrexia                                                             | 12 (4.4%)         | 3 (1.1%)          | 0         | 8 (3.0%)            | 2 (0.8%)           | 0        | 8 (3.0%)           | 4 (1.5%)           | 0         |
| Cardiac disorders                                                   | 16 (5.8%)         | 15 (5.5%)         | 0         | 19 (7.2%)           | 11 (4.2%)          | 1 (0.4%) | 4 (1.5%)           | 3 (1.1%)           | 0         |
| Atrial fibrillation                                                 | 8 (2.9%)          | 7 (2.5%)          | 0         | 12 (4.5%)           | 8 (3.0%)           | 0        | 1 (0.4%)           | 1 (0.4%)           | 0         |
| Investigations                                                      | 12 (4.4%)         | 6 (2.2%)          | 0         | 11 (4.2%)           | 5 (1.9%)           | 0        | 11 (4.1%)          | 7 (2.6%)           | 0         |
| Blood creatinine increased                                          | 6 (2.2%)          | 1 (0.4%)          | 0         | 5 (1.9%)            | 0                  | 0        | 4 (1.5%)           | 0                  | 0         |
| Platelet count decreased                                            | 5 (1.8%)          | 5 (1.8%)          | 0         | 0                   | 0                  | 0        | 6 (2.2%)           | 6 (2.2%)           | 0         |
| Respiratory, thoracic and mediastinal disorders                     | 8 (2.9%)          | 6 (2.2%)          | 1 (0.4%)  | 3 (1.1%)            | 2 (0.8%)           | 0        | 7 (2.6%)           | 5 (1.9%)           | 2 (0.7%)  |
| Injury, poisoning and procedural complications                      | 7 (2.5%)          | 6 (2.2%)          | 0         | 7 (2.6%)            | 6 (2.3%)           | 0        | 4 (1.5%)           | 3 (1.1%)           | 0         |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 7 (2.5%)          | 4 (1.5%)          | 2 (0.7%)  | 5 (1.9%)            | 4 (1.5%)           | 1 (0.4%) | 1 (0.4%)           | 0                  | 1 (0.4%)  |
| Nervous system disorders                                            | 7 (2.5%)          | 5 (1.8%)          | 0         | 14 (5.3%) 11 (4.2%) | 11 (4.2%)          | 0        | 7 (2.6%)           | 5 (1.9%)           | 0         |
| Metabolismandnutritiondisorders Vascular disorders                  | 6 (2.2%) 6 (2.2%) | 4 (1.5%) 5 (1.8%) | 0 0       | 5 (1.9%)            | 11 (4.2%) 4 (1.5%) | 0 0      | 11 (4.1%) 5 (1.9%) | 11 (4.1%) 1 (0.4%) | 0 0       |

Key:ASCT=autologous stem cell transplant,A=ASCT,A+I=ASCT+Ibrutinib,I=Ibrutinib,TESAE=treatment-emergent serious adverse event.

Note: Adverse events are presented by decreasing frequency of system organ class and preferred term within A+I column; those with the same frequency are presented alphabetically.

Note: Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event. The event experienced by the subject with the worst toxicity isused.If a subject hasmissing toxicity for a specific adverse event, the subjectis only counted in theAll Grades column for that adverse event.

Note:Percentages are calculated with the number of subjects in safety analysis set as denominator.

Adverse events are coded using MedDRA Version 26.1.

## Other significant events

Treatment-emergent Adverse Events of Clinical Interest: Major Haemorrhage

Table 35 Incidence of Treatment-emergent Major Hemorrhage Events; Safety Analysis Set (Study 54179060MCL3003)

<div style=\"page-break-after: always\"></div>

|                                          | A+I        | A+I       | A+I      |            |           |         | A          | A         | A        |
|------------------------------------------|------------|-----------|----------|------------|-----------|---------|------------|-----------|----------|
|                                          | All Grades | Grade 3/4 | Grade 5  | All Grades | Grade 3/4 | Grade 5 | All Grades | Grade 3/4 | Grade 5  |
| Analysis set: Safety                     | 275        |           |          | 265        |           |         | 268        |           |          |
| Subjectswith anyTEMajorHemorrhage Events | 11 (4.0%)  | 8 (2.9%)  | 1 (0.4%) | 10 (3.8%)  | 8 (3.0%)  | 0       | 9 (3.4%)   | 8 (3.0%)  | 1 (0.4%) |
| PreferredTerm                            |            |           |          |            |           |         |            |           |          |
| Gastrointestinal haemorrhage             | 2 (0.7%)   | 2 (0.7%)  | 0        | 0          | 0         | 0       | 1 (0.4%)   | 1 (0.4%)  | 0        |
| Post procedural haemorrhage              | 2 (0.7%)   | 2 (0.7%)  | 0        | 0          | 0         | 0       | 0          | 0         | 0        |
| Catheter site haemorhage                 | 1 (0.4%)   | 0         | 0        | 2 (0.8%)   | 2 (0.8%)  | 0       | 0          | 0         | 0        |
| Diverticulumintestinal haemorrhagic      | 1 (0.4%)   | 1 (0.4%)  | 0        | 0          | 0         | 0       | 0          | 0         | 0        |
| Epistaxis                                | 1 (0.4%)   | 1 (0.4%)  | 0        | 3 (1.1%)   | 3 (1.1%)  | 0       | 3 (1.1%)   | 3 (1.1%)  | 0        |
| Gastric haemonhage                       | 1 (0.4%)   | 0         | 1 (0.4%) | 0          | 0         | 0       | 1 (0.4%)   | 0         | 1 (0.4%) |
| Haematuria                               | 1 (0.4%)   | 0         | 0        | 0          | 0         | 0       | 0          | 0         | 0        |
| Petechiae                                | 1 (0.4%)   | 1 (0.4%)  | 0        | 0          | 0         | 0       | 0          | 0         | 0        |
| Retroperitoneal haemorrhage              | 1 (0.4%)   | 1 (0.4%)  | 0        | 0          | 0         | 0       | 0          | 0         | 0        |
| Anal haemorrhage                         | 0          | 0         | 0        | 1 (0.4%)   | 0         | 0       | 0          | 0         | 0        |
| Blood loss anaemia                       | 0          | 0         | 0        | 0          | 0         | 0       | 1 (0.4%)   | 1 (0.4%)  | 0        |
| Haematoma                                | 0          | 0         | 0        | 3 (1.1%)   | 2 (0.8%)  | 0       | 1 (0.4%)   | 1 (0.4%)  | 0        |
| Haemorrhage intracranial                 | 0          | 0         | 0        | 1 (0.4%)   | 1 (0.4%)  | 0       | 0          | 0         | 0        |
| Intestinal haemorrhage                   | 0          | 0         | 0        | 0          | 0         | 0       | 1 (0.4%)   | 1 (0.4%)  | 0        |
| Rectal haemorrhage                       | 0          | 0         | 0        | 0          | 0         | 0       | 1 (0.4%)   | 1 (0.4%)  | 0        |
| Subarachnoid haemorrhage                 | 0          | 0         | 0        | 0          | 0         | 0       | 1 (0.4%)   | 1 (0.4%)  | 0        |

Key:ASCT=autologous stem cell transplant, A=ASCT, A+I=ASCT+Ibrutinib,I=Ibrutinib,TE=treatment-emergent.

Note: Adverse events are presented by decreasing frequency of preferred term within A+I column; those with the same frequency are presented alphabetically.

Note: Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event.The event experienced by the subject with the worst toxicity isused.Ifa subject hasmissing toxicity for a specificadverse event,the subjectis only countedin theAll Gradescolumn for that adverse event.

Note:Percentages are calculated with the number of subjects in safety analysis set as denominator.

Adverseeventsarecoded usingMedDRAVersion26.1.

## Other Safety Observations:

## Atrial Fibrillation

The incidence of any grade atrial fibrillation was higher in both ibrutinib-containing arms: Arms A+I (23 [8.4%]) and Arm I (26 [9.8%]) compared with participants in Arm A (6 [2.2%]). Grade 3 and 4 events were reported in 13 (4.7%) and 10 (3.8%) participants in Arm A+I and Arm I, respectively, compared to 5 (1.9%) participants in Arm A. Serious atrial fibrillation was reported in 8 (2.9%) and 12 (4.5%) participants in Arm A+I and Arm I compared to 1 (0.4%) participant in Arm A. There were no fatal events of atrial fibrillation. Atrial fibrillation resulted in ibrutinib discontinuation in 6 (2.2%) and 5 (1.9%) participants in Arm A+I and Arm I, respectively . In 5 (1.9%) participants, atrial fibrillation led to an ibrutinib dose reduction in Arm I, no ibrutinib dose reduction occurred in Arm A+I due to atrial fibrillation.

## Induction Period

The number of participants with atrial fibrillation during induction period was higher in Arm A+I (14 [5.1%]) and Arm I (14 [5.3%] participants), as compared to participants receiving induction immunochemotherapy without ibrutinib in Arm A (3 [1.1%] participants). Serious TEAEs of atrial fibrillation were reported in 4 (1.5%) and 6 (2.3%) participants in Arm A+I and Arm I, and in 1 (0.4%) participant from Arm A. In Arm A+I and Arm I, 4 (1.5%) and 1 (0.4%) participant(s) respectively, had a TEAE of atrial fibrillation that led to ibrutinib treatment discontinuation, and 2 participants in Arm I had a TEAE of atrial fibrillation that resulted in ibrutinib dose reduction.

## Ventricular Tachyarrhythmias

Table 36 Incidence of Treatment-emergent Ventricular Tachyarrhythmia by Preferred Term and Toxicity Grade; Safety Analysis Set (Study 54179060MCL3003)

<div style=\"page-break-after: always\"></div>

|                                             | A+I        | A+I       | A+I     |            |           |        | A         | A         | A       |
|---------------------------------------------|------------|-----------|---------|------------|-----------|--------|-----------|-----------|---------|
|                                             | All Grades | Grade 3/4 | Grade 5 | All Grades | Grade 3/4 | Grade5 | AllGrades | Grade 3/4 | Grade 5 |
| Analysis set: Safety                        | 275        |           |         | 265        |           |        | 268       |           |         |
| SubjectswithanyTEVentricularTachyarrhythmia | 2 (0.7%)   | 1 (0.4%)  | 0       |            | 0         |        | 0         |           | 0       |
| PreferredTerm                               |            |           |         |            |           |        |           |           |         |
| Ventriculararhythmia                        | 1 (0.4%)   | 0         | 0       | 0          | 0         | 0      | 0         | 0         | 0       |
| Ventricularfibrillation                     | 1 (0.4%)   | 1 (0.4%)  | 0       | 0          | 0         | 0      | 0         | 0         | 0       |

Key: ASCT=autologous stem cell transplant, A=ASCT, A+I=ASCT+Ibrutinib, I=Ibrutinib, TE=treatment-emergent.

Note: Subjects are coumted only once for any given event, regardless of the number of times they actually experienced the event. The event experienced by the subject with theworst toxicityisused.Ifasubject hasmissingtoxicityfora specific adverseevent,the subjectisonly countedin theAll Grades columnfor that adverseevent.

Note:Adverse events arepresented by decreasing frequency of preferred term within A+I column; those with the same frequency are presented alphabetically.

Note: Percentages are calculated with the number of subjects in safety analysis set as denominator.

AdverseeventsarecodedusingMledDRAVersion26.1.

## Other Cardiac Arrhythmias (Excluding Atrial Fibrillation and Ventricular Tachyarrhythmia)

Table 37 Incidence of Treatment-emergent Cardiac Arrhythmias (Excluding Atrial Fibrillation and Ventricular Tachyarrhymia) Adverse Events by Toxicity Grade, System Organ Class and Preferred Term - MCL3003; Safety Population

|                                                      | A+I            | A+I       | A+I     |                |           |         | A              | A         | A        |
|------------------------------------------------------|----------------|-----------|---------|----------------|-----------|---------|----------------|-----------|----------|
| Analysis set: Safety Population                      | All Grades 275 | Grade 3/4 | Grade 5 | All Grades 265 | Grade 3/4 | Grade 5 | All Grades 268 | Grade 3/4 | Grade 5  |
| Subjects with any TEAE                               | 34 (12.4%)     | 10 (3.6%) | 0       | 34 (12.8%)     | 7 (2.6%)  | 0       | 24 (9.0%)      | 7 (2.6%)  | 1 (0.4%) |
| System organ class Preferred term                    |                |           |         |                |           |         |                |           |          |
| Cardiac disorders                                    | 24 (8.7%)      | 3 (1.1%)  | 0       | 27 (10.2%)     | 1 (0.4%)  | 0       | 14 (5.2%)      | 3 (1.1%)  | 0        |
| Tachycardia                                          | 7 (2.5%)       | 1 (0.4%)  | 0       | 7 (2.6%)       | 0         | 0       | 6 (2.2%)       | 1 (0.4%)  | 0        |
| Sinus tachycardia                                    | 5 (1.8%)       | 0         | 0       | 5 (1.9%)       | 0         | 0       | 3 (1.1%)       | 1 (0.4%)  | 0        |
| Palpitations                                         | 4 (1.5%)       | 1 (0.4%)  | 0       | 7 (2.6%)       | 0         | 0       | 1 (0.4%)       | 0         | 0        |
| Supraventricular tachycardia                         | 4 (1.5%)       | 0         | 0       | 0              | 0         | 0       | 0              | 0         | 0        |
| Atrial flutter                                       | 3 (1.1%)       | 1 (0.4%)  | 0       | 2 (0.8%)       | 0         | 0       | 0              | 0         | 0        |
| Atrial tachycardia                                   | 1 (0.4%)       | 0         | 0       | 0              | 0         | 0       | 0              | 0         | 0        |
| Bradycardia                                          | 1 (0.4%)       | 0         | 0       | 3 (1.1%)       | 0         | 0       | 4 (1.5%)       | 1 (0.4%)  | 0        |
| Bundle branch block right                            | 1 (0.4%)       | 0         | 0       | 0              | 0         | 0       | 0              | 0         | 0        |
| Sinoatrial block                                     | 1 (0.4%)       | 0         | 0       | 0              | 0         | 0       | 0              | 0         | 0        |
| Supraventricular extrasystoles                       | 1 (0.4%)       | 0         | 0       | 0              | 0         | 0       | 0              | 0         | 0        |
| Arrhythmia                                           | 0              | 0         | 0       | 1 (0.4%)       | 0         | 0       | 0              | 0         | 0        |
| Atrioventricular block                               | 0              | 0         | 0       | 1 (0.4%)       | 0         | 0       | 0              | 0         | 0        |
| Atrioventricular block first degree                  | 0              | 0         | 0       | 1 (0.4%)       | 0         | 0       | 0              | 0         | 0        |
| Extrasystoles                                        | 0              | 0         | 0       | 1 (0.4%)       | 0         | 0       | 0              | 0         | 0        |
| Paroxysmal arrhythmia                                | 0              | 0         | 0       | 1 (0.4%)       | 0         | 0       | 0              | 0         | 0        |
| Sinus bradycardia                                    | 0              | 0         | 0       | 1 (0.4%)       | 0         | 0       | 0              | 0         | 0        |
| Sinus node dysfunction                               | 0              | 0         | 0       | 1 (0.4%)       | 1 (0.4%)  | 0       | 0              | 0         | 0        |
| Nervous system disorders                             | 10 (3.6%)      | 7 (2.5%)  | 0       | 12 (4.5%)      | 6 (2.3%)  | 0       | 10 (3.7%)      | 5 (1.9%)  | 0        |
| Syncope                                              | 10 (3.6%)      | 7 (2.5%)  | 0       | 12 (4.5%)      | 6 (2.3%)  | 0       | 10 (3.7%)      | 5 (1.9%)  | 0        |
| Investigations                                       | 3 (1.1%)       | 0         | 0       | 0              | 0         | 0       | 0              | 0         | 0        |
| ElectrocardiogramQTprolonged                         | 1 (0.4%)       | 0         | 0       | 0              | 0         | 0       | 0              | 0         | 0        |
| Heart rate increased                                 | 1 (0.4%)       | 0         | 0       | 0              | 0         | 0       | 0              | 0         | 0        |
| Heart rate irregular                                 | 1 (0.4%)       | 0         | 0       | 0              | 0         | 0       | 0              | 0         | 0        |
| General disorders and administration site conditions | 0              | 0         | 0       | 0              | 0         | 0       | 1 (0.4%)       | 0         | 1 (0.4%) |
| Sudden death                                         | 0              | 0         | 0       | 0              | 0         | 0       | 1 (0.4%)       | 0         | 1 (0.4%) |

Note: Percentages calculated with the number of subjects in safety population as denominator. Worst toxicity grade was used for subjects who had multiple events per system organ class or per preferred term. A subject who had event with missing toxicity grade was counted in the all grades column but not listed separately.

Adverse events are presented by descending total frequency of SOC and PT within SOC in the Am A+I group; those with the same total frequency are presented alphabetically. Adverseevents arecodedusingMedDRAVersion26.1.

## Cardiac Failure

Table 38 Incidence of Treatment-emergent Cardiac Failure Adverse Events by Toxicity Grade, System Organ Class and Preferred Term - MCL3003; Safety Population

<div style=\"page-break-after: always\"></div>

|                                             | A+I            | A+I      | A+I     |                |           |         | A             | A         | A       |
|---------------------------------------------|----------------|----------|---------|----------------|-----------|---------|---------------|-----------|---------|
| Analysis set:Safety Population              | All Grades 275 | Grade3/4 | Grade 5 | All Grades 265 | Grade 3/4 | Grade 5 | AllGrades 268 | Grade 3/4 | Grade 5 |
| Subjects with any TEAE                      | 5 (1.8%)       | 2 (0.7%) | 0       | 5 (1.9%)       | 0         | 0       | 3 (1.1%)      | 1 (0.4%)  | 0       |
| System organclass Preferred term            |                |          |         |                |           |         |               |           |         |
| Cardiac disorders                           | 4 (1.5%)       | 2 (0.7%) | 0       | 3 (1.1%)       | 0         |         | 0             | 0         | 0       |
| Cardiacfailure                              | 4 (1.5%)       | 2 (0.7%) | 0       | 1 (0.4%)       | 0         | 0       | 0             | 0         | 0       |
| Cardiacfailure chronic                      | 0              | 0        | 0       | 2 (0.8%)       | 0         | 0       | 0             | 0         | 0       |
| Respiratory,thoracicandmediastinaldisorders | 1 (0.4%)       | 0        | 0       | 0              | 0         | 0       | 1 (0.4%)      | 1 (0.4%)  | 0       |
| Pulmonaryoedema                             | 1 (0.4%)       | 0        | 0       | 0              | 0         | 0       | 1 (0.4%)      | 1 (0.4%)  | 0       |
| Investigations                              | 0              | 0        | 0       | 2 (0.8%)       | 0         | 0       | 2 (0.7%)      | 0         | 0       |
| Ejectionfractiondecreased                   | 0              | 0        | 0       | 2 (0.8%)       | 0         | 0       | 2 (0.7%)      | 0         | 0       |

Note:Percentagescalculatedwiththe number of subjects insafetypopulationas denominator.Worsttoxicitygrade was usedfor subjectswhohad multiple eventspersystem organ classorperpreferred term.A subject whohadevent with missing toxicitygradewascounted in the all gradescolumnbut not listedseparately.

Adverseeventsarepresented by descending totalfrequency ofSOCandPTwithinSOCin theArmA+Igroup;thosewith thesame totalfrequency arepresented alphabetically. AdverseeventsarecodedusingMedDRAVersion26.1.

## Hypertension

Table 39 Incidence of Treatment-emergent Hypertension by Preferred Term and Toxicity Grade; Safety Analysis Set (Study 54179060MCL3003)

|                                   | A+I        | A+I       | A+I     |            |           |         | A          | A         | A       |
|-----------------------------------|------------|-----------|---------|------------|-----------|---------|------------|-----------|---------|
|                                   | All Grades | Grade 3/4 | Grade 5 | All Grades | Grade 3/4 | Grade 5 | All Grades | Grade 3/4 | Grade 5 |
| Analysis set:Safety               | 275        |           |         | 265        |           |         | 268        |           |         |
| Subjects with any TE Hypertension | 27 (9.8%)  | 12 (4.4%) |         | 36 (13.6%) | 14 (5.3%) | 0       | 24 (9.0%)  | 12 (4.5%) | 0       |
| PreferredTerm                     |            |           |         |            |           |         |            |           |         |
| Hypertension                      | 23 (8.4%)  | 10 (3.6%) | 0       | 33 (12.5%) | 11 (4.2%) | 0       | 21 (7.8%)  | 12 (4.5%) | 0       |
| Hypertensivecrisis                | 4 (1.5%)   | 2 (0.7%)  | 0       | 2 (0.8%)   | 2 (0.8%)  | 0       | 2 (0.7%)   | 0         | 0       |
| Bloodpressureincreased            | 2 (0.7%)   | 1 (0.4%)  | 0       | 0          | 0         | 0       | 0          | 0         | 0       |
| Bloodpressuresystolicimcreased    | 0          | 0         | 0       | 1 (0.4%)   | 1 (0.4%)  | 0       | 0          | 0         | 0       |
| Metabolicsyndrome                 | 0          | 0         | 0       | 0          | 0         | 0       | 1 (0.4%)   | 0         | 0       |

Key:ASCT=autologousstemcell transplant,A=ASCT,A+I=ASCT+Ibrutinib,I=Ibrutinib,TE=treatment-emergent.

Note: Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event. The event experienced by the subject with the worst toxicity is used.Ifasubject hasmissing toxicityfora specific adverse event, thesubjectis only counted in theAll Grades columnfor that adverse event.

Note:Adverse events arepresentedbydecreasingfrequency of preferred temwithinA+Icolumn;thosewith thesame frequency arepresented alphabetically.

Note:Percentages arecalculatedwith thenumberof subjectsin safety analysisset asdenominator.

Adverse events arecoded usingMedDRAVersion 26.1.

## Ischemic Stroke

Table 40 Incidence of Treatment-emergent Ischaemic Stroke by Preferred Term and Toxicity Grade; Safety Analysis Set (Study 54179060MCL3003)

|                                  | A+I        | A+I      | A+I     |            |           |         | A          | A         | A       |
|----------------------------------|------------|----------|---------|------------|-----------|---------|------------|-----------|---------|
|                                  | All Grades | Grade3/4 | Grade 5 | All Grades | Grade 3/4 | Grade 5 | All Grades | Grade 3/4 | Grade 5 |
| Analysis set:Safety              | 275        |          |         | 265        |           |         | 268        |           |         |
| SubjectswithanyTEIschaemicStroke | 0          |          |         | 2 (0.8%)   |           |         | 2 (0.7%)   |           |         |
| PreferredTerm                    |            |          |         |            |           |         |            |           |         |
| Amaurosisfugax                   | 0          | 0        | 0       | 0          | 0         | 0       | 1 (0.4%)   | 0         | 0       |
| Cerebralinfarction               | 0          | 0        | 0       | 0          | 0         | 0       | 1 (0.4%)   | 0         | 0       |
| Transientischaemicattack         | 0          | 0        | 0       | 2 (0.8%)   | 0         | 0       | 0          | 0         | 0       |

Key: ASCT=autologous stem cell transplant, A=ASCT, A+I=ASCT+Ibrutinib, I=Ibrutinib, TE=treatment-emergent.

Note:Subjects arecountedonlyonceforanygivenevent,regardlessof thenumber oftimesthey actuallyexperienced theevent.The eventexperienced by the subjectwith theworst toxicityisused.Ifasubjecthasmissingtoxicityforaspecificadverseevent,thesubjectisonlycountedintheAllGradescolumnforthatadverseevent.

Note:Adverse events arepresented bydecreasingfrequencyof preferred termwithinA+I column;thosewith thesamefrequency arepresented alphabetically

Note:Percentages are calculatedwith thenumber of subjects insafety analysis set asdenominator.

AdverseeventsarecodedusingMledDRAVersion26.1.

## Infections (Including Viral Reactivation)

A higher proportion of participants in Arm A+I (81.1%) compared to Arm I (70.2%) and Arm A (51.1%) had TEAEs within the SOC of Infections and Infestations. Treatment-emergent infections reported in ≥10% of participants in any study arm included pneumonia (20.4% participants in Arm A+I, 10.2% in Arm I, and 5.2% in Arm A), COVID-19 (14.9% in Arm A+I, 14.0% in Arm I, and 1.1% in Arm A), herpes zoster (10.5% in Arm A+I, 2.3% in Arm I, and 0.4% in Arm A), and upper respiratory tract infection (10.5% in Arm A+I, 6.4% in Arm I, and 3.7% in Arm A).

<div style=\"page-break-after: always\"></div>

The proportion of participants with Grade 3 or 4 TEAEs was higher in participants in Arm A+I (38.5%) compared to Arm I (27.2%) and Arm A (20.9%). The most frequently reported Grade 3 or 4 infection was pneumonia which was reported in a higher proportion of participants in Arm A+I (10.2%) compared to Arm I (5.3%) and Arm A (3.7%).

Treatment-emergent SAEs of any grade were reported at a higher incidence in Arm A+I (37.5%) compared to Arm I (27.2%) and Arm A (13.4%). Pneumonia , the most commonly reported serious infection of any grade and at Grade 3 or 4 was numerically higher in Arm A+I (9.5% and 7.3%) but similar in Arm I (4.2% and 3.4%) and Arm A (3.0% and 2.6%). Ten participants (3.6%) in Arm A+I, 4 (1.5%) participants in Arm I and 6 (2.2%) participants in Arm A were reported with a fatal infection. Infections and infestations leading to ibrutinib dose reduction or treatment discontinuation were reported for 1.8% and 13.1% participants in Arm A+I and 2.6% and 7.2% participants in Arm I.

## Induction Phase

The incidence of treatment-emergent infections of any grade was higher in participants receiving induction therapy in combination with ibrutinib (Arm A+I 39.6% and Arm I 37.7%) compared to participants in Arm A (29.5%). The rate of Grade 3 or 4 events was comparable across the treatment arms (11.6% in Arm A+I, 12.1% in Arm I and 8.6% in Arm A). Fatal TEAEs were reported in one participant (0.4%) of each arm during the induction period. As for the entire treatment-emergent period, the most frequently reported infectious event during induction was pneumonia with similar incidences of any grade and Grade 3 or 4 across treatment arms (3.3% and 1.5% in Arm A+I, 1.5% and 1.1% in Arm I and 3.0% and 1.9% in Arm A). Whilst 0.7% and 1.5% had infections resulting in ibrutinib discontinuation, no ibrutinib dose reductions were reported for infectious events in either arm.

## Second Primary Malignancies

## Table 41 Incidence of Second Primary Malignancies During the Entire Study Period by Preferred Term; Safety Analysis Set (Study 54179060MCL3003)

<div style=\"page-break-after: always\"></div>

|                                               | A+I       |           | A         |
|-----------------------------------------------|-----------|-----------|-----------|
| Analysis set: Safety                          | 275       | 265       | 268       |
| Subjects with any second primary malignancies | 21 (7.6%) | 20 (7.5%) | 11 (4.1%) |
| Non-Melanoma Skin Cancer                      | 7 (2.5%)  | 3 (1.1%)  | 1 (0.4%)  |
| Basal cell carcinoma                          | 3 (1.1%)  | 3 (1.1%)  | 1 (0.4%)  |
| Squamouscell carcinoma                        | 2 (0.7%)  | 0         | 0         |
| Neoplasm skin                                 | 1 (0.4%)  | 0         | 0         |
| Squamouscell carcinoma of skin                | 1 (0.4%)  | 0         | 0         |
| Non-Skin cancer (malignant)                   | 14 (5.1%) | 16 (6.0%) | 10 (3.7%) |
| Angiosarcoma                                  | 1 (0.4%)  | 0         | 0         |
| Bladder cancer                                | 1 (0.4%)  | 0         | 0         |
| Breast cancer                                 | 1 (0.4%)  | 1 (0.4%)  | 0         |
| Colon cancer                                  | 1 (0.4%)  | 0         | 0         |
| Invasive ductalbreastcarcinoma                | 1 (0.4%)  | 0         | 0         |
| Leiomyosarcoma                                | 1 (0.4%)  | 0         | 0         |
| Lung adenocarcinoma                           | 1 (0.4%)  | 1 (0.4%)  | 0         |
| Lung neoplasm malignant                       | 1 (0.4%)  | 0         | 0         |
| Malignant neoplasm of thymus                  | 1 (0.4%)  | 0         | 0         |
| Metastases to meninges                        | 1 (0.4%)  | 0         | 0         |
| Myelodysplastic syndrome                      | 1 (0.4%)  | 0         | 1 (0.4%)  |
| Neoplasm malignant                            | 1 (0.4%)  | 1 (0.4%)  | 0         |
| Neuroendocrine tumour                         | 1 (0.4%)  | 0         | 0         |
| Prostate cancer                               | 1 (0.4%)  | 6 (2.3%)  | 1 (0.4%)  |
| Renal cell carcinoma                          | 1 (0.4%)  | 0         | 0         |
| Renal neoplasm                                | 1 (0.4%)  | 1 (0.4%)  | 0         |
| Acute myeloid leukaemia                       | 0         | 0         | 2 (0.7%)  |
| Adenosquamous cell lung cancer                | 0         | 1 (0.4%)  | 0         |
| B-cell lymphoma                               | 0         | 0         | 1 (0.4%)  |
| Bladder cancer recurent                       | 0         | 1 (0.4%)  | 0         |
| Bladder transitionalcell carcinoma            | 0         | 0         | 1 (0.4%)  |
| Follicular thyroid cancer                     | 0         | 1 (0.4%)  | 0         |
| Metastases to central nervous system          | 0         | 1 (0.4%)  | 0         |
| Oesophageal adenocarcinoma                    | 0         | 1 (0.4%)  | 0         |
| Pancreatic carcinoma                          | 0         | 0         | 1 (0.4%)  |
| Plasma cell myeloma                           | 0         | 1 (0.4%)  | 0         |
| Rectal adenocarcinoma                         | 0         | 0         | 1 (0.4%)  |
| Renal cancer                                  | 0         | 0         | 1 (0.4%)  |
| Small cell lung cancer                        | 0         | 1 (0.4%)  | 0         |
| Transitional cell carcinoma                   | 0         | 0         | 1 (0.4%)  |
| Transitionalcellcarcinomarecurrent            | 0         | 0         | 1 (0.4%)  |
|                                               | A+I       | 一         | A         |
| Melanoma Skin Cancer                          | 1 (0.4%)  | 1 (0.4%)  | 0         |
| Malignant melanoma                            | 1 (0.4%)  | 1 (0.4%)  | 0         |

Key: ASCT=autologous stem cell transplant, A=ASCT, A+I=ASCT+Ibrutinib, I=Ibrutinib.

Note: Adverse events are presented by decreasing frequency of preferred tem within A+I column, those with the same frequency are presented alphabetically.

Note: Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event.

Note: Percentages are calculated with the number of subjects in safety analysis set as denominator.

Adverse events are coded usingMedDRAVersion 26.1.

## Interstitial Lung Disease (ILD)

Table 42 Incidence of Treatment-emergent Interstitial Lung Disease (ILD) by Preferred Term and Toxicity Grade; Safety Analysis Set (Study 54179060MCL3003)

|                                                    | A+I            | A+I       | A+I     |                |          |         | A              | A         | A       |
|----------------------------------------------------|----------------|-----------|---------|----------------|----------|---------|----------------|-----------|---------|
| Analysisset:Safety                                 | All Grades 275 | Grade 3/4 | Grade 5 | All Grades 265 | Grade3/4 | Grade 5 | All Grades 268 | Grade 3/4 | Grade 5 |
| Subjects with anyTE Interstitial LungDisease (ILD) | 7 (2.5%)       | 4 (1.5%)  | 0       | 12 (4.5%)      | 2 (0.8%) | 0       | 1 (0.4%)       | 1 (0.4%)  | 0       |
| PreferredTerm                                      |                |           |         |                |          |         |                |           |         |
| Pneumonitis                                        | 4 (1.5%)       | 2 (0.7%)  | 0       | 7 (2.6%)       | 0        | 0       | 1 (0.4%)       | 1 (0.4%)  | 0       |
| Interstitiallungdisease                            | 2 (0.7%)       | 2 (0.7%)  | 0       | 3 (1.1%)       | 1 (0.4%) | 0       | 0              | 0         | 0       |
| Alveolitis                                         | 1 (0.4%)       | 1 (0.4%)  | 0       | 1 (0.4%)       | 1 (0.4%) | 0       | 0              | 0         | 0       |
| Lunginfiltration                                   | 1 (0.4%)       | 0         | 0       | 0              | 0        | 0       | 0              | 0         | 0       |
| Pulmonaryfibrosis                                  | 0              | 0         | 0       | 1 (0.4%)       | 0        | 0       | 0              | 0         | 0       |

Key: ASCT=autologous stem cell transplant, A=ASCT, A+I=ASCT+Ibrutinib, I=Ibrutinib, TE=treatment-emergent.

Note: Subjects are coumted only once for any given event,regardless of the number oftimes they actually experienced the event.The event experienced by the subject with the worst toxicity is used.Ifasubject has missing toxicity fora specific adverse event,the subjectis only counted intheAll Gradescolumnfor that adverse event.

Note: Adverse events are presented by decreasing frequency of preferred term within A+I column; those with the same frequency are presented alphabetically.

Note:Percentagesare calculatedwith thenumberof subjects insafety analysisset asdenominator.

Adverseevents arecodedusingMedDRAVersion26.1.

## Cytopenic Adverse Events

<div style=\"page-break-after: always\"></div>

Table 43 Incidence of Treatment-emergent Cytopenia Adverse Events by Toxicity Grade, Grouped Term and Preferred Term - MCL3003; Safety Population

|                                | A+I         | A+I         | A+I     | 1           | 1           | 1       | A           | A           | A       |
|--------------------------------|-------------|-------------|---------|-------------|-------------|---------|-------------|-------------|---------|
|                                | All Grades  | Grade 3/4   | Grade 5 | All Grades  | Grade 3/4   | Grade 5 | All Grades  | Grade 3/4   | Grade 5 |
| Analysis Set:Safety Population | 275         |             |         | 265         |             |         | 268         |             |         |
| Subjectswith anyCytopenicTEAE  | 251 (91.3%) | 245 (89.1%) | 0       | 224 (84.5%) | 209 (78.9%) | 0       | 233 (86.9%) | 225 (84.0%) | 0       |
| Grouped Term PreferredTerm     |             |             |         |             |             |         |             |             |         |
| Anaemia*                       | 162 (58.9%) | 121 (44.0%) | 0       | 122 (46.0%) | 58 (21.9%)  | 0       | 157 (58.6%) | 93 (34.7%)  | 0       |
| Anaemia                        | 162 (58.9%) | 121 (44.0%) | 0       | 119 (44.9%) | 57 (21.5%)  | 0       | 155 (57.8%) | 92 (34.3%)  | 0       |
| Haemoglobin decreased          | 1 (0.4%)    | 0           | 0       | 3 (1.1%)    | 1 (0.4%)    | 0       | 2 (0.7%)    | 1 (0.4%)    | 0       |
| Febrile neutropenia            | 98 (35.6%)  | 98 (35.6%)  | 0       | 37 (14.0%)  | 37 (14.0%)  | 0       | 71 (26.5%)  | 71 (26.5%)  | 0       |
| Neutropenia                    | 210 (76.4%) | 205 (74.5%) | 0       | 167 (63.0%) | 158 (59.6%) | 0       | 171 (63.8%) | 163 (60.8%) | 0       |
| Neutropenia                    | 141 (51.3%) | 136 (49.5%) | 0       | 112 (42.3%) | 104 (39.2%) | 0       | 110 (41.0%) | 104 (38.8%) | 0       |
| Neutrophil count decreased     | 89 (32.4%)  | 86 (31.3%)  | 0       | 68 (25.7%)  | 64 (24.2%)  | 0       | 65 (24.3%)  | 62 (23.1%)  | 0       |
| Thrombocytopenia               | 214 (77.8%) | 197 (71.6%) | 0       | 182 (68.7%) | 162 (61.1%) | 0       | 202 (75.4%) | 193 (72.0%) |         |
| Thrombocytopenia               | 124 (45.1%) | 109 (39.6%) | 0       | 105 (39.6%) | 92 (34.7%)  | 0       | 121 (45.1%) | 114 (42.5%) | 0:0     |
| Platelet count decreased       | 100 (36.4%) | 98 (35.6%)  | 0       | 87 (32.8%)  | 78 (29.4%)  | 0       | 91 (34.0%)  | 89 (33.2%)  | 0       |

Key:TEAE=Treatment-emergent adverse event.*Grouped term.

Note: Percentages calculated with the number of subjects in safety population as denominator. Worst toxicity grade was used for subjects who had multiple events per system organ class or per preferred term. A subject who had event with missing toxicity grade was counted in the all grades column but not listed separately. Adverse events are coded using MedDRA Version 26.1.

## Hepatic Toxicity Including Hepatic Failure

Table 44 Incidence of Treatment-emergent Hepatotoxicity Adverse Events by Toxicity Grade, System Organ Class and Preferred Term - MCL3003; Safety Population

|                              | A+I        | A+I      | A+I     |            |           |         | A         | A         | A       |
|------------------------------|------------|----------|---------|------------|-----------|---------|-----------|-----------|---------|
|                              | All Grades | Grade3/4 | Grade 5 | All Grades | Grade 3/4 | Grade 5 | AllGrades | Grade 3/4 | Grade 5 |
| Analysisset:SafetyPopulation | 275        |          |         | 265        |           |         | 268       |           |         |
| Subjects with any TEAE       | 4 (1.5%)   | 2 (0.7%) | 0       | 5 (1.9%)   | 0         | 0       | 2 (0.7%)  | 0         |         |
| System organ class           |            |          |         |            |           |         |           |           |         |
| Preferred term               |            |          |         |            |           |         |           |           |         |
| Hepatobiliarydisorders       | 4 (1.5%)   | 2 (0.7%) | 0       | 5 (1.9%)   | 0         | 0       | 2 (0.7%)  | 0         |         |
| Hepatotoxicity               | 2 (0.7%)   | 1 (0.4%) | 0       | 4 (1.5%)   | 0         | 0       | 0         | 0         | 0       |
| Hepatic failure              | 1 (0.4%)   | 1 (0.4%) | 0       | 0          | 0         | 0       | 0         | 0         | 0       |
| Hepatitis                    | 1 (0.4%)   | 0        | 0       | 0          | 0         | 0       | 0         | 0         | 0       |
| Hepatic steatosis            | 0          | 0        | 0       | 1 (0.4%)   | 0         | 0       | 0         | 0         | 0       |
| Liver disorder               | 0          | 0        | 0       | 0          | 0         | 0       | 2 (0.7%)  | 0         | 0       |

Note:Percentages calculatedwiththenumberof subjects insafetypopulation asdenominator.Worsttoxicitygradewas usedforsubjectswhohadmultipleeventspersystem organclass orperpreferred term.Asubjectwhohadeventwithmissingtoxicitygradewascountedintheallgradescolumnbutnotlistedseparately.

Adverse events are presented by descending total frequency of SOC and PT within SOC in the Amm A+I group; those with the same total frequency are presented alphabetically. AdverseeventsarecodedusingMedDRAVersion26.1.

## Laboratory findings

## Hematologic Abnormalities

Table 45 Haematology: Incidence of Treatment-Emergent Worst Toxicity Grade During Treatment - MCL3003; Safety Population

|                      | A+I         | A+I         | A+I         |             |             |             | A           | A           | A           |
|----------------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|
|                      | Any Grade   | Grade 1/2   | Grade3/4    | Any Grade   | Grade 1/2   | Grade 3/4   | Any Grade   | Grade 1/2   | Grade3/4    |
| Analysisset:Safety   | 275         |             |             | 265         |             |             | 268         |             |             |
| Hemoglobin(Decrease) | 254 (92.4%) | 127 (46.2%) | 127 (46.2%) | 210(79.2%)  | 156 (58.9%) | 54 (20.4%)  | 238 (88.8%) | 142 (53.0%) | 96 (35.8%)  |
| Platelets(Decrease)  | 271 (98.5%) | 11 (4.0%)   | 260 (94.5%) | 253 (95.5%) | 65 (24.5%)  | 188 (70.9%) | 262 (97.8%) | 11 (4.1%)   | 251 (93.7%) |
| ANC(Decrease)        | 266 (96.7%) | 15 (5.5%)   | 251 (91.3%) | 239 (90.2%) | 46 (17.4%)  | 193 (72.8%) | 245 (91.4%) | 14 (5.2%)   | 231 (86.2%) |

Key:ANC =Absolute neutrophils counts.

Note:Onlysubjectswhosegradeworsenedfrombaseline were counted innumerator.Percentagesarecalculatedwith thenumber of subjectsinsafetypopulation as the denominators. Note:Baselineresultsincludevaluescollectedoutsideofthe28-dayscreeningwindow.

## Clinical Chemistry

## Table 46 Chemistry: Incidence of Treatment-Emergent Worst Toxicity Grade During Treatment - MCL3003; Safety Population

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Discontinuation due to adverse events

Table 47 Incidence of Treatment-emergent Adverse Events Leading to Discontinuation of Ibrutinib by System Organ Class, Preferred Term and Toxicity Grade; Safety Analysis Set (Study 54179060MCL3003)

<div style=\"page-break-after: always\"></div>

|                                                                                  | All Grades                  | A+I Grade 3/4        | Grade 5    | All Grades        | Grade 3/4                  | Grade 5    | All Grades   | A Grade 3/4   | Grade 5   |
|----------------------------------------------------------------------------------|-----------------------------|----------------------|------------|-------------------|----------------------------|------------|--------------|---------------|-----------|
| Analysis set: Safety                                                             | 275                         |                      |            | 265               |                            |            | 268          |               |           |
| Subjects with any TEAE leading to treatmentdiscontinuation                       | 105 (38.2%)                 | 64 (23.3%)           | 12 (4.4%)  | 61 (23.0%)        | 34 (12.8%)                 | 5 (1.9%)   | 0            | 0             | 0         |
| System organ class                                                               |                             |                      |            |                   |                            |            |              |               |           |
| Preferred tem Infections and infestations                                        | 36 (13.1%)                  | 12 (4.4%)            | 9 (3.3%)   | 19 (7.2%)         | 11 (4.2%)                  | 4 (1.5%)   | 0            | 0             | 0         |
| COVID-19                                                                         | 8 (2.9%)                    | 2 (0.7%)             | 4 (1.5%)   | 4 (1.5%) 2 (0.8%) | 2 (0.8%) 1 (0.4%)          | 2 (0.8%)   | 0            | 0             | 0         |
| Pneumonia Hepatitis E                                                            | 7 (2.5%) 2 (0.7%)           | 3 (1.1%) 1 (0.4%)    | 2 (0.7%) 0 | 0                 | 0                          | 0 0        | 0 0          | 0 0           | 0 0       |
| Herpes zoster                                                                    | 2 (0.7%)                    | 0                    | 0          | 0                 | 0                          | 0          | 0            | 0             | 0         |
| Pneumonia fungal Sepsis                                                          | 2 (0.7%)                    | 0                    | 0 1 (0.4%) | 1 (0.4%) 0        | 0 0                        | 0 0        | 0 0          | 0 0           | 0 0       |
| Septic shock                                                                     | 2 (0.7%) 2 (0.7%)           | 1 (0.4%) 1 (0.4%)    | 1 (0.4%)   | 0                 | 0                          | 0          | 0            | 0             | 0         |
| Bronchitis                                                                       | 1 (0.4%)                    | 0                    | 0          | 0                 | 0                          | 0          | 0            | 0             | 0         |
|                                                                                  |                             | 0                    | 0          | 6 (2.3%)          | 3 (1.1%)                   | 2 (0.8%)   | 0            | 0             | 0         |
| COVID-19 pneumonia                                                               | 1 (0.4%) 1 (0.4%)           |                      | 0          | 0                 | 0                          | 0          | 0            | 0             | 0         |
| Campylobacter gastroenteritis Campylobacterinfection                             | 1 (0.4%)                    | 1 (0.4%) 1 (0.4%)    | 0          | 0                 | 0                          | 0          | 0            | 0             | 0         |
| Coronavirus infection                                                            | 1 (0.4%)                    | 0                    | 0          | 0                 | 0                          | 0          | 0            | 0             | 0         |
| Impetigo                                                                         | 1 (0.4%)                    | 0                    | 0          | 0                 | 0                          | 0 0        | 0            | 0             | 0         |
| Influenza                                                                        | 1 (0.4%)                    | 1 (0.4%)             | 1 (0.4%)   | 0                 | 0                          | 0          | 0            | 0             | 0         |
| Meningitis bacterial                                                             | 1 (0.4%)                    | 0                    | 0          | 0                 | 0                          |            | 0            | 0             | 0         |
| Paronychia                                                                       | 1 (0.4%)                    | 1 (0.4%)             | 0          | 0                 | 0                          | 0          | 0            | 0             | 0         |
| Pneumonia viral                                                                  | 1 (0.4%) 1 (0.4%)           | 0                    | 1 (0.4%)   | 0                 | 0                          | 0          | 0            | 0             | 0         |
| Sinusitis                                                                        |                             | 0                    | 0          | 0                 | 0                          | 0          | 0            | 0             | 0         |
| Tooth infection                                                                  | 1 (0.4%)                    | 0                    | 0          | 0                 | 0                          | 0          | 0            | 0             | 0         |
| Cerebral fungal infection Enterovirus infection                                  | 0 0                         | 0 0                  | 0          | 1 (0.4%)          | 1 (0.4%)                   | 0          | 0            | 0 0           | 0 0       |
|                                                                                  | 0                           | 0                    | 0 0        | 1 (0.4%)          | 1 (0.4%) 1 (0.4%)          | 0 0        | 0 0          | 0             | 0         |
| Erysipelas Fungal infection                                                      | 0                           | 0                    | 0          | 1 (0.4%) 1 (0.4%) | 0                          | 0          | 0            | 0             | 0         |
| Infection                                                                        | 0                           | 0                    | 0          | 1 (0.4%)          | 1 (0.4%)                   | 0 0        | 0            | 0             | 0         |
| Intervertebral discitis                                                          | 0                           | 0                    | 0          | 1 (0.4%)          | 1 (0.4%)                   |            | 0            | 0             | 0 0       |
| Soft tissue infection Urosepsis                                                  | 0 0                         | 0 0                  | 0          | 1 (0.4%)          | 0 1 (0.4%)                 | 0 0        | 0 0          | 0 0           | 0         |
| Blood and lymphatic system disorders                                             | 20 (7.3%)                   | 18 (6.5%)            | 0 0        | 1 (0.4%) 4 (1.5%) | 3 (1.1%)                   | 0          | 0            | 0             | 0         |
| Neutropenia                                                                      | 14 (5.1%)                   | 13 (4.7%)            | 0          | 2 (0.8%)          | 2 (0.8%)                   | 0          | 0            | 0             | 0         |
| Thrombocytopenia                                                                 | 3 (1.1%)                    | 2 (0.7%)             | 0          | 1 (0.4%)          | 0                          | 0          | 0            | 0             | 0         |
| Anaemia Febrile neutropenia                                                      | 2 (0.7%)                    | 1 (0.4%)             | 0          | 1 (0.4%)          | 1 (0.4%)                   | 0          | 0            | 0             | 0         |
|                                                                                  |                             |                      |            |                   |                            |            |              |               | 0         |
|                                                                                  | 2 (0.7%)                    | 2 (0.7%)             | 0          |                   |                            | 0          |              | 0             |           |
|                                                                                  |                             |                      |            | 0                 | 0                          |            | 0            |               |           |
|                                                                                  | All Grades                  | A+I Grade 3/4        | Grade 5    | All Grades        | Grade3/4                   | Grade 5    | All Grades   | A Grade 3/4   | Grade 5   |
| Neutrophil count decreased Platelet coumt decreased C-reactive protein increased | 11 (4.0%) 5 (1.8%) 1 (0.4%) | 10 (3.6%) 4 (1.5%) 0 | 0 0 0      | 1 (0.4%) 0 0      | 1 (0.4%) 0 0               | 0 0 0      | 0 0          | 0 0           | 0 0       |
|                                                                                  | 1 (0.4%)                    |                      | 0          |                   |                            |            | 0            | 0 0           | 0 0       |
| Gamma-glutamyltransferase increased                                              |                             | 1 (0.4%)             |            | 1 (0.4%) 0        | 1 (0.4%)                   | 0          | 0            |               | 0         |
| Weight decreased White blood cell count decreased                                | 1 (0.4%) 1 (0.4%)           | 0                    | 0 0        | 0                 | 0 0                        | 0 0        | 0 0          | 0             |           |
| Cardiac disorders Atrial fibrillation                                            | 12 (4.4%) 6 (2.2%)          | 1 (0.4%) 10 (3.6%)   | 0          | 9 (3.4%) 5 (1.9%) | 4 (1.5%)                   | 1 (0.4%) 0 | 0 0          | 0 0 0         | 0 0 0 0   |
| Atrial flutter                                                                   |                             | 5 (1.8%)             | 0 0        | 1 (0.4%)          | 4 (1.5%) 0                 | 0 0        | 0 0          | 0             | 0         |
| Cardiac disorder                                                                 | 1 (0.4%) 1 (0.4%)           | 1 (0.4%) 1 (0.4%)    | 0          | 0                 | 0                          |            |              |               | 0 0       |
| Cardiac failure                                                                  | 1 (0.4%)                    | 1 (0.4%)             | 0 0        | 0 0               | 0 0                        | 0 0        | 0 0          | 0 0 0         | 0         |
| Myocardial infarction Sinoatrial block                                           | 1 (0.4%)                    | 1 (0.4%)             | 0          |                   | 0                          |            | 0            | 0             |           |
| Ventricularfibrillation                                                          | 1 (0.4%) 1 (0.4%)           | 0 1 (0.4%)           | 0          | 0 0               | 0                          | 0 0        |              |               | 0 0 0     |
|                                                                                  | 0                           | 0                    | 0          |                   | 0                          | 0          | 0 0 0        | 0 0           |           |
| Acute myocardial infarction Cardiac failure chronic                              | 0                           | 0                    |            | 1 (0.4%)          | 0                          | 1 (0.4%)   |              | 0 0           | 0         |
| Tachycardia                                                                      | 0 0                         | 0 0                  | 0          | 1 (0.4%)          | 0                          | 0 0        | 0            | 0             |           |
| Tachycardia induced cardiomyopathy                                               |                             |                      | 0 0        | 1 (0.4%) 1 (0.4%) |                            | 0 0        | 0 0          | 0             |           |
| Gastrointestinal disorders                                                       | 8 (2.9%) 5 (1.8%)           | 4 (1.5%) 3 (1.1%)    | 1 (0.4%) 0 | 4 (1.5%) 2 (0.8%) | 1 (0.4%) 3 (1.1%) 1 (0.4%) |            | 0            | 0 0           | 0 0 0     |
| Diarhoea Abdominal pain upper Chronic gastritis                                  | 1 (0.4%) 1 (0.4%)           | 0                    | 0          | 0 0               | 0 0                        | 0 0        |              | 0             |           |
|                                                                                  |                             | 0                    | 0          |                   |                            |            | 0 0 0        |               |           |
| Gastric haemorhage                                                               | 1 (0.4%)                    | 0                    |            | 0                 | 0                          |            | 0            | 0 0           | 0         |
| Nausea                                                                           | 1 (0.4%) 1 (0.4%)           | 0                    | 1 (0.4%) 0 | 0 0               | 0 0                        | 0 0        | 0 0          | 0             | 0 0       |
| Vomiting                                                                         | 1 (0.4%)                    | 1 (0.4%) 0           | 0 0        |                   |                            | 0          |              |               | 0         |
| Retroperitoneal haemorrhage Intestinal perforation                               | 0                           | 0                    | 0          |                   |                            |            | 0            |               | 0         |
|                                                                                  |                             |                      |            | 1 (0.4%) 1 (0.4%) | 1 (0.4%) 1 (0.4%)          | 0 0        |              | 0 0           | 0 0       |
| conditions                                                                       |                             |                      | 0          | 3 (1.1%)          | 1 (0.4%)                   | 0          | 0            | 0             | 0         |
| General disorders and administration site                                        | 6 (2.2%)                    | 0                    | 0          | 0                 | 0                          | 0          | 0            | 0             | 0         |
| Pyrexia                                                                          | 2 (0.7%) 1 (0.4%)           | 0 0                  | 0          | 0                 | 0                          | 0 0        | 0 0          | 0 0           | 0 0       |
| Asthenia Fatigue Localised oedema                                                | 1 (0.4%) 1 (0.4%)           | 0 0                  | 0          | 1 (0.4%) 0        | 0 0                        |            | 0            | 0             | 0         |
|                                                                                  | 1 (0.4%)                    | 0                    | 0          | 1 (0.4%)          | 1 (0.4%)                   | 0          |              |               |           |
| Mucosal inflammation Malaise                                                     | 0                           | 0                    | 0 0        | 1 (0.4%)          | 0                          | 0          | 0            | 0             | 0         |
| Nervous system disorders                                                         | 5 (1.8%)                    | 1 (0.4%)             | 0          | 6 (2.3%)          | 5 (1.9%)                   | 0 0 0      | 0 0          | 0 0           | 0         |
| Neuropathy peripheral                                                            | 2 (0.7%)                    | 0                    | 0          | 1 (0.4%)          | 1 (0.4%)                   |            |              |               | 0         |
|                                                                                  |                             |                      |            |                   |                            |            | 0            | 0             |           |
|                                                                                  |                             |                      |            |                   |                            |            |              |               | 0         |

<div style=\"page-break-after: always\"></div>

|                                                           | A+I        | A+I       | A+I               |            |            | A                    | A         | A   | A       |
|-----------------------------------------------------------|------------|-----------|-------------------|------------|------------|----------------------|-----------|-----|---------|
|                                                           | All Grades | Grade 3/4 | Grade 5           | All Grades | Grade 3/4  | Grade 5 All Grades 0 | Grade 3/4 |     | Grade 5 |
| Peripheral sensory neuropathy                             | 1 (0.4%)   | 1 (0.4%)  | 0                 | 0          | 0          | 0                    | 0 0       | 0   | 0       |
| Polyneuropathy                                            | 1 (0.4%)   | 0         | 0                 | 0          | 0          | 0 0                  |           | 0   | 0       |
| Tremor                                                    | 1 (0.4%)   | 0         | 0                 | 0          | 0          | 0 0                  | 0         | 0   | 0       |
| Encephalitis autoimmune                                   | 0          | 0         | 0                 | 1 (0.4%)   | 1 (0.4%)   | 0 0                  | 0         | 0   | 0       |
| Haemorhage intracranial                                   | 0          | 0         | 0                 | 1 (0.4%)   | 1 (0.4%)   | 0 0                  | 0         | 0   | 0       |
| Headache                                                  | 0          | 0         | 0                 | 1 (0.4%)   | 1 (0.4%)   | 0 0                  | 0         | 0   | 0       |
| Radiculopathy                                             | 0          | 0         | 0                 | 1 (0.4%)   | 1 (0.4%)   | 0 0                  | 0         | 0   | 0       |
| Transientischaemic attack                                 | 0          | 0         | 0                 | 1 (0.4%)   | 0          | 0 0                  | 0         | 0   | 0       |
| Respiratory, thoracic and mediastinal                     |            |           |                   |            |            |                      |           |     |         |
| disorders                                                 | 5 (1.8%)   | 1 (0.4%)  | 0                 | 6 (2.3%)   | 1 (0.4%)   | 0 0                  | 0         | 0   | 0       |
| Cough                                                     | 2 (0.7%)   | 0         | 0                 | 0          | 0          | 0 0                  | 0         | 0   | 0       |
| Chronic obstructive pulmonary disease                     | 1 (0.4%)   | 0         | 0                 | 0          | 0          | 0 0                  | 0         | 0   | 0       |
| Dyspnoea exertional                                       | 1 (0.4%)   | 0         | 0                 | 0          | 0          | 0                    | 0         | 0   | 0       |
| Pneumonitis                                               | 1 (0.4%)   | 1 (0.4%)  | 0                 | 2 (0.8%)   | 0          | 0 0                  | 0         | 0   | 0       |
| Interstitial lung disease                                 | 0          | 0         | 0                 | 2 (0.8%)   | 1 (0.4%)   | 0 0 0                | 0         | 0   | 0       |
| Noctumal dyspnoea                                         | 0          | 0         | 0                 | 1 (0.4%)   | 0          | 0 0                  | 0         | 0   | 0       |
| Organising pneumonia                                      | 0          | 0         | 0                 | 1 (0.4%)   | 0          | 0                    | 0         | 0   | 0       |
| Skin and subcutaneous tissue disorders                    | 5 (1.8%)   | 0         | 0                 | 3 (1.1%)   | 2 (0.8%)   | 0 0 0                | 0         | 0   | 0       |
| Rash                                                      | 2 (0.7%)   | 0         | 0                 | 1 (0.4%)   | 1 (0.4%)   | 0 0                  | 0         | 0   | 0       |
| Acute febrile neutrophilic dermatosis                     | 1 (0.4%)   | 0         | 0                 | 0          | 0          | 0 0                  | 0         | 0   | 0       |
| Neurodermatitis                                           | 1 (0.4%)   | 0         | 0                 | 0          | 0          | 0 0                  | 0         | 0   | 0       |
| Skin lesion                                               | 1 (0.4%)   | 0         | 0                 | 0          | 0          | 0 0                  | 0         | 0   | 0       |
| Drug eruption                                             | 0          | 0         | 0                 | 1 (0.4%)   | 0          | 0 0                  | 0         | 0   | 0       |
| Toxic skin eruption                                       | 0          | 0         | 0                 | 1 (0.4%)   | 1 (0.4%)   | 0 0                  | 0         | 0   | 0       |
| Musculoskeletal and connectivetissue                      |            |           |                   |            |            |                      |           |     |         |
| disorders                                                 | 4 (1.5%)   | 3 (1.1%)  | 0                 | 5 (1.9%)   | 1 (0.4%)   | 0 0                  | 0         | 0   | 0       |
| Muscle spasms                                             | 2 (0.7%)   | 1 (0.4%)  | 0                 | 1 (0.4%)   | 0          | 0 0                  | 0         | 0   | 0       |
| Arthritis                                                 | 1 (0.4%)   | 1 (0.4%)  | 0                 | 0          | 0          | 0 0                  | 0         | 0   | 0       |
| Myalgia                                                   | 1 (0.4%)   | 1 (0.4%)  | 0                 | 1 (0.4%)   | 0          | 0 0                  | 0         | 0   | 0       |
| Arthralgia                                                | 0          | 0         | 0                 | 1 (0.4%)   | 0          | 0 0                  | 0         | 0   | 0       |
| Muscular weakmess                                         | 0          | 0         | 0                 | 1 (0.4%)   | 0          | 0 0                  | 0         | 0   | 0       |
| Myositis                                                  | 0          | 0         | 0                 | 1 (0.4%)   | 1 (0.4%)   | 0 0                  | 0         | 0   | 0       |
| Neoplasms benign, malignant and                           |            |           |                   |            |            |                      |           |     |         |
| unspecified (incl cysts and polyps)                       | 4 (1.5%)   | 3 (1.1%)  | 1 (0.4%)          | 0          | 0          | 0 0                  | 0         | 0   | 0       |
| Lung adenocarcinoma                                       | 1 (0.4%)   | 1 (0.4%)  | 0                 | 0          | 0          | 0 0                  | 0         | 0   | 0       |
| Lung neoplasm malignant                                   | 1 (0.4%)   | 1 (0.4%)  | 0                 | 0          | 0          | 0 0                  | 0         | 0   | 0       |
| Malignant neoplasm of thymus                              | 1 (0.4%)   | 0         | 1 (0.4%)          | 0          | 0          | 0 0                  | 0         | 0   | 0       |
| Metastases to meninges                                    | 1 (0.4%)   | 1 (0.4%)  | 0                 | 0          | 0          | 0 0                  | 0         | 0   | 0       |
| Ear and labyrinth disorders                               | 2 (0.7%)   | 0         | 0                 | 0          | 0          | 0 0                  | 0         | 0   | 0       |
| Tinnitus                                                  | 1 (0.4%)   | 0         | 0                 | 0          | 0          | 0 0                  | 0         | 0   | 0       |
|                                                           |            |           |                   |            | =          |                      | A         |     |         |
|                                                           |            | A+I       |                   |            | Grade 3/4  |                      | Grade 5   |     |         |
|                                                           | All Grades | Grade 3/4 | Grade 5           | All Grades |            | Grade 5 All Grades   | Grade 3/4 |     |         |
| Vestibular disorder                                       | 1 (0.4%)   | 0         | 0                 | 0          | 0          | 0 0                  | 0         | 0   | 0       |
| Hepatobiliary disorders                                   | 1 (0.4%)   | 1 (0.4%)  | 0                 | 0          | 0          | 0 0                  | 0         | 0   | 0       |
| Hepatic failure                                           | 1 (0.4%)   | 1 (0.4%)  | 0                 | 0          | 0          | 0 0 0                | 0         | 0   | 0       |
| Metabolism and nutrition disorders                        | 1 (0.4%)   | 0         | 0                 | 1 (0.4%)   | 1 (0.4%)   | 0 0                  | 0         | 0   | 0       |
| Dehydration                                               | 1 (0.4%)   | 0         | 0                 | 0          | 0          | 0                    | 0         | 0   | 0       |
| Decreased appetite                                        | 0          | 0         | 0                 | 1 (0.4%)   | 1 (0.4%)   | 0 0                  | 0         | 0   | 0       |
| Psychiatric disorders                                     | 1 (0.4%)   | 0 0       | 1 (0.4%) 1 (0.4%) | 0          | 0          | 0 0                  | 0         | 0 0 | 0 0     |
| Completed suicide                                         | 1 (0.4%)   | 0         |                   | 0          | 0          | 0 0 0                | 0         |     |         |
| Renal and urinary disorders                               | 1 (0.4%)   |           | 0                 | 3 (1.1%)   | 3 (1.1%)   |                      | 0         | 0   | 0       |
| Renal failure                                             | 1 (0.4%)   | 0         | 0                 | 1 (0.4%)   | 1 (0.4%)   | 0 0                  | 0         | 0   | 0       |
| Acute kidney injury                                       | 0          | 0         | 0 0               | 2 (0.8%) 0 | 2 (0.8%) 0 | 0 0 0                | 0         | 0 0 | 0 0     |
| Vascular disorders                                        | 1 (0.4%)   | 0         |                   | 0          | 0          | 0 0                  | 0         | 0   | 0       |
| Haematoma                                                 | 1 (0.4%)   | 0         | 0                 | 1 (0.4%)   | 0          | 0 0                  | 0 0       | 0   | 0       |
| Reproductivesystemandbreastdisorders Erectile dysfunction | 0 0        | 0 0       | 0 0               | 1 (0.4%)   | 0          | 0 0 0                | 0         | 0   | 0       |

Key: ASCT=autologous stem cell transplant, A=ASCT, A+I=ASCT+Ibrutinib, I=Ibrutinib, TEAE=treatment-emergent adverse event.

Note: Adverse events are presented by decreasing frequency of system organ class and preferred term within A+I column; those with the same frequency are presented alphabetically. Note: Percentages are calculated with the number of subjects in safety analysis set as denominator.

Note:Subjects are counted only once for any given event,regardless of the number of times they actually experienced the event.The event experienced by the subject with the worst toxicity isused.Ifa subject hasmissing toxicity for a specific adverse event,the subjectis only counted in the All Grades column for that adverse event.

Adverseevents arecoded usingMedDRAVersion 26.1.

## Table 48 Incidence of Treatment-emergent Adverse Events Leading to Dose Reduction by Toxicity Grade, System Organ Class and

<div style=\"page-break-after: always\"></div>

|                                                      | A+I            | A+I       | A+I     |                |           |         | A              | A         | A       |
|------------------------------------------------------|----------------|-----------|---------|----------------|-----------|---------|----------------|-----------|---------|
| Analysis set: Safety                                 | All Grades 275 | Grade 3/4 | Grade 5 | All Grades 265 | Grade 3/4 | Grade 5 | All Grades 268 | Grade 3/4 | Grade 5 |
| Subjects with any TEAE leading to dosereduction      | 4 (1.5%)       | 4 (1.5%)  | 0       | 10 (3.8%)      | 9 (3.4%)  | 0       | 0              | 0         | 0       |
| System organ class                                   |                |           |         |                |           |         |                |           |         |
| Preferred term                                       |                |           |         |                |           |         |                |           |         |
| Blood andlymphaticsystemdisorders                    | 4 (1.5%)       | 4 (1.5%)  | 0       | 5 (1.9%)       | 5 (1.9%)  | 0       | 0              | 0         | 0       |
| Neutropenia                                          | 2 (0.7%)       | 2 (0.7%)  | 0       | 4 (1.5%)       | 4 (1.5%)  | 0       | 0              | 0         | 0       |
| Leukocytosis                                         | 1 (0.4%)       | 1 (0.4%)  | 0       | 0              | 0         | 0       | 0              | 0         | 0       |
| Thrombocytopenia                                     | 1 (0.4%)       | 1 (0.4%)  | 0       | 2 (0.8%)       | 2 (0.8%)  | 0       | 0              | 0         | 0       |
| Cardiac disorders                                    | 0              | 0         | 0       | 2 (0.8%)       | 2 (0.8%)  | 0       | 0              | 0         | 0       |
| Atrial fibrillation                                  | 0              | 0         | 0       | 2 (0.8%)       | 2 (0.8%)  | 0       | 0              | 0         | 0       |
| Gastrointestinal disorders                           | 0              | 0         | 0       | 2 (0.8%)       | 2 (0.8%)  | 0       | 0              | 0         | 0       |
| Diarrhoea                                            | 0              | 0         | 0       | 1 (0.4%)       | 1 (0.4%)  | 0       | 0              | 0         | 0       |
| Gastritis                                            | 0              | 0         | 0       | 1 (0.4%)       | 1 (0.4%)  | 0       | 0              | 0         | 0       |
| Nausea                                               | 0              | 0         | 0       | 1 (0.4%)       | 1 (0.4%)  | 0       | 0              | 0         | 0       |
| Vomiting                                             | 0              | 0         | 0       | 1 (0.4%)       | 1 (0.4%)  | 0       | 0              | 0         | 0       |
| General disorders and administration site conditions | 0              | 0         | 0       | 1 (0.4%)       | 1 (0.4%)  | 0       | 0              | 0         | 0       |
| Mucosalinflammation                                  | 0              | 0         | 0       | 1 (0.4%)       | 1 (0.4%)  | 0       | 0              | 0         | 0       |
| Investigations                                       | 0              | 0         | 0       | 1 (0.4%)       | 1 (0.4%)  | 0       | 0              | 0         | 0       |
| Platelet count decreased                             | 0              | 0         | 0       | 1 (0.4%)       | 1 (0.4%)  | 0       | 0              | 0         | 0       |
| Skin and subcutaneous tissue disorders               | 0              | 0         | 0       | 1 (0.4%)       | 1 (0.4%)  | 0       | 0              | 0         | 0       |
| Rash                                                 | 0              | 0         | 0       | 1 (0.4%)       | 1 (0.4%)  | 0       | 0              | 0         | 0       |
| Vascular disorders                                   | 0              | 0         | 0       | 1 (0.4%)       | 0         | 0       | 0              | 0         | 0       |
| Hypertension                                         | 0              | 0         | 0       | 1 (0.4%)       | 0         | 0       | 0              | 0         | 0       |

Key:TEAE=Treatment-emergent adverseevent.

Adverse events are coded using MedDRA Version 26.1.

Note: Percentages calculated with the number of subjects in safety population as denominator. Worst toxicity grade was used for subjects who had multiple events per system organ class or per preferred term. A subject who had event with missing toxicity grade was counted in the all grades column but not listed separately. Adverse events are presented by descending total frequency of SOC and PT within SOC in the Am A+I group; those with the same total frequency are presented alphabetically.

## Table 49 Dose Reduction of Ibrutinib during Induction Therapy; Safety Analysis Set (Study 54179060MCL3003)

<!-- image -->

|                        | A+I         | I          |
|------------------------|-------------|------------|
| Analysisset:Safety     | 275         | 265        |
| Numberofdosereductions |             |            |
| D                      | 268 (97.5%) | 251(94.7%) |
|                        | 5 (1.8%)    | 10 (3.8%)  |
|                        | 0           | 3 (1.1%)   |
|                        | 0           | 1 (0.4%)   |

Key:ASCT=autologousstemcell transplant,A=ASCT,A+I=ASCT+Ibrutinib,I=Ibrutinib

Referstonumberofreductionsindoselevel.Themaximumdosereductionisconsideredforeachsubject.

Note:Percentagesare calculatedwith thenumberofsubjectsinthesafety analysissetineachtreaomentgroupasthedenominators.

## Table 50 Dose Reduction of Ibrutinib during Maintenance Period; Safety Analysis Set (Study 54179060MCL3003)

|                                                       | A+I         |             |
|-------------------------------------------------------|-------------|-------------|
| Analysis set:Safety                                   | 275         | 265         |
| Subjects that received at least one dose of Ibrutinib | 230         | 245         |
| Numberofdosereductions                                |             |             |
| 0                                                     | 152 (66.1%) | 191 (78.0%) |
|                                                       | 36 (15.7%)  | 28 (11.4%)  |
|                                                       | 35(15.2%)   | 20 (8.2%)   |
|                                                       | 7 (3.0%)    | 6 (2.4%)    |

Key:ASCT=autologous stem cell transplant,A=ASCT,A+I=ASCT+Ibrutinib,I=Ibrutinib.

Referstonumberofreductionsindoselevel.Themaximumdosereductionisconsideredforeachsubject.

Note:Percentages are calculated with the number of subjects in the safety analysis set that received at least one dose of Ibrutinib during Maintenance in each treatment group as the denominators.

## Post marketing experience

<div style=\"page-break-after: always\"></div>

## 2.5.1. Discussion on clinical safety

The key safety data in support of this application derive from the primary analysis of Study MCL3003 (TRIANGLE) with a data cutoff date of 09 May 2024.

The safety data base is considered of an acceptable magnitude for detecting any changes to the already known safety profile of ibrutinib and/or identifying new safety concerns including those related to this new treatment combination and patient population.

The median treatment duration was approx. 29 months (range 0 to 39.3) for Arm A+I, 28 months (range 0.2 to 35.5) for Arm I and 5 months (range 0.2 to 12.7) for Arm A.

As judged by the data on the extent of exposure during the induction phase, ibrutinib appears well tolerated in both the A+I and the I arm (dose intensity median 560 mg/day and relative dose intensity median 100 for both arms).

Not unexpectedly (especially with reference to the A+I arm which included high-dose chemotherapy and ASCT), this changed during the maintenance phase where a tendency to less tolerability for ibrutinib was noted.

It is also notable that due to the definition of TEAE's (AEs that started or worsened in severity after the first dose of study treatment up to 30 days following the last dose of study treatment or until the start of subsequent anti-cancer therapy) observation-time is substantially longer in the ibrutinib-containing arms. Thus, time-unadjusted incidence rates are biased in favour of the reference arm (arm A).

## Common TEAEs

The only PT occurring at a ≥10% higher frequency in Arm I as compared with Arm A was COVID-19 (Arm A+I: 14.9%; Arm I:14.0%; Arm A: 1.1%).

Most common TEAEs by PT occurring at a ≥10% higher frequency in Arm A or Arm A+I as compared with Arm I were: Anaemia (Arm A+I: 58.9%, Arm I: 44.9%; Arm A: 57.8%); Febrile neutropenia (Arm A+I: 35.6%; Arm I: 14.0%; Arm A: 26.5%); Pneumonia (Arm A+I: 20.4%; Arm I: 10.2%; Arm A: 5.2%; Pyrexia (Arm A+I: 34.9%; Arm I: 21.5%; Arm A: 33.2%); Mucosal inflammation (Arm A+I: 31.3%; Arm I: 8.3%; Arm A: 27.6%).

## Induction Phase

TEAEs that were reported with an incidence of ≥5% difference between participants receiving ibrutinib during the induction period (Arm A+I or Arm I) compared to participants who did not receive ibrutinib as part of the induction regimen (Arm A) were Leukocytosis (Arm A+I: 7.3%, Arm I: 1.9%, Arm A: 1.5%); Diarrhoea (Arm A+I: 13.8%, Arm I: 21.9%, Arm A: 12.7%); Fatigue : (Arm A+I: 15.3%, Arm I: 14.0%, Arm A: 8.2%) and Rash : (Arm A+I: 5.1%, Arm I: 7.2%, Arm A: 0.7%). Table 28

## TEAEs by Grade

The proportion of participants with Grade 3 or 4 TEAEs was similar for Arm A+I, Arm I, and Arm A (92.0%, 90.9% and 89.2%, respectively).

The only Grade 3 or 4 TEAE occurring at a≥10% higher frequency in Arm A+I as compared with Arm A was neutropenia (Arm A+I: 49.5%; Arm I: 39.2%; Arm A: 38.8%).

Grade 3 or 4 TEAEs occurring at a≥10% higher frequency in Arm A+I or Arm A as compared with Arm I were Anaemia (Arm A+I: 44.0%; Arm I: 21.5%; Arm A: 34.3%), Neutropenia (Arm A+I: 49.5%; Arm I: 39.2%; Arm A: 38.8%), Febrile neutropenia (Arm A+I: 35.6%; Arm I: 14.0%; Arm A: 26.5%), Mucosal inflammation (Arm A+I: 15.6%; Arm I: 1.9%; Arm A: 13.1%).

<div style=\"page-break-after: always\"></div>

## Induction Phase

The only Grade 3 or 4 TEAE reported with a ≥5% difference between participants in any of the treatment arms was anaemia (Arm A+I: 29.1%; Arm I: 20.4%; Arm A: 22.0%).

## Ibrutinib-related TEAEs

The most frequently reported TEAEs related to ibrutinib (≥5%) by SOC and PT are provided in Table 30. The proportion of any Grade TEAEs related to ibrutinib was 84.7% in Arm A+I and 80.0% in Arm I. The proportion of Grade 3 or 4 TEAEs related to ibrutinib was higher in participants in Arm A+I (66.9%) compared with Arm I (54.0%). There were two Grade 5 ibrutinib-related events reported in Arm A+I which included septic shock and malignant melanoma .

## Induction Phase

All-grade ibrutinib-related TEAEs were reported for similar proportions of participants in the ibrutinibcontaining arms during the Induction Phase: 54.5% in Arm A+I and 55.8% in Arm I. Grade 3/4 ibrutinib-related TEAEs were reported in 36.4% in Arm A+I and 33.6% in Arm I. There were no Grade 5 TEAE reported in either arm.

## Deaths

At the time of the CCO, there were in total 127 deaths (15.7%) with 22.4% occurring in Arm A compared with Arm I (12.5%), and Arm A+I (12.4%). A total of 53 deaths (6.6%) were caused by progressive disease (3.3% in Arm A+I, 5.3% in Arm I, and 11.2% in Arm A).

A total of 32 deaths were attributed to AEs. Fewer fatal AEs were observed for participants in Arm I (2.3%) compared with both ASCT-containing arms (5.5% and 4.1% events in Arm A+I and Arm A, respectively).

## Induction Phase

Treatment-emergent SAEs during the induction period were reported in 42.9% of the participants in Arm A+I and in 44.9% participants in Arm I compared with 41.0% participants in Arm A. The most frequently reported (≥5% in any treatment arm) treatment -emergent SAEs by PT were febrile neutropenia (Arm A+I: 9.8%, Arm I: 9.8%, Arm A: 6.7%) and acute kidney injury (Arm A+I: 5.5%, Arm I: 6.8%, Arm A: 4.9%).

## Adverse Events Leading to Ibrutinib Treatment Discontinuation

The incidence of TEAEs leading to ibrutinib discontinuation was higher in participants in Arm A+I (38.2%) compared with participants in Arm I (23.0%).

In regard to the induction phase, the proportion of ibrutinib discontinuation due to AEs is considered low and comparable between the ibrutinib-containing arms: Arm A+I (6.5%) and Arm I (4.9%). However, as may be expected, the majority of TEAEs leading to ibrutinib discontinuation occurred during the maintenance period, with a higher incidence in Arm A+I compared with Arm I with a majority of TEAEs leading to ibrutinib discontinuation in the SOCs of Infections and infestations and Blood and lymphatic system disorders.

The most frequent (≥5% in either ibrutinib -containing arm) TEAEs leading to ibrutinib discontinuation were within the SOCs of Infections and infestations (13.1% and 7.2% in Arm A+I and Arm I, respectively), Blood and lymphatic system disorders (7.3% and 1.5% in Arm A+I and Arm I, respectively), and Investigations (6.5% and 0.8% in Arm A+I and Arm I, respectively).

## Adverse Events Leading to Ibrutinib Dose Reduction

<div style=\"page-break-after: always\"></div>

TEAEs leading to ibrutinib dose reduction were reported for comparable proportions of participants in Arm A+I (19.6%) and in Arm I (16.2%). At the SOC level, TEAEs leading to ibrutinib dose reduction were most commonly (≥5% in either arm) classified as Blo od and lymphatic system disorders (10.5% of Arm A+I and 4.9% of Arm I participants).

Whilst the proportions of TEAEs leading to ibrutinib dose reduction during the Induction Phase were reported at a low level (98% and 95% with no dose reductions in the A+I and I arm, respectively (Table 49), this changed during the maintenance phase thus  indicating a lesser tolerability for ibrutinib (66% and 78% with no dose reductions in the A+I and I arms, respectively).

## Other Safety Observations

For Major haemorrhage, Cardiac failure and Cytopenic Adverse Events, there were similar rates reported between the three arms. In terms of Other Cardiac Arrhythmias, Hypertension, ILD and Atrial fibrillation, the rates of reports were higher in the I arm compared to the other two arms. Ventricular Tachyarrhythmias were only reported for the A+I arm. Reports of Ischemic stroke were similar in the I and A arm (about 1%). Rates of reports for Second Primary Malignancies and Hepatic Toxicity Including Hepatic Failure were similar in the A+I and I arm.

During the induction phase, the ibrutinib + R-CHOP combination appears well-tolerated as judged by a high extent of exposure, low proportions of ibrutinib discontinuations due to AEs and low proportions of dose reductions. That changes during the maintenance phase however, where the extent of ibrutinib exposure decreases which is most obvious in the A+I arm with high-dose chemotherapy and ASCT preceding the ibrutinib maintenance treatment.

When comparing the overall toxicity profile of Arm I to that of arm A, the former appears overall more tolerable in comparison with the exception of a slightly higher rate of reports for SAEs (including grade ≥3). Notably, the proportion of deaths due to A Es (including deaths within 30 days of last dose of study treatment) is lower in arm I compared to arm A (in total 2.3% and 4.1%, respectively). There is no indication of a detrimental effect on overall survival when substituting ibrutinib for ASCT.

At PT level, certain differences in the safety profiles were observed between Arm A and Arm I. Whilst the rate of reports of neutropenia were similar between the arms, reports of febrile neutropenia was almost twice as high in Arm A compared to Arm I.

In comparison with arm A and arm I, the A+I arm, appears overall less tolerable with higher rates of reports for TEAEs Grade ≥3, SAEs, SAEs grade ≥3, deaths due to AEs (including deaths within 30 days of last dose of study treatment), ibrutinib discontinuations and reductions.

## 2.5.2. Conclusions on clinical safety

Based on the data from the TRIANGLE study no new safety concerns have been identified. The safety profile is mainly in line with what has previously been established for ibrutinib. The safety profile of ibrutinib is considered acceptable for the proposed use.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

<div style=\"page-break-after: always\"></div>

## 2.6. Risk management plan

The MAH submitted/was requested to submit an updated RMP version with this application.

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 23.1. is acceptable.

The CHMP endorsed this advice without changes.

## Safety concerns

No update of the safety concerns is required by this procedure.

Table 51 Summary of Safety Concerns

| Important identified risks   | Hemorrhage                                                                                                                                                   |
|------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important potential risks    | Infections (including viral reactivation) Progressive multifocal leukoencephalopathy (PML) Cardiac arrhythmia (excluding atrial fibrillation and ventricular |
|                              | tachyarrhythmias) Other malignancies (excluding non-melanoma skin cancer)                                                                                    |

<div style=\"page-break-after: always\"></div>

## Pharmacovigilance plan

No update of the pharmacovigilance plan is required

## Table 52: Ongoing and Planned Additional Pharmacovigilance Activities

Study &amp; Status

Summary of Objectives

Safety Concerns Addressed

Milestones

Due Dates

Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization

Not applicable

Category 2 - Imposed mandatory additional pharmacovigilance activities which are specific obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances

Not applicable

Category 3 - Required additional pharmacovigilance activities

Not applicable

## Risk minimisation measures

No additional risk minimisation measures are required.

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.8, 5.1 and 5.2. of the SmPC have been updated. The Package Leaflet has been updated accordingly.

In addition, the list of local representatives in the PL has been revised to amend contact details for the representative(s) of Cyprus and Greece.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable for the following reasons:

Full user testing in compliance with the above-mentioned legislative requirements was performed (n= 20 participants) on the package leaflet in the initial Marketing Authorisation Application and subsequently on the combined package leaflet for IMBRUVICA 140 mg, 280 mg, 420 mg, 560 mg filmcoated tablets, in a tablet line extension application.

Based on the above, with the currently proposed Type II variation to extend the existing IMBRUVICA indication in MCL, minimal changes have been introduced to the package leaflet and the proposed changes reflect language and a format that is consistent with that in the currently approved leaflet. The use of lay language for the additional indication and side effects aligns with the currently approved leaflet.

However, as MAH has proposed major changes to section 4, a focus test for section 4 is requested.

<div style=\"page-break-after: always\"></div>

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The final approved indication is:

IMBRUVICA in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (IMBRUVICA + R-CHOP) alternating with R-DHAP (or R-DHAOx) without IMBRUVICA, followed by IMBRUVICA monotherapy, is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who would be eligible for autologous stem cell transplantation (ASCT)'

## 3.1.2. Available therapies and unmet medical need

Newly diagnosed patients with MCL have so far typically been categorized into 2 subpopulations defined by their suitability and eligibility for intensive treatment including autologous stem cell transplant (ASCT).

For the younger (&lt; 65 years) and transplant-eligible patients, an intensive treatment approach including induction therapy followed by ASCT with rituximab maintenance therapy has represented the present standard of care treatment (ESMO GL 2017). Alternating R-CHOP with cytarabine-containing regimens are among the most commonly used combinations for induction therapy.

Despite an intensive approach with ASCT, no curative treatment is available for MCL. Hence, there is an unmet medical need for more effective treatments.

## 3.1.3. Main clinical studies

Study MCL3003 (TRIANGLE) which is a randomized, 3-arm, open-label, multicenter Phase 3 study, compared three alternating courses of R-CHOP/R-DHAP followed by ASCT (control Arm A), versus the combination with ibrutinib in induction and maintenance (experimental Arm A+I), and the experimental arm without ASCT (experimental Arm I) in patients ≤ 65 years with previously untreated MCL who were eligible for ASCT. Due to the implementation of rituximab maintenance in national treatment guidelines during the study, this approach was introduced to all 3 treatment arms throughout the study.

The primary endpoint failure-free survival (FFS) was defined as the time from randomization to stable disease at the end of induction immunochemotherapy, progressive disease, or death from any cause, whichever comes first.

## 3.2. Favourable effects

An improvement in FFS was seen for Arm I compared with Arm A, HR of 0.639 (0.428, 0.953), pvalue: 0.0068 (post-hoc analysis performed for registrational purposes).

<div style=\"page-break-after: always\"></div>

Improvement in OS was observed for participants in in Arm I vs Arm A (Cox regression HR [95% CI] of 0.522 [0.341, 0.799]; 2-sided nominal p value=0.0023)..

## 3.3. Uncertainties and limitations about favourable effects

The impact of rituximab maintenance given with ibrutinib monotherapy during the maintenance phase was not investigated and therefore remains unclear.

## 3.4. Unfavourable effects

Based on the data from the TRIANGLE study no new safety concerns have been identified. The safety profile is mainly in line with what has previously been established for ibrutinib.

The overall incidence of TEAEs (any grade) was similar in Arm I (99.2%), and Arm A (99.6%). The proportion of participants with Grade 3 or 4 TEAEs was also similar for Arm I, and Arm A (90.9% and 89.2%, respectively).

The most frequently reported (≥10%) Grade 3 or 4 TEAEs in either treatment arm by PT were e.g. Neutropenia (39.2% in Arm I, and 38.8% in Arm A);  Anaemia (21.5% in Arm I, and 34.3% in Arm A), Thrombocytopenia (34.7% in Arm I, and 42.5% in Arm A); Febrile neutropenia (14% in Arm I, and 26.5% in Arm A); Leukopenia (9.4% in Arm I, and 11.2% in Arm A), Pneumonia (5.3% in Arm I, and 3.7% in Arm A); Mucosal inflammation (1.9% in Arm I, and 13.1% in Arm A).

## Deaths

At the time of the CCO, there were in total 127 deaths (15.7%) with 22.4% occurring in Arm A compared with Arm I (12.5%). A total of 32 deaths were attributed to AEs.

Fewer fatal AEs were observed for participants in Arm I (2.3%) compared with ASCT (4.1% events).

## 3.5. Uncertainties and limitations about unfavourable effects

No uncertainties are identified.

## 3.6. Effects Table

Table 1. Effects Table for Study MCL3003 (TRIANGLE), data cut-off: 09 May 2024

| Effect                 | Short description                                                                                                                  | Unit                   | Treatme nt Treatment Control   | Treatme nt Treatment Control   | Treatme nt Treatment Control   | Uncertainties / Strength of evidence                                                                                                                                                                                                              | Referen ces        |
|------------------------|------------------------------------------------------------------------------------------------------------------------------------|------------------------|--------------------------------|--------------------------------|--------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|
|                        | Favourable Effects                                                                                                                 | Favourable Effects     | Favourable Effects             | Favourable Effects             | Favourable Effects             | Favourable Effects                                                                                                                                                                                                                                | Favourable Effects |
| Treatment arms         | Full analysis set (FAS) n=809                                                                                                      |                        |                                | ibrutinib                      | ASCT                           |                                                                                                                                                                                                                                                   |                    |
| FFS (primary endpoint) | Time from randomization to stable disease at end of induction, progressive disease, or death from any cause, whichever comes first | Median, months (95%CI) |                                | NE (NE, NE)                    | NE (NE, NE)                    | HR unstratified Cox regression (2-sided 98.33% CI), two- sided p-value from unstratified log-rank test: Arm I vs A, HR of 0.639 (0.428, 0.953), p-value: 0.0068. Median time on study 54.9 months with 61 FFS events (22.8%) in Arm I, and 87 FFS | MCL300 3           |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Effect                                   | Short description                    | Unit                 | Treatme nt           | Treatment Control    | Uncertainties /                                                                               | Referen              |
|------------------------------------------|--------------------------------------|----------------------|----------------------|----------------------|-----------------------------------------------------------------------------------------------|----------------------|
|                                          |                                      |                      |                      |                      | Strength of evidence events (32.3%) in Arm A Unc: Post-hoc, no type-I control, FAS population | ces                  |
|                                          |                                      |                      |                      |                      | error                                                                                         |                      |
| Unfavourable Effects                     | Unfavourable Effects                 | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects                                                                          | Unfavourable Effects |
| Treatment arms                           | Safety analysis set                  |                      |                      | Arm I N=265          | Arm A N=268                                                                                   |                      |
| TEAEs any grade                          | Incidence of TEAEs Occurring in ≥10% | %                    |                      | 99.2                 | 99.6                                                                                          |                      |
| Grade ≥3                                 |                                      | %                    |                      | 93.2                 | 93.3                                                                                          |                      |
| Grade 3/4                                |                                      | %                    |                      | 90.9                 | 89.2                                                                                          |                      |
| Anaemia                                  |                                      |                      |                      | 21.5                 | 34.3                                                                                          |                      |
| Neutropenia                              |                                      |                      |                      | 39.2                 | 38.8                                                                                          |                      |
| Pneumonia                                |                                      |                      |                      | 5.3                  | 3.7                                                                                           |                      |
| Diarrhoea                                |                                      |                      |                      | 5.3                  | 6.0                                                                                           |                      |
| Deaths due to AEs                        |                                      | %                    |                      | 2.3                  | 4.1                                                                                           |                      |
| Discontinuati on of ibrutinib due to AEs |                                      | %                    |                      | 23.0                 | N/A                                                                                           |                      |

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

FFS analyses of study MCL3003 demonstrate a clinically meaningful improvement of FFS in Arm I vs Arm A, together with a different safety profile when ASCT is substituted by the use of ibrutinib in induction and maintenance phase. This finding is supported by descriptive OS data indicating a potential benefit. Importantly, there is no indication of a detrimental OS effect when substituting ibrutinib for ASCT.

In summary, there is a nominally large improvement in FFS (further supported by encouraging OS data) when substituting ibrutinib for ASCT, in combination with a different, and arguably more favorable, safety profile. Given that this is a substitution, in principle similar efficacy could be acceptable. Thus, despite the uncertainty introduced by the lack of proper type 1 error control, efficacy as well as positive B/R is inferred for this treatment modality.

The results from MCL3003 did not demonstrate any additional benefits of combining ibrutinib with ASCT and provided no clear indications of such benefits in any specific subgroup. Moreover, ASCT is associated with substantial toxicity, including treatment-related deaths. Thus, data support an

<div style=\"page-break-after: always\"></div>

extension of indication to substitute ibrutinib for ASCT, but the support for their combined use was not compelling and during the procedure, the MAH dropped their claim for use in combination with ASCT

## 3.7.2. Balance of benefits and risks

The benefit-risk balance of IMBRUVICA in the proposed patient population is positive, since the demonstrated benefits of IMBRUVICA in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (IMBRUVICA + R-CHOP) alternating with R-DHAP without IMBRUVICA, followed by IMBRUVICA monotherapy for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who would be eligible for autologous stem cell transplant (ASCT) are considered to outweigh the toxicity of this treatment regimen, which is considered generally acceptable and manageable in the current clinical setting.

## 3.7.3. Additional considerations on the benefit-risk balance

N/A

## 3.8. Conclusions

The overall B/R of Imbruvica as proposed for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who would be eligible for autologous stem cell transplantation (ASCT) is positive.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include Imbruvica in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) alternating with R-DHAP without IMBRUVICA, followed by Imbruvica monotherapy, is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who would be eligible for autologous stem cell transplantation (ASCT).

Consequently, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated

<div style=\"page-break-after: always\"></div>

in accordance. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet. Version 23.1 of the RMP has also been submitted.

The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annexes I and IIIB and to the Risk Management Plan are recommended.

## 4.1. Conclusions

The overall B/R of Imbruvica in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) alternating with R-DHAP (or R-DHAOx) without IMBRUVICA, followed by IMBRUVICA monotherapy, is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who would be eligible for autologous stem cell transplantation (ASCT)is positive

## Similarity with authorised orphan medicinal products

The CHMP by consensus is of the opinion that Imbruvica is not similar to Tecartus within the meaning of Article 3 of Commission Regulation (EC) No. 847/200. See appendix.

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module 8 \" steps after the authorisation \" will be updated as follows:

## Scope

Please refer to the Recommendations section above.

## Summary

Please refer to Scientific Discussion 'Product Name-H-C-Product Number-II-Var.No'